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ACBT Active cycle of breathing 
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L Litres 
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ATP Ambient temperature, 
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LCI Lung clearance index 
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washout 
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BTPS Body temperature, pressure, 
saturated 
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BTS British Thoracic Society MRI Magnetic resonance imaging 
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RVRTC Raised volume, rapid thoracic 
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transmembrane regulator 
Sacin Progression of phase III slope 
corresponding to 
inhomogeneity in the acinar 
region  
Cinit Initial concentration Scond Progression of phase III slope 
corresponding to 
inhomogeneity in the 
conductive region  
CO2 Carbon dioxide SD Standard deviation 
COPD Chronic obstructive 
pulmonary disease 
SF6 Sulphur Hexafluoride 
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VDI Ventilation defects per image 
FRC Functional residual capacity Vexp Expired volume 
FVC Full vital capacity Vt Tidal volume 








This thesis has been composed entirely by me. The work presented in this thesis was 
primarily conducted by me, however where planning, execution and analysis was 
conducted in collaboration with other researchers this has been clearly indicated.  
This work has not been submitted for any other degree or professional qualification. 
Some of the results of the studies described in this thesis have been previously 
presented elsewhere; a list of publications is presented. 
This work was funded in part by the UK Cystic Fibrosis Gene Therapy Consortium, 












Multiple breath washout (MBW) of inert gas for assessment of airway disease in 
children is an emerging technique. In many studies Lung Clearance Index (LCI), 
derived from multiple breath washout of SF6, is more able to detect early or mild 
lung disease than standard lung function measurements. It is also able to detect very 
early lung disease in progressive conditions such as Cystic Fibrosis (CF). Where 
infants born with this condition were thought to have minimal lung disease activity, 
LCI is higher in these children than healthy controls. Lack of available commercial 
devices has hampered expansion of this technique to centres other than specialist 
research teams.  
Innocor (Innovision, Dk), a photoacoustic mass spectrometer capable of performing 
multiple breath washout, was adapted within this research group for use in adults. 
This thesis describes the setup, adaptation and validation of Innocor for use in 
children. 
In 4 studies, healthy controls, children with asthma and children with CF were 
recruited to perform MBW.  
In one study, 29 healthy controls and 31 children with asthma were recruited. 
Healthy controls performed 1 set of washouts, establishing a normative range. 
Children with asthma performed measurements before and after bronchodilator. 
Results showed increased LCI in children with asthma even though they were 
clinically stable as defined by symptoms. LCI stayed high even following 
bronchodilator suggesting evidence of residual airway disease in well controlled 
asthmatics despite adequate symptom control. 
To investigate short term variability of MBW measurements, two other studies 
recruited 18 children with CF in each. They performed measurements before and 
after standard physiotherapy manoeuvres and during sitting and lying posture. LCI 
did not change significantly after airway clearance physiotherapy, compared with 
children who did no intervention. Variability was high in both groups however 
suggesting CF lung disease is a complex interaction of changing ventilation in 
adjacent lung units. Lying posture induced greater changes in lung function in 
children with CF than controls. LCI appears to be more sensitive to this change than 
standard lung function measurements (spirometry). 
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In another study 32 children with CF were recruited to perform serial lung function 
measurements over 18 months. These were data collected as part of the UK Cystic 
Fibrosis Gene Therapy Consortium (CFGTC) clinical studies in preparation for 
planned gene therapy trials. LCI appears comparable to FEV1 and may be able to 
detect another aspect of airway disease. 
All initial studies were performed in older children (>5yrs). The basic Innocor device 
is unsuitable for testing of younger patients with low breath volume and high 
respiratory rate. In-house adaptations following detailed lung model experimentation 
led to a faster analyser response, potentially capable of MBW in younger children. 
The second part of this thesis concerns lab experiments and an in-vivo comparison 
with the current gold-standard MBW device, a respiratory mass spectrometer. 16 
healthy volunteers and 9 children with CF were recruited. Ages ranged from 0.4 yrs 
to 49 yrs. Innocor values for lung volume estimation compared favourably with the 
mass spectrometer. No evidence of bias caused by Innocor error was seen, however 
intra-test variability was rather high, reducing the precision of the results.  
These studies indicate Innocor is a robust, simple to use device with potential as a 
commercial lung function system. Modifications were made to make it suitable for 
use in all ages. Further development will need to focus on the patient interface and 
software, which is the domain of the manufacturers. The experiments contained in 
this thesis are therefore of interest to the wider respiratory research community as 
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Chapter 1 - Introduction to validation of Innocor for 
MBW in children 
Lung function in respiratory disease 
In the UK, respiratory disease is common, being the cause of death in 1 in 5 people 
overall. This carries a large cost to the NHS in terms of care provision and drug 
prescribing, with associated costs in terms of loss of workforce productivity . There 
have been improvements in the past 20 years, with reduced mortality. However, the 
relative burden of respiratory disease is unchanged due to greater advances in the 
treatment of other conditions such as heart disease and cancer(The Burden of Lung 
Disease 2nd Edition  2006). 
In infants and children, respiratory disease is the most commonly reported illness, 
with a long-term diagnosis reported in 10-12%. This can be chronic or acute, with a 
highly variable clinical picture, meaning determining prognosis is difficult. Factors 
such as peri-natal history, co-morbidities, socioeconomic status and family history 
alter the mortality and morbidity of respiratory disease in children. 
A major goal, following a respiratory diagnosis, is to minimise or eliminate 
symptoms. Long-term care in progressive conditions (e.g. Cystic Fibrosis) has the 
extra challenge of treating symptoms while endeavouring to preserve normal growth 
and development, balancing the need for intensive management with effects of 
treatments on development and quality of life. Given this complexity, accurate 
measurement of disease severity is crucial to minimise under- or over treatment.  
Lung function in paediatric research 
Lung function is universally used in adult clinical settings to measure disease and 
detect an improvement following institution of treatment. In children, lung function 
can currently only be widely used clinically in older co-operative children (generally 
>4 years). In research settings, lung function is commonly used as a “gold standard” 
with which to measure the sensitivity of novel assays. There are a variety of lung 
function measurements, including lung volume, flow, gas mixing, ventilation-
perfusion relationships and lung mechanics. No single measurement provides 
complete information on the whole respiratory system. In conjunction with other 
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measurements, lung function is able to indicate the extent of disease and detect an 
acute or chronic change in severity following institution of a treatment or 
physiological challenge. For slowly progressing conditions, lung function is used as a 
surrogate measure of lung disease, representing longer term outcomes such as death 
or severe disability. 
For these reasons, along with its simplicity and repeatability, lung function is 
commonly used as an outcome variable, but ongoing research is attempting to find 
improvements.  
In paediatric research, there are a number of reasons why measurements used in 
adults are not suitable in younger age groups. These issues are discussed below: 
1. sensitivity to disease 
2. different basic physiology 
3. different factors contributing to abnormalities in function 
4. ability/cooperation with test 
5. availability of normative data 
1. Commonly used tests are not able to detect mild/early 
disease 
Evidence of early infection, inflammation and structural changes in children with CF, 
prior to abnormalities in spirometry, have led to the opinion that standard lung 
function testing (spirometry), may not be suitable for detection and tracking of lung 
disease in children(Sly and Brennan 2004). There is also evidence in children with 
asthma that early structural changes occur in the airways of children who wheeze, 
and that they may progress, contributing to the faster decline in lung function seen in 
adults with a history of asthma, compared to those with no respiratory 
history(Edwards et al. 2003).  
 
2. Lungs in childhood are not just smaller than adults 
A comprehensive review of human lung growth by Merkus et al provides the basis 
for understanding the importance of lung function tests designed specifically for 
younger subjects(Merkus et al. 1996). It is understood that the acinus develops prior 
to 20 weeks gestation, but the alveolar phase does not begin until 24 weeks gestation. 
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Even at birth, only 15% of alveoli have developed (~55million). Therefore, both lung 
development, as well as increase in size (volume) occurs in the first 2 years 
following birth, possibly up to 8 years of age. Infant and child airways are clearly 
smaller than in adulthood. Post-mortem studies indicate that peripheral airway 
resistance contributes more to total airway resistance in childhood compared with 
adulthood. It appears that the airways mainly increase in size along with an increase 
in alveolar size, at around 4-5 yrs old. 
Compliance and elastic lung recoil are increased in infancy compared with the adult 
lung(Crystal and West 1991). Combined with increased chest wall compliance, there 
is reduced respiratory reserve (resting lung volume). In addition, because of 
increased elastic recoil, a larger proportion of the lung volume is expired earlier in 
expiration (decreased expiratory time constant). Infants control this to some extent 
by increasing post-inspiratory activity of the chest wall muscles and adducting the 
vocal cords. All of these physiological and mechanical factors lead to increased 
energy expenditure - accounting for differences in lung volume - in infants at rest 
compared with adults. The presence of airway obstruction (disease) 
disproportionately increased respiratory effort (symptoms) in children – especially 
infants - compared with adults. 
3. Multiple pre- and post- natal factors contribute to lung 
development 
Lung development in children has multiple influences of pre- and post- natal 
factors(Merkus et al. 1996). The main factors are summarised in Table 1. 
It is recognised that many respiratory conditions affecting children and adults have 
origins in infancy(Warke et al. 2002, Kiley et al. 2007, Bush 2005, Dezateux and 








Pre-natal  Post-natal 
Oligohydramnios Mechanical stretch (muscle activity) 
Chest wall anomalies and diaphragmatic 
hernia 
Hypoxia/ hyperoxia 
Foetal movement and lung liquid Nutrition 
Maternal hypoxia, nutrition and drug use Prematurity 
Maternal hormonal abnormalities (e.g. 
insulin, chatecholamines, growth factors) 
Respiratory disease –infection, wheeze 
Pollution 
Table 1 - Factors influencing pre- and post- natal lung development(Merkus et al. 1996). 
 
4. Patient ability and cooperation strongly influence selection 
of appropriate lung function measurements 
Testing large numbers of young children is recognised as a challenging task(Stocks 
2004). This is due to test complexity as well as the lack of cooperation, sedation 
requirements, and availability of willing healthy control subjects with which to 
compare disease groups. To allow meaningful comparisons between populations, the 
test reproducibility and repeatability within and between patients for each individual 
lung function test is also required(Miller et al. 2005a), with multiple measurements 
performed over time in the same children. 
 
In young children (<5 yrs) and infants, unable to cooperate with breath manoeuvres, 
lung function was, until recently, limited to sedated and artificially ventilated 
subjects. A large number of data were collected about infant lung volumes and tidal 
flow measurements but many of these studies did not contribute much to the clinical 
care(Schibler and Frey 2002), and were prone to inconsistencies in equipment and 
analysis methods(Stocks 2004). The recent increase in lung function studies, 
including MBW, in non-ventilated infants and young children has been driven by 
efforts from a small number of groups eager to improve standards. Published safety, 
reproducibility and applicability standards intend to encourage multi-centre studies in 
large numbers of patients(Beydon et al. 2002, Beydon et al. 2007, Stocks 1996). 
These standards are based around use of equipment appropriate to the size of the 
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subject and an understanding of paediatric respiratory physiology with enhanced 
safety requirements(Gaultier et al. 1995, Lum 2006, Frey et al. 2000a, Beardsmore et 
al. 2007).  
5. Reference ranges are only recently available in children 
Lung function tests are readily performed in healthy populations to compare with 
disease states. Such reference ranges also take into account major factors that 
influence healthy populations, including age, height, ethnicity and sex. The most 
widely used adult spirometry reference values in Europe were published by the 
European Coal and Steel Community in 1983('Standardized lung function testing. 
Report working party'  1983). Standards are less clear in children as difficulties arise 
from using reference equations out-with the age range of the original population. 
Subbarao et. al. studied a healthy population of 70 children aged 6-18 years and 
compared their results against a selection of reference equations with both wide 
paediatric and adult age ranges, as well as those specifically limited to 
children(Subbarao et al. 2004). They found that those with specific paediatric age 
ranges were more accurate than those from wider age-ranges. Another study by 
Rosenthal et al sought to incorporate pubertal growth changes into the equations for 
adolescents as it is recognised that lung growth is not necessarily linear in this age 
range(Rosenthal et al. 1993). These studies highlight the importance of the use of 
correct reference ranges in the age range to be tested. Over the past 20 years, a 
greater emphasis has been placed on developing ranges in children of all ages, 
resulting in a large body of experience(Beydon et al. 2007, Stocks et al. 2001, Sly et 
al. 2000, Quanjer et al. 1995, Quanjer et al. 1989, Morris et al. 2001, Frey et al. 
2000a, Frey et al. 2000b, Stocks and Quanjer 1995, Quanjer et al. 1997, Gustafsson 
2005, Gustafsson 2002, Gappa et al. 2006, Gappa et al. 1993b, Gappa et al. 2001, 
Dundas et al. 1995, Castellsague et al. 1998, Brody et al. 2004, Beydon et al. 2002, 
Beardsmore et al. 2007, Bates et al. 2000). This now allows comparisons between 
studies, something that limited the applicability of early infant lung function 
studies(Stocks 2004). To enable a single set of reference equations to be used in all 
ages for spirometry, Stanojevic et. al. have released look-up tables assembled from 4 
adult and paediatric population surveys. This mainly utilises data from a North 
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American population, with 2 smaller European populations. This publication is a 
valuable new tool(Stanojevic et al. 2008). 
Cystic fibrosis  
Cystic Fibrosis (CF) is an example of a progressive paediatric condition requiring 
early detection of mild disease and life-long follow up. Most recent paediatric 
respiratory studies have involved CF populations. A large proportion of this thesis 
concerns studies in children with CF, therefore I will provide a brief explanation of 
the condition with a summary of recent advances. 
Cystic Fibrosis (CF) is a multi-system disease caused by a single gene defect. It has 
an autosomal recessive inheritance, affecting approximately 1 in 2500 live births in 
Caucasian populations. Disease is caused by a defect in the cystic fibrosis 
transmembrane conductance regulator (CFTR) protein. This protein is expressed in 
multiple organs and has a role in ion transport across epithelial linings.  
CF is a fatal disease with a current life expectancy of 30-35. The lungs are thought to 
be nearly pristine at birth(Sturgess and Imrie 1982) but are quickly affected  in early 
childhood by progressive infection and inflammation of the airways leading to 
permanent and irreversible lung damage(Hoo et al. 2012). This is characterised by 
decline in lung function and loss of airway architecture (bronchiectasis)(Gustafsson 
et al. 2008, Dakin et al. 2002a, de Jong et al. 2006, Ranganathan et al. 2004, Mall et 
al. 2006, Bush and Davies 2005, Rosenfeld et al. 2001, Armstrong et al. 1997). There 
have been a number of advances in care of CF in the past 20 years leading to an 
improvement in survival. The widespread introduction of newborn screening for CF 
is designed to institute early respiratory and nutritional treatment to prevent 
progression of disease(Wagener et al. 1997). The  advantages of this programme, in 
terms of improved lung function and increased survival however, have still to be 
convincingly shown(McKay et al. 2005, Farrell et al. 2005). The following aspects of 
CF lung disease are commonly measured disease surrogates used in investigation and 
management.  
 lung function – e.g. spirometry, multiple breath washout 
 inflammation and infection – e.g. sputum analysis 
 airway structure  - e.g. CT scanning 
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Lung function 
Spirometry (FEV1) is the most commonly used lung function measurement in CF 
research and the gold standard for assessing short- and long-term changes in older 
patients. Despite being highly reproducible and repeatable with affordable and 
widely available equipment, use in children is limited. The forced expiratory 
manoeuvre requires cooperation and an understanding of the procedure. It is 
therefore not suitable for infants. In addition, it may not be sensitive enough to detect 
early, subtle CF lung disease manifested in inflammatory and structural changes. 
This period of progressive lung disease manifested by clinical symptoms with little 
or no information from lung function testing have been termed the “silent years” of 
CF. The use of infant forced expiratory measurements and multiple breath washout 
have gained attention in the research community. Both are still highly specialised 
techniques and limited to a few centres. Multiple breath washout is the central 
technique in this thesis and will be explained in detail with particular attention to its 
use with a novel device in children. The main measure derived from multiple breath 
washout is lung clearance index (LCI). This will be fully explained in future sections. 
Inflammation and infection 
Recent discoveries have increased interest in the understanding of the genetic and 
molecular basis behind CF lung disease. Because of this, research groups have 
developed highly specific assays to measure inflammation severity and assess how 
these aspects of lung disease relate to other important measurements.  
CF lung disease originates, conventionally, from a lack of functional CFTR protein, 
leading to abnormal electrolyte balance across airway epithelial cells. There is 
thought to be a reduced airway surface liquid height, leading to impaired ciliary 
function and therefore muco-ciliary clearance(Bush 2006). Trapping of debris and 
bacteria leads to a heightened inflammatory response. Until recently, it was not clear 
at what point this process started, and whether inflammation was directly related to 
bacterial infection, or whether absence of CFTR in itself is a trigger for inflammatory 
changes. 
Evidence of early inflammation in the absence of infective organisms(Konstan and 
Berger 1997), by sampling Broncho-alveolar lavage fluid (BAL), has led 
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investigations into the primary role of dysfunctional CFTR in establishing airway 
inflammation.  
Armstrong(Armstrong et al. 1997) sought to investigate inflammation in early CF by 
performing BAL in patients diagnosed by the newborn screening programme. In 
patients classed as infected (definitive infection at time of BAL) there was evidence 
of increased cell count, neutrophil elastase activity and cytokine concentration. There 
was an association between level of bacteria and inflammatory response. Those 
classed as pristine (no evidence of infected organisms, no symptoms and no previous 
antibiotics) showed similar cytokine levels as healthy control patients with no 
previous respiratory disease and those patients diagnosed with CF with previous 
evidence of bacterial infection (by previous BAL) or who were given antibiotics 
previously.  
Bacterial infection stimulates an inflammatory response that is excessive and 
prolonged compared to similar bacterial load in non-cf patients(Rosenfeld et al. 
2001, Muhlebach and Noah 2002). Levels of IL-8 and neutrophil numbers were 
higher compared to control. IL-10 (anti-inflammatory cytokine involved in 
inflammation reduction after infection) is lower in adult CF compared to non-cf, 
leading to the belief that inflammation may be prolonged due to intrinsic effect of 
CFTR dysfunction, or that it is due to inflammation dysregulation as a consequence 
of chronic, unrelenting infective stimulation. 
To investigate the correlation of CF airway inflammation and lung function (FEV1), 
Sagel et. al. investigated 20 CF patients (8-19yrs) who expectorated sputum either 
spontaneously or by induction(Sagel et al. 2001, Sagel et al. 2002). All showed 
increased inflammatory indices (cell count, absolute neutrophil count, IL-8 and 
neutrophil elastase activity) vs. healthy control patients (n=11). Airway infection 
(bacterial counts) was also higher in CF patients. When analysing markers of 
inflammation against spirometry (FEV1) in the same cohort of patients, Sagel found 
a significant negative correlation between FEV1 and cell and polymorphonuclear 
(PMN) counts, IL-8 and elastase. Bacterial count, however, did not correlate with 
lung function or indices of inflammation. Furthermore, sputum matrix 
metalloproteinase 9 (implicated in the process of degradation of airways and lung 
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parenchyma) levels showed significant negative correlation with FEV1 indicating the 
role of these proteolytic enzymes in ongoing lung disease(Sagel et al. 2005).  
Airway structure 
High Resolution Computed Tomography (HRCT) is suggested as a surrogate 
outcome measure for longitudinal studies of lung disease in children with CF due to 
the highly detailed information gained(Brody et al. 2005). Widespread use is limited 
due to concerns about the 20x increased radiation exposure compared to standard 
chest x-ray radiographs. The development of appropriate protocols that minimise 
radiation exposure and scoring systems that accurately quantify early disease have 
led to a number of units using  regular CT at yearly or two-yearly intervals as part of 
routine clinical care(Gustafsson et al. 2008, de Jong et al. 2006, Tiddens and de Jong 
2006, Tiddens 2006). 
HRCT gives detailed information about structural airway and parenchymal changes. 
CT has been shown to detect evidence of air trapping and airway wall thickness in 
patients as young as 8 months(Martinez et al. 2005).   
In 34 children with CF, Dakin et al performed HRCT along with lung function 
(FEV1, FVC) and sputum sample analysis for inflammatory markers (IL-8 and 
cytology). While lung function correlated with most elements of the CT score, 
sputum inflammatory markers only correlated weakly with overall Bhalla 
score(Dakin et al. 2002b).  
CT score therefore appears useful in detecting early structural evidence of 
inflammatory change but does not seem to correlate with sputum inflammatory 
markers.  
An important recent study by Gustafsson et al investigated the agreement between 
lung function measurements (LCI and FEV1) and measurements of structural lung 
disease in 44 children [5-19 yrs] with CF. LCI correlated with CT score (adapted 
Brody score) better than FEV1, indicating increased sensitivity to structural disease. 
LCI also detected abnormality in some patients with normal CT score. This indicates 
LCI may even be more sensitive than CT at detecting early CF lung disease. 
Important data is now available to allow detailed evaluation of CF lung disease. 
Many of the most widely studied measures are invasive or involve high doses of 
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radiation. This is of concern to many clinicians caring for young CF patients. Regular 
HRCT may provide much need information about the progression of CF lung disease 
but regular CT, combined with longer life expectancy due to improved treatment, 
may result in increase in iatrogenic malignancies. 
United Kingdom Cystic Fibrosis Gene Therapy Consortium 
CF is amongst the few conditions with a single gene defect, theoretically ideal for 
correction by transfection of the correct gene code. The UK CF Gene Therapy 




Evaluation of the success of gene therapy depends on measures which detect a 
change in the primary defect (CFTR function, mucociliary clearance) and clinical 
assays that detect an improvement or slowing of deterioration in lung disease 
(structure, function, inflammation, infection and symptoms).  
It is recognised that lung disease slowly progresses from birth throughout life. This 
decline can be measured over time and used as a surrogate for disease severity or as a 
predictor of death. In designing a clinically relevant gene therapy, it is thought that 
those with less advanced disease are likely to benefit most; however, measuring 
clinical benefit following treatment is difficult as lung disease is mild and decline in 
function progresses relatively slowly. FEV1 as a sole measure may be insensitive to 
change after treatment, and a major task for the consortium is to assess relevant 
surrogate markers of lung disease that will be able to detect change following 
treatment in patients with mild to moderate lung disease. A further task is to decide 
which patients have disease that is advanced enough to detect a change with 
treatment but that is not so advanced as to render gene therapy ineffective due to 
physical barriers to inhaled gene transfection (e.g. mucous and inflammation)
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Currently planned therapeutic studies will involve patients aged 12 years and over, 
however future trials may recruit younger patients. Surrogate markers of lung disease 
developed for the first wave of therapeutic trials therefore also need to be relevant to 
younger patients. The current “run-in” study aims to assess the longitudinal 
repeatability and variability of markers of disease progression in individual patients 
as well as the suitability of these assays in future therapeutic trials. One important 
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assay is lung clearance index (LCI). Using the Innocor device, studies conducted by 
the UKCFGTC have been able to perform MBW as a standard assay. Therefore, 
development and validation of MBW equipment (Innocor) and measurement 
standards has immediate as well as future relevance. Validation of Innocor for 
measurement of LCI is central to this thesis. 
Despite advances in understanding of the pathophysiology of CF, it remains a fatal 
condition. It is now better understood how early structural and inflammatory changes 
relate to functional deficits and with emphasis on early, mild disease the hope is that 
decline in health over time will be minimal, leading to prolonged life expectancy and 
decreased overall morbidity. Despite improvements, there are few non-invasive 
assays widely available that are able to detect and track lung disease. LCI, derived 
from MBW, is able to detect early, mild lung disease better than other lung function 
measurements, however there is still only limited use due to lack of standardisation 
and poor availability of equipment. Given the great need for improved lung function 
measurements, development of MBW and validation of equipment is central to 
progress in this field. 
Available lung function assays for use in children and infants 
Spirometry 
Spirometry, a forced expiratory manoeuvre, is the most widely used measure of 
respiratory function. It assesses flow and lung volume at maximum forced expiration 
(airway flow limitation). In disease states, particularly inflammatory conditions (e.g. 
asthma), maximum flow is reduced because of decreased airway calibre (airway wall 
thickening, mucous and bronchospasm). In other conditions (e.g. emphysema), 
expired volume may be reduced because of loss of lung elastic recoil (disrupted lung 
architecture). Mainly because of its simplicity and relative independence of effort, 
spirometry has become a widely used test, able to detect acute and chronic 
deterioration. It is also able to distinguish between obstructive and restrictive causes 
of functional deficit.  
While spirometry is useful in advanced disease states and can predict terminal 
decline in CF, it is not sensitive enough to detect early disease-related changes in 
patients with mild lung disease(de Jong et al. 2004). It generally cannot be 
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successfully performed in children <5yrs old, however modification of the technique 
and coaching has allowed reproducible results with evidence of flow limitation in 
children as young as 3 years(Eigen et al. 2001). For further advances to be made with 
treatment strategies, rigorously evaluated in double-blind placebo controlled trials, 
there must be alternative repeatable measures even in the youngest patients(Weiser 
and Kerem 2007).  
In response to the above limitations of forced expiratory volume measurements in 
young children and infants, standardisation of the Raised Volume Rapid Thoraco-
abdominal Compression Technique (RVRTC) has been reviewed(Lum et al. 2006). 
This technique obtains forced expiratory flow measurements (FEV0.5) at flow 
limitation, similar to spirometry, in sedated infants and young children. In those with 
clinically diagnosed CF, with and without other evidence of lower airway disease, 
FEV0.5 is reduced compared with controls(Ranganathan et al. 2004). The obvious 
advantage of this technique is high sensitivity to the presence of disease. It is, 
however, difficult to perform without expert support, requiring sedation in all but the 
youngest infants. 
This thesis commonly uses standard spirometry as a comparison measurement for 
validation of LCI. This is because most similar published articles do the same, and 
spirometry is the most widely available measurement with recently updated reference 
ranges(Cole et al. 2009, Stanojevic et al. 2007a, Stanojevic et al. 2007b, Stanojevic et 
al. 2009, Stanojevic et al. 2008). It is also the technique most familiar to the patients 
taking part in these studies. 
Multiple breath washout 
Multiple Breath Washout (MBW) of inert gas is of particular interest for this thesis 
and will be discussed in detail in the following chapters. Lung function indices, 
derived from MBW, e.g. Lung Clearance Index (LCI), have been evaluated for use in 
children with mild, early CF. MBW studies are not new(Larsson et al. 1988, de Vries 
et al. 1981), however studies in children have only been conducted 
recently(Stromberg and Gustafsson 2000). Aurora et al showed that LCI in infants 
and children with CF was raised, showing a distinct separation from controls(Aurora 
et al. 2005b). This phenomenon is unusual in lung function testing and generated a 
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great deal of interest. Furthermore, the LCI upper limit of normal does not change 
from pre-school age to adulthood in health, allowing accurate comparisons to be 
made over time independent of height or age. Comparing LCI with standard 
spirometry in children aged 3-18 years with CF, Gustafsson et al showed ventilation 
heterogeneity in all patients with abnormal FEV1, and in more than half of those in 
whom spirometry was normal(Gustafsson et al. 2003a). Aurora et al also 
demonstrated that LCI, along with specific airways resistance and forced expiratory 
volume in 0.5 seconds (FEV0.5), were raised in children with CF aged 2-5 yrs(Aurora 
et al. 2005a). In his study, LCI was higher in patients infected with Pseudomonas 
Aeruginosa, whereas other measures were normal, suggesting LCI is more able to 
detect abnormalities in this age-group than other lung function measures.  
It is assumed that lung function in children with CF declines over time along with an 
increase in chronic inflammation, bacterial colonisation and structural airway 
damage. As a highly repeatable technique, studies have yet to confirm LCI as a 
useful clinical tool to detect and track this decline over time, with the ability to detect 
improvements following initiation of treatment. Early indications are that such 
studies will bear fruit(Kieninger et al. 2011, Robinson et al. 2009a, Aurora et al. 
2011, Amin et al. 2010, Amin et al. 2011). There has been an increase in studies 
performing MBW in infants and children with CF, but without rigorous 
standardisation of equipment, method and data analysis, results cannot currently be 
confidently compared between centres. Commercially available devices are only now 
being marketed. An ERS/ATS “state of the art” article is currently being prepared to 
document up-to-date experience with MBW [in press]. This will allow comparison of 
results across centres, and encourage new users, as well as further commercial 
development of suitable equipment.  
Multiple breath washout in Edinburgh 
Innocor 
In 2006, when this project began, only a few centres had published data from 
multiple breath washout studies. Devices available either utilised mass spectrometry 
for direct measurement of expired gas concentration, or molar mass calculations for 
indirect concentration estimates.  
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Innocor (Innovision, Denmark), a device marketed for non-invasive measurement of 
cardiac output, was initially purchased by the UKCFGTC as an alternative to mass 
spectrometer and molar mass technology for MBW. Its relative affordability and 
simple design made it ideal for planned multi-site clinical studies. It is not designed 
or sold for MBW testing, therefore a series of technical adaptations, with clinical 
studies, were conducted by Dr Alex Horsley, Clinical Research Fellow based at the 
Western General Hospital, within our academic group. Importantly, no previous 
MBW experiments had been conducted using this device. These initial validation 
experiments are reviewed in a later chapter. 
Prior to my thesis project, Innocor was untested in paediatric subjects (<16yrs old). 
The following chapters therefore discuss the use of Innocor, specifically in children, 
and the process of MBW equipment validation. Given the need for suitable 
equipment for MBW in young children, it was felt that limiting Innocor’s use to 
older children and adults would severely hamper the interest in a specific commercial 
MBW device. While no funding or impetus for these experiments came from 
Innovision, the device manufacturer, it was hoped they would use the validation 
work conducted in Edinburgh for a clinically applicable MBW device. Innovision 
have been supportive of this work and interested in further applications of their gas 
analyser technology, however they were not directly involved in the validation work 
in Edinburgh, and did not provide financial support for any of the studies. 
Paediatric lung function standards 
In 2000, a European Respiratory Society/ American Thoracic Society lung function 
task force was established, aiming to publish widely agreed standards for infant lung 
function testing. This series provides guidance in performing lung function in young 
children and infants, as well as technical details for device manufacturers.  
Frey et al published two documents in 2000, which dealt specifically with technical 
requirements for lung function equipment(Frey et al. 2000a, Frey et al. 2000b). 
These highlight important differences in equipment used for paediatric populations 
compared with adults. Because infant volumes and flows are much smaller, errors 
considered negligible in adult equipment (e.g. equipment dead space), must be 
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reduced or eliminated. Signal quality and analysis of data must be examined 
carefully to minimise error from additional factors (e.g. faster respiratory rate). 
Recognising differences in basic physiology, a number of subsequent papers have 
introduced standards for lung model devices and comparison experiments between 
lung function equipment. Again, Frey et. al. described the components and 
performance of a mechanical lung model to test infant respiratory function 
equipment(Frey et al. 2001) Fuchs et al and Pillow et al  used task force guidelines to 
compare lung function equipment as a process of validation(Fuchs et al. 2006, Pillow 
et al. 2004). More recently Beydon et al, on behalf of the ERS/ATS taskforce, 
published a complete statement of standards required for all aspects of respiratory 
function testing in infants(Beydon et al. 2007). From these, clinicians, research 
groups and equipment manufacturers may begin to use these techniques.  
Equipment validation 
For any clinical measurement, it is important that new equipment is properly 
validated, taking into account potential sources of error to minimise systematic 
bias(Beardsmore et al. 2007). Also, for a novel device or technique to be compared 
with an established alternative, the two must be similar in terms of individual 
component performance criteria (Frey et al. 2000a). It may not be feasible to have 
identical equipment in all centres, but comparisons of normative populations, 
longitudinal observational studies and interventional studies will only have limited 
application unless all equipment is fully validated. 
The validation process described in this thesis seeks to understand and document the 
factors that limit accurate multiple breath washout in children using Innocor. Specific 
hardware, methodology and analysis changes have been made to compensate for 
equipment limitations as well as adjusting for physiological differences between 
children and adults. Accepted standards are often based on good evidence; but where 
evidence does not exist the standards are examined and challenged where 
appropriate. In addition, as MBW is performed in all devices using the same basic 
technique, the findings of this thesis are potentially relevant to other groups 
developing or validating similar equipment. 
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This thesis also describes the clinical studies conducted as part of this validation 
process. These allow comparisons to be made with other studies in similar 
populations to confirm the suitability of the Innocor device, but also add to the 
understanding of gas mixing and its relevance to airways disease in children. 
Thesis aims 
1. Show that MBW indices are a suitable selection for detecting and tracking 
lung disease in CF and other paediatric airway diseases. 
2. Describe the MBW technique and modified Innocor equipment in detail. 
3. Demonstrate through a series of clinical studies the use of Innocor in health 
and disease. 
4. Evaluate suitability of Innocor equipment in younger children (<5 years) and 
demonstrate validity. 
Conclusion 
Given the convenience and relative ease of performing repeated lung function, even 
in children, and the disadvantages and risks involved in more invasive measures (e.g. 
HRCT or bronchoscopy), there is a concerted research effort to find suitable lung 
function measurements to replace spirometry(Beydon et al. 2007). The ideal situation 
is to have a highly reproducible, non-invasive measurement, such that the same test 
is used in infants, children, adolescents and adults, allowing tracking of lung function 
over time. This is vital to understanding the natural history of chronic respiratory 
diseases (e.g. asthma or cystic fibrosis) and the long-term effects of interventions and 
the implications of early life events on adult lung function (e.g. prematurity). The 
above scientific advances suggest this is possible with MBW; therefore, this thesis 
explores the use of Innocor in children and a series of validation studies. Because of 
this work using Innocor, it is hoped that development of commercially available 
MBW equipment will be stimulated, fulfilling a pressing need in paediatric 
respiratory research. Despite marketing of newer MBW devices, including nitrogen 
washout modules and SF6 devices for older children, there is still not a device for 
use in all ages. 
This thesis is presented in 10 chapters. There are 2 chapters concerned with methods, 
to provide the basis for the subsequent clinical studies. Each clinical study presents 
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data based on a hypothesis, with overall contribution to the main thesis aims 
presented after each discussion section. To complete the thesis there is a summary 
chapter describing how all the chapters contribute to the main thesis aims above and 







Chapter 2 – methods I: multiple breath washout 
description and initial Innocor validation  
Introduction 
This chapter describes multiple breath washout (MBW) methods. The aim is to 
prepare the reader for clinical studies in subsequent chapters, as well as to provide 
basic principles for adaptations to the Innocor setup in later chapters.  
MBW is a study of gas mixing. While the test itself and the principles behind it have 
been studied for some 50 years(Cantor and Evans 1970, de Vries et al. 1981, Gappa 
et al. 1993a, Jonmarker et al. 1985, Light et al. 1980, Saidel et al. 1975, Schibler et 
al. 2000, Wall 1985, Engel 1985), it is only recently that technology has enabled 
MBW studies with larger numbers of subjects(Gustafsson 2005, Fuchs et al. 2006, 
Gustafsson 2007, Gustafsson et al. 2003b, Lum et al. 2007, Aurora et al. 2005a, 
Aurora et al. 2004, Aurora et al. 2005b). One of the greatest advantages is its 
applicability to all age groups from newborn babies to adults, which will potentially 
enable tracking of lung disease in infancy through childhood, right up to adult age. 
This is especially important for inherited progressive conditions but is also important 
for other paediatric airway disease. 
An understanding of basic lung anatomy and respiratory physiology is important in 
development of this technique. This chapter therefore reviews the physiological 
principles behind MBW.  
Many of the methods described are only recently published. There is some 
disagreement on the details of MBW methodology, and at the time of writing, these 
have not been resolved. A “state of the art” document, to be published in late 2012, 
seeks to resolve many of these issues, encouraging development of suitable 
commercially available equipment and wider clinical use of MBW. Some of the 
method development described in this thesis has contributed to this international 
document. 
This chapter also contains detailed description of the MBW technique along with 
data analysis. Alex Horsley, who initially led the development of the Innocor device 
in Edinburgh, has recently published a thesis describing much of this. However, 
given the need for measurements to accurately detect and track lung disease from 
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infancy, there is particular interest in applying MBW specifically to early years. 
There is also a discussion of the main difficulties encountered during the experiments 
and clinical studies. 
Background to MBW 
 Gas Mixing 
 Conduction, Convection and Diffusion 
 Quantifying Gas Mixing 
 Multiple Breath Washout Basics 
Gas mixing 
Simple anatomical studies of the airways reveal central branches repeatedly dividing 
into smaller and smaller diameters (Figure 1). These branches serve simply to 
conduct inspired gas into the smaller airways and alveoli, the region involved in gas 














This system of branching airways increases the efficiency of the system conducting 
inspired air to the gas exchange areas with minimal effort at rest. Oxygen is brought 
to the gas exchange membrane during inspiration, with carbon dioxide removal 
during expiration. This process is remarkably efficient because of an elegant airway 
bifurcation structure and the large cross-sectional surface area of the alveolar gas 
Figure 1 - anatomy of airway tree 
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exchange zone. At each bifurcation, the successive cumulative area of the daughter 
airways is larger than the parent. This has the advantage of reducing total resistance 
and slowing convective flow, enabling optimal gas mixing. Weibel’s symmetrical 
model illustrates this, describing exponentially increasing total cross-sectional area 
with successive airway generations (Figure 2). The respiratory zone starts at 
approximately division 17, where gas exchange begins to take place. Prior to that, the 
airways simple conduct gas with no respiratory exchange. Initial research interest 
was in how gas behaves in the smaller airways, and how the lungs achieve such a 
degree of gas exchange so efficiently.  
 
 
Figure 2 - Weibel's schematic description of airway levels 
Conduction, convection and diffusion 
Early gas mixing studies have attempted to measure physiological processes, 
building on prior knowledge of lung anatomy. 
Initial results showed that the lungs do not completely empty with each breath, 
therefore inspired oxygen in the air must mix with the residual airway gas to reach 
the alveoli. A method to measure the volume of this functional residual capacity 
(FRC), using Fick’s first law of diffusion and the Bohr equation, was published by 
Fowler(Engel 1985). This states that gas diffuses from areas of high concentration to 
low, and assumes that all gas mixing occurs in the relatively large alveolar 
compartment, as opposed to the conducting airways. Recent gas dynamics studies 
have shown that the conducting airways do not only feed gas to the alveoli, but are 
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also involved in gas mixing by longitudinal and axial gas mixing. Whilst the Bohr 
equation, as applied by Fowler, is easily applied to physiological tests, it is probably 
an oversimplification of multiple influences. Conclusions about the anatomical 
location of abnormalities, based on changing gas washout patterns, are balanced by 
the assumption that other regions simultaneously contribute to gas mixing to a lesser 
extent. 
Fowler made another important contribution to gas washout studies in disease when 
he showed that, along with being able to measure lung volumes with gas washout, 
the expired N2 concentration following a breath of 100% oxygen followed 
predictable phases (Figure 3).  
 
 
Figure 3 - typical pattern of single breath expired gas concentration. Phases of breath are shown 
in shaded areas. 
 
 Phase I corresponds to the dead space within the conducting airways. In the case 
of N2 washout with 100% O2, the phase I concentration is near to zero, 
representing largely unmixed inspired oxygen. 
 Phase II corresponds to the rapid rise in concentration associated with switching 
from the airway dead space with no nitrogen to the alveolar compartments with 
high N2 concentration. There is a diffusion front such that the concentration rise 
is sigmoid rather than instantaneous. This demonstrates the degree of axial and 
longitudinal mixing of gas within the conducting zone. 
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 Phase III (alveolar slope) represents the gas concentration in the alveolar 
compartment. The alveolar slope is such because rather than all lung units 
emptying at the same rate, there is a degree of sequencing, generating a gentle 
rise in concentration to the end of the breath. This rise in concentration during 
phase III steepens in disease. 
 
Single breaths of nitrogen have subsequently been extensively studied after inhaling 
100% oxygen(Engel 1985). Much information is now known about the effect of 
disease processes (e.g. obstruction) and physiological changes (e.g. increased flow) 
on the pattern of expired tracer gas concentration. In disease states, an increasing 
alveolar slope indicates greater sequencing of parallel lung units. The concept of 
ventilation heterogeneity and sequential emptying of parallel lung units therefore 
began with single breath washout analysis(Engel 1985). 
Initial work with Nitrogen Washout techniques was conducted to investigate the 
effect of different physiological parameters (e.g. tidal volume, breath holding, lung 
volume) on gas mixing. In addition, Paiva and Engel pioneered lung modelling 
studies to describe the relative contributions of convection (movement of gas) and 
diffusion (mixing of molecules from high concentration to low) to gas mixing(Engel 
1985). They developed early single breath washout tests to use exogenous tracer 
gases of different diffusivities. The hypothesis was that differences in the washout 
pattern between these gases would indicate to what extent diffusion of gas 
contributes to gas mixing. Differences in concentration at different airway levels 
indicated the anatomical location of the diffusion front. After multiple detailed 
studies analysing gas concentrations at various airway divisions, it appears that the 
convection diffusion interaction - where bulk flow (convection) stops and molecular 
diffusion takes over - exists within the acinus.  This initial work was initially 
important for physiological studies in health, but is now important in studying 
disease states. 
Single breath tests give comprehensive information only in very heterogeneous 
lungs. In situations with patchy mild lung disease, where some regions are not 
emptied until later on in a multiple breath washout, abnormalities may not be 
detected. Multiple breath washout (MBW), initially measuring washout of resident 
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nitrogen with 100% O2, was developed as a way of assessing sequential emptying of 
heterogeneously ventilated lung units because gas concentration is followed until it is 
almost completely washed out. Indices derived from MBW are now discussed. 
Work by Verbanck and Gustafsson in separate institutions has widened the use of 
MBW techniques to various disease states such as COPD, CF and asthma(Verbanck 
et al. 1998, Verbanck et al. 2010). Importantly, its use is now extended to young 
children and infants, who are unable to cooperate with standard lung function 
measurements(Morris et al. 2001, Beydon et al. 2007).  
Quantifying gas mixing 
As described above, the lungs readily mix gas by conduction, convection and 
diffusion. With each breath, air is directed down 16 airway branches to reach the gas 
exchange zone in the terminal bronchioles and alveoli. At this level, the single 
trachea has divided into 60,000 small airways. There are multiple, self-contained 
lung units that extend from each airway bifurcation. It is useful to consider the lungs 
as a series of distinct parallel lung units, whatever the level, to understand how 
disease affects gas mixing. Parallel units in this situation could be lungs, lobes, 
lobules or acini. 
With each breath, a complex balance of airway surface tension and tissue tethering 
forces in the lung parenchyma ensure even distribution of air(Engel 1985). There are 
physiological regional differences in ventilation between the apex and base, but 
between parallel alveolar units, the difference is negligible in health. Disease (e.g. 
inflammation) causes patchy obstruction in airways, distributing gas unequally 
throughout the airways.  
To expand on this, consider two hypothetical parallel lung units in disease. 
Obstruction is different between units, therefore air is preferentially distributed to the 
unit of lower resistance. This increases the volume of this unit, unbalancing the 
tethering forces. The degree of filling between these units is imbalanced, affecting 
surrounding units. Even differences in small airways can lead to large differences in 
air distribution through imbalanced lung expansion. 
This principle is important in gas mixing measurements, as the pattern of gas 
washout during multiple breath tests can be explained by interactions between 
parallel lung units, sampling the washout of a tracer gas over time. During both large 
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vital capacity breaths and simple tidal breaths, the lungs do not completely empty at 
the end of expiration. Therefore, gas mixing takes place to dilute the residual gas in 
the inspired portion. In health, where gas is distributed to parallel units evenly, a 
certain number of breaths are required to wash a tracer gas out of the lungs. Again, 
considering two single parallel units, if gas is not distributed evenly due to areas of 
obstruction causing imbalances in ventilation, one unit will wash out quicker than the 
other. These units could therefore be considered heterogeneous. Over the whole lung, 
a proportion of lung units will wash gas out at the same rate as a healthy lung, or 
even faster as they are preferentially ventilated. Only later in the washout, once the 
concentration gradient between inspired and residual gas is greater, will poorly 
ventilated units wash out gas. Depending on the degree of heterogeneity between 
parallel units, the difference in washout rates may be great. There are 2 phases to gas 
washout in this highly simplified situation - a fast phase and a slow phase, as 
illustrated in Figure 4. The whole lung is more complex than two parallel units, but 
principles of heterogeneity of ventilation between multiple lung units over the whole 















Figure 4 - this shows that in parallel units within the airway tree, a partial obstruction increasing resistance 
allows preferential ventilation of the unaffected unit, washing out the gas more quickly than the affected 
unit. Before the washout is over, the well-ventilated unit is empty of gas, while the concentration in the 
affected arm is still high. This leads to a prolonged washout with greater breaths required to empty the 
affected portion, and two phases to the washout. 
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Tracer gases 
To measure ventilation heterogeneity, a suitable tracer is used to follow gas washout. 
This gas is measured on a breath-by-breath basis, therefore a relatively fast gas 
analyser is needed, responding accurately to sudden changes during inspiration and 
expiration. Concentration, followed as it is washed out, is plotted against volume of 
expired gas to calculate washout indices. The tracer gas selected should be inert, with 
no effect on airway patency, no endogenous production and no airway absorption. 
The choice of gas is normally determined by available technology. Fast Nitrogen 
analysers have been available for many years, leading to the development of nitrogen 
washout tests, where inhaled 100% Oxygen displaces resident nitrogen. Other gases 
have been used more recently as suitable analysers have become available. Often a 
non-resident gas such as helium or sulphur hexafluoride is chosen in low 
concentrations as this minimally disrupts inspired viscosity and natural gas mixing. 
Details of the three main gases used are given below. Additional gases, such as 
methane or argon, are occasionally used to compare the effect of gas density on 
washout pattern. 
 Nitrogen  
As early as 1941, multiple breath nitrogen washout (MBNW) tests were designed to 
assess gas mixing in the lungs(Cournand et al. 1941). This technique was simple, 
requiring subjects to washout residual nitrogen with tidal breath inhalations of 100% 
oxygen. The advantage to this system was the ready availability of accurate fast 
nitrogen analysers and 100% oxygen. This principle of nitrogen washout is still used 
today although the technique has been significantly refined since its early 
conception(Downie et al. 2007, Verbanck et al. 1998, Verbanck et al. 1999, 
Verbanck et al. 2001, Verbanck et al. 2003, Verbanck et al. 1997). Nitrogen washout 
is simple and requires no washin period. However, nitrogen is absorbed and 
produced in the lung and must be corrected for during washout calculations. Also, 
switching between air and 100% oxygen greatly alters gas viscosity, leading to 
difficulties in flow measurement. Additionally, there is a documented decrease in 
FRC in infants breathing 100% O2, which is not seen in older children and 
adults(Newth et al. 1997). 
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 Helium 
As an additional method for obtaining information about lung volumes, helium has 
been used since 1948 to calculate functional residual capacity in human 
subjects(Meneely and Kaltrieder 1949). The advantage of using a non-resident gas is 
the lack of requirement to calculate consumed or endogenously produced gas during 
the washout Helium is readily available as a test gas and this technique is well 
established for calculating functional residual capacity today in lung function 
laboratories(Cotes et al. 2006). Helium has a very low molecular weight. This makes 
it very prone to leaks during testing. During prolonged washouts leaks may be great 
and unpredictable, leading to inaccuracies in volume and gas mixing calculations. 
 
Sulphur hexafluoride 
Sulphur hexafluoride (SF6) is a synthetic, non-polar and insoluble non-organic 
compound. Importantly, it is inert and therefore is used in many industrial and 
medical applications. It was discovered in 1901, but was first used for lung function 
measurements in the 1970’s(Paiva et al. 1976, Lacquet et al. 1975). With its high 
molecular weight, it was used in contrast to helium to measure gas mixing, 
particularly assessing differences in convection and diffusion of gas in the lung 
periphery. Adequate gas analysers for SF6 are less readily available. Mass 
spectrometry is most commonly used, with other technologies only recently being 
developed for breath-by-breath measurement. This has hampered its use in centres 
without mass spectrometer technology and has limited clinical washout studies to 
very few centres. The utilisation of the Innocor gas analyser has enabled our 
department to develop SF6 washout techniques without purchasing mass 
spectrometer equipment.  
 
Innocor 
With a view to development of multiple breath washout techniques, the UK CF Gene 
Therapy Consortium investigated the use of an appropriate device to measure gas 
mixing in clinical studies. The mass spectrometer is the most commonly used device, 
however cost and complexity were prohibitive. Given its high SF6 signal quality and 
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resolution, this department investigated the Innocor device as a more affordable 
novel alternative for MBW. 
Innocor is manufactured by Innovision, Denmark (www.innovision.dk). The gas 
analyser technology is central to this company’s research and development, with a 
spin-off company in designing techniques for the space industry. Importantly, the 
Innocor device is not designed or marketed as an MBW device, as the internal 
construction and software is solely intended for exercise testing and cardiac output 
measurement. Because of safety regulations (CE0543, ref aur5a0711v141f282, 
cardiopulmonary function test equipment class IIa) and commercial reasons, the 
company are not able to alter the software to optimise it for MBW testing. For this 
reason, the software was adapted to include a simple protocol, allowing constant gas 
analysis without interruption. Programmes to perform daily flow meter and gas 
analyser calibration are present in the software package, however, MBW analysis is 
performed offline on a separate computer using a custom-built programme. 
Basic system components 
 
Figure 5 - Innocor gas analyser and touchscreen computer. 
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Innocor (Figure 5) consists of a computer, gas analysers, gas pumps, switches and a 
touch screen in one compact and portable unit. The detachable Respiratory Valve 
Unit (RVU, Figure 6) consists of the patient interface (filter and mouthpiece), flow 
meter and valve unit which automatically switches between a re-breathing circuit of 
inert gases and air. Re-breathing is a method of washing in gases from a closed large-
volume bag to minimise gas wastage. The gas mix is stored in an integral small 
compressed gas cylinder (18L uncompressed volume, 5% N2O, 1% SF6, 94% O2). 
This volume and method of delivery is not appropriate for prolonged MBW testing, 
therefore the first adaptation is a separate gas supply delivered in an open, bias flow 
fashion. A separate large gas cylinder containing SF6 0.2% in medically balanced air 




Figure 6 - Rebreathing valve unit with connections. 1- gas sampling tube, 2- flow meter, 3- 
bacterial/viral filter, 4- mouthpiece, 5- rebreathing bag, 6- exhaust port, 7- rebreathe port 
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There is no need for constant online visual display of gas concentration in cardiac 
output testing. Because of interest in this new MBW application, the company were 
willing to add a software module. This allows a “live” view of flow and gas 
concentration, with a constantly updated numerical display of gas concentration to 
ensure high quality washouts with minimal leaks and disruptions to flow.  
There were very few barriers to development of Innocor as a MBW device. There 
are, however, a number of inconvenient aspects remaining. Future developments 
have improved some of these but full development requires investment by 
Innovision. 
One problem with the current software is the regular timed flow meter reset. These 
reset intervals can be altered prior to, but not during, a washout. While signal resets 
are important for volume calculations as flow meters have a natural drift over time, 
this generates a sudden large flow signal for 1 second during the washout (100L/s). 
Therefore, during testing, a flow reset needs to be avoided to prevent data errors. 
Furthermore, different subjects take variable lengths of time to complete a washout. 
It is desirable for the subject to limit total testing time for reasons of comfort and 
tolerability. If the flow reset is set at too short an interval some subjects may not be 
washed in by the reset time.  
Photo-acoustic gas analyser 
The core technology within Innocor is the photo-acoustic gas analyser (PGA). The 
principle of photoacoustic spectroscopy is that gas molecules absorb light in 
proportion to their concentration. An infra-red light, split by specific frequencies by a 
rotating wheel, is shone on sampled gas. Light absorbed by sampled gas results in 
temperature/pressure changes, which are heard as sound by a sensitive microphone. 
Change in amplitude is directly proportional to gas concentration. The photoacoustic 
method can only measure di-atomic molecules, and the PGA is specifically set to 




Figure 7 - schematic of photo-acoustic gas analyser (PGA). Light, chopped at specific 
frequencies, is shone on sampled gas which emits an acoustic response. The amplitude of this 
response is directly proportional to the concentration. 
 
The advantages of this technology are the compact design and high signal-to-noise 
ratio. The disadvantages are the relatively large volume of sampled gas required and 
relatively slow response to changes in gas concentration. This will be discussed in 
detail in subsequent chapters. 
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Comparison with most commonly used MBW device. 
Even with the above limitations, there is an incentive to develop Innocor for MBW. 
Table 2 compares Innocor with a mass spectrometer to illustrate the benefits and 
disadvantages of each device against the other.   
 Mass spectrometer Innocor 
Size Large Small and portable 
Durability Sensitive to any moving. Requires 
frequent servicing and technical 
support. 
Can be readily moved. Requires only 
annual analyser calibration. 
Cost £65,000 £30,000 
Gas Analyser Highly specific, multigas analyser. 
Very fast response time 
Very limited range of gases 
analysed. Moderate response time. 
Gas Signal 
quality 
Very high Very high 
Software Requires offline MBW software. 
Excellent on-line visual signals 
Requires export and offline analysis. 





Very fast, specific analyser with 
further research potential. Multiple 
gas capacity.  
Limited further research potential 





Requires external flow meter and 
calibration equipment. Unlikely to 
be available in clinical setting due to 
high costs and servicing 
requirements. 
Compact, self-contained device. 
Potential for clinical use only after 
commercial development. 
Table 2 - comparison of Innocor with gold standard MBW device. 
Environmental considerations 
SF6 is a known greenhouse gas, with a 24000x greater potency than the same weight 
of CO2. Before MBW becomes more widespread, many ethics committees and 
device manufacturers may wish to consider the environmental impact of washout 
tests. 
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SF6 consumption varies with age and extent of heterogeneity. An older patient with 
advanced CF may take 8 minutes to wash in, whereas an infant may take less than 2 
minutes. Larger subjects also require a higher gas flow rate. 
Conventionally 3 washins are performed, with MBW indices calculated from 
washout, although this is not universal. Calculating “MBW” indices from the washin 
potentially reduces gas consumption(Bell et al. 2008). 
Using basic figures, the consumption of SF6 was calculated for various ages of 
patient, with the equivalent weight of CO2 (Table 3). Figures quoted are based on 
average uses of SF6 during washins of 0.2%, rather than 4%. These numbers are also 
illustrated in Figure 8. With increasing age of subject, SF6 consumption increases 














of gas mix 
(L) 
consumption 
of pure sf6 
(L) 
consumption 
of pure sf6 
for 3 washins 
(L) 
equivalent vol 
of CO2  





1 2 3 6 0.012 0.036 864 1.554 
3 2 4 8 0.016 0.048 1152 2.071 
5 2 6 12 0.024 0.072 1728 3.107 
8 3 8 24 0.048 0.144 3456 6.213 
12 4 10 40 0.080 0.240 5760 10.357 
16 4 12 48 0.096 0.288 6912 12.428 
20 5 15 75 0.150 0.450 10800 19.418 




According to the Intergovernmental Panel on Climate Change (IPCC, 2001) SF6 is 
24,000 times more potent than CO2 in terms of greenhouse 
potential(Intergovernmental Panel on Climate Change. et al. 2001). Providing 
equivalent CO2 consumption is important to ease environmental concerns about 
widespread MBW testing. 
One flight from London to New York (~33400 L (0.6 tons) CO2 per person) is 
equivalent to MBW in about 46 average people each performing 3 washouts 
(Innocor, 0.2% SF6). If the alternative 4% SF6 concentration is used, as in other 
systems, 1 flight to New York is be equivalent to only ~2.5 average people 
performing 3 washouts each. Also, 1 adult with CF (greatest SF6 consumption) 
would use the equivalent of 20kg CO2 per 3 washouts (0.2% sf6) (This is the same 
as driving 116km (72 miles) in a 1.8L car). With 4% sf6, 3 washouts would be the 






























Consumption of pure sf6 (L)
for 3 washins
Figure 8 - illustration of exponential increase in SF6 consumption because of increased bias flow 
requirement and prolonged washin duration 
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It is important to stress that a child with CF (e.g. 5 yrs old), would use approximately 
6 times less SF6 than an adult with CF (2 minute washin at 6l/min vs. 5 minute 





Equipment   
Equipment for performing multiple breath washout is much the same as that used in 
previous studies using nitrogen washout with oxygen. The subject breathes through a 
pneumotach to measure flow, while delivering gas via a bias flow system. This 
delivery system allows the patient to breath normally with no valves or switches. On 
inspiration, the flow to the subject is biased towards gas coming from the flow of 
SF6. On expiration, the bias is towards expired gas leaving the system via the 
exhaust end (Figure 9 below). 
SF6 
The SF6 concentration used for measuring lung volume and gas washout should be 
high enough to provide high signal to noise ratio right to the end of the washout. 
High concentrations of gas, however, may interfere with normal gas mixing due to 
changes in viscosity and density. Concentrations of 0.5 % were used in early SF6 
washout studies using an infrared analyser(Larsson et al. 1987). Studies using mass 
spectrometry commonly use 4% SF6 due to poor signal to noise ratio at lower 
concentrations. The Innocor device uses 0.2% SF6, as there is high signal to noise 
ratio with this analyser throughout the washout. This is an advantage, as any changes 
in viscosity that may alter flow readings with higher SF6 concentrations are not a 
concern at 0.2%. There is also less gas consumption, which may be an ecological 
advantage as discussed above. 
Gas analyser 
The lack of fully developed gas analysers, suitable for breath-by-breath analysis, has 
hampered the wider use of MBW of SF6. According to published guidelines, the 
ideal gas analyser must: 
 be capable of detecting breath-by-breath changes in gas concentration, with 
high update frequency and high signal to noise ratio(Beydon et al. 2007) 
 ensure accurate estimation of end-tidal gas concentration, expired gas volume 
and alveolar slope analysis(Beydon et al. 2007)  
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 be able to respond quickly to sudden changes in flow. The speed of response 
is often quoted as the 10-90% rise time(Brunner and Westenskow 1988). This 
issue is discussed in detail in a later chapter (8). 
In a side-stream system such as the Innocor, gas is sampled from the subject’s 
expired flow. A metal capillary is positioned in the stream of the subject’s breath, 
usually within the Pneumotach flow meter (Figure 10). 
Pneumotach requirements 
Pneumotach (PNT) flow meters are highly standardised devices that estimate flow 
over a pre-defined range. Any device employed to measure flow in small children 
should be a balance of low resistance against low dead space(Frey et al. 2000a). The 
most commonly used flow meters are: screen pneumotachs, hot wire anemometers or 
ultrasonic devices. The most commonly used screen PNT for MBW testing is the 
Fleisch-type, which is durable and easy to clean but expensive. Hans-Rudolph flow 
heads are cheaper but required dismantling before sterilisation. A number of Hans 
Rudolph sizes are available, operating within set recommended flow ranges and 
minimising equipment dead space. Importantly, PNTs do not measure volume 
directly. They estimate flow by utilising the phenomenon of a linear increasing 
pressure differential with increased flow across a partial obstruction. In the case of a 
Hans-Rudolph PNT, the partial obstruction is a mesh within the flow head. Pressure 
difference is converted to flow by an electronic transducer, and integrated with time 
to calculate volume. Care is taken to ensure that a PNT is calibrated accurately. A 
number of variables affect the pressure differential, e.g. humidity, gas composition, 
temperature, size of breath and magnitude of flow.  
 
Published guidelines recommend PNT specifications for use in patients of all 
ages(Miller et al. 2005a, Wanger et al. 2005). Of particular interest to this thesis are 
guidelines relating to children and infants(Frey et al. 2000a, Beydon et al. 2007). 
Expected infant tidal volume (2-12kg) is 5-8 ml/kg, and total PNT dead space should 
be no more than 2ml/kg. Heating is also required in small low-flow devices to 
prevent condensation build-up on the PNT screen, especially when used within 
humidified circuits (e.g. mechanical ventilation). Temperature within a heated PNT 
should be 30-37
o
C. The PNT frequency response should be measured using all the 
58 
pieces of equipment in place and should be within ± 5dB at up to 10Hz. The 
frequency response is defined as ability of the equipment to accurately convert a 
physiological signal to an electrical signal, faithful to the magnitude (attenuation) 
and temporal relationship (phase lag) over a defined frequency range(Frey et al. 
2000b).  
Linearisation and daily calibration of flow meters is essential(Frey et al. 2000a). This 
involves using a calibration syringe to deliver known volumes of air over the flow 
ranges expected during testing, tuning the electrical voltage response. Daily 
calibration measurements should be within ±5% of each other.  
Bias flow gas supply 
The bias flow system is a simple way to deliver tracer gas while encouraging tidal 
breathing. Without valves, there is also low dead space. A stream of gas is passed via 
elephant tubing over the end of the pneumotach, with a longer distal exhaust arm, to 
create greater resistance than the proximal section during inspiration to minimise re-
inspiration of expired gas (Figure 9). The gas flow rate should be higher than the 
subject’s maximal tidal inspiratory flow. This setup ensures that during inspiration, 
the subject receives only fresh gas, not expirate. During expiration, because of fresh 
gas flow, there is minimal back flow of expirate up the proximal tubing.  
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Figure 9 - Pneumotach with gas sample line and bias flow gas delivery 
Mouthpiece and noseclip  
Estimated gas quantity should be accurately measured throughout the test, and leaks 
in the system increase error. In older children and adults, a mouthpiece and noseclip 
is used. This can be of any type but must be able to achieve a good seal with minimal 
discomfort. The mouthpieces used in Innocor experiments were obtained from nspire 
(www.nspirehealth.com).  To avoid dismantling and disinfecting the Pneumotach 
after each patient, a single use bacterial/viral filter (Air Safety ltd.) is used in all 
subjects where deadspace restrictions did not prevent it. After each use, the 
mouthpiece and nose clip were cleaned and disinfected. 
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In children younger than 5 years, a facemask is used, as noseclips do not fit easily 
and infants are obligate nose-breathers. Again, a good seal must be achieved with 
minimal equipment dead-space.  
Current recommendations for infant lung function testing state that equipment dead-
space be minimised to less than 2ml/kg body weight(Frey et al. 2000a). This is 
primarily for safety reasons, as proportionally large volumes of re-breathed air 
compared with tidal volume can cause CO2 retention. In addition, a large narrow 
dead-space increases respiratory effort and may change tidal breathing pattern. 
Rendell-baker masks are low dead-space and fit easily with the addition of malleable 
putty(Frey et al. 2000a), which also minimises dead-space(Beydon et al. 2007). The 
volume of the facemask is measured by water displacement, subtracting 50% of this 
volume to take into account the approximate volume occupied by the subject’s 
face(Morris 1999). 
Standard multiple breath washout procedure 
Multiple breath washouts estimate functional residual capacity (FRC) by gas dilution 
and ventilation heterogeneity indices, by analysing the pattern and rate of gas 
washout. 
To properly analyse inert gas washout, the gas is first washed in, via the bias flow 










Figure 10 - Image of standard patient interface - mouthpiece, filter, 
pneumotach and bias flow circuit 
61 
Over time, the concentration in the lungs becomes evenly distributed, therefore the 
expired concentration approximately represents the concentration throughout all the 
airways. If equilibration is not reached, conclusions cannot be reached about washout 
of gas.  
At equilibrium, the gas supply is detached during expiration, leaving the subject to 
wash out the gas with relaxed tidal breathing. With each breath, air is inspired, 
diluting the gas within the lungs and over time the gas is washed out completely. To 
reduce the time taken to complete the test, and with a recognition that gas analysers 
lose signal resolution at very low concentrations, the end point of the test is not 
complete washout of gas. Once the concentration in the breath (measured at the end 
of each breath, end tidal concentration [Cet]) reaches 1/40
th
 of the starting 
concentration the test is ended. 1/40
th
 is chosen by convention rather than particular 
sensitivity or specificity. This is the end-point for all MBW devices, whatever the 
starting concentration(Beydon et al. 2007). 
In the Innocor system the starting concentration is 0.2%, therefore the final end-tidal 
washout concentration is 0.005%.  
The operating procedure below has been developed using published 
guidelines(Beydon et al. 2007, Gustafsson 2005), refined with local department 
experience. While the basic technique applies to all age groups, different approaches 
are required with children and infants, as shown below. 
Wash in phase 
1. The subject performs the test seated, in an upright chair. Slouching should be 
avoided so that uniform lung volumes are maintained. 
2. The mouthpiece and noseclip are attached, with the head positioned so the 
neck is neither flexed nor extended. 
3. Gas is delivered with the flowpast T-piece connected to the end of the 
pneumotach. The flow-past rate should be set at a sufficient rate to ensure 
that no expired air is re-inspired. For an adult this will be 10-15 L/min, but is 
increased if the patient breathes more deeply than expected. Insufficient flow-
past can be viewed on the Innocor screen as a dip in SF6 concentration during 
inspiration. 
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4. The subject breathes in a relaxed fashion throughout, expiring to FRC, or 
relaxed lung volume, avoiding long pauses between breaths. 
5. Subjects should be distracted with television or a DVD. This ensures the tidal 
breathing is as relaxed as possible. Concentrating too much on breathing 
pattern can disrupt the normal regular rhythm. 
6. The online gas concentration should be observed until the constant online 
concentration reaches 0.2%. 
7. Time taken to achieve equilibrium varies depending on lung volume and 
extent of disease. Infants take less than 30 seconds; adults with advanced 
disease can take many minutes. 
8. In practice, some patients may take a long time to reach equilibrium. In 
advanced disease, this may take 10 minutes. In addition, small leaks may 
prevent reaching complete equilibrium. As a compromise, the washin is 
judged complete once the maximum and minimum concentrations differ by 
no more than 0.004% (absolute concentration) 
9. To ensure poorly ventilated regions are all equilibrated, the washin should 
continue for approximately 30 seconds after the equilibrium point is reached.  
 
Figure 11 shows a typical washin of SF6. The black tracing is flow (left axis, L/s) and 
the green is SF6 concentration (%). With each breath (positive flow), the gas is 
progressively washed in to equilibrium. The regular flow meter reset is seen near the 
end of the washin (sudden extreme drop in flow).  
 
Figure 11 - Standard washout trace. Black line is flow. Green line is SF6 concentration. 







































Wash out phase 
1. Once the SF6 has been fully washed in, the bias flow T-piece is disconnected 
rapidly and smoothly during expiration. A swift detachment means no gas is 
inspired in the first washout breath. 
2. The patient now breathes room air until the end-expiratory SF6 concentration 
has fallen to less than 1/40
th
 of the starting concentration, or 0.005%.  
3. Careful attention must be paid to pauses in breathing or evidence of leaks 
(sudden drops in concentration). The subject may need some encouragement 
to breathe regularly. 
 
Figure 12 shows a typical washout pattern. The first sudden drop in concentration is 
the first inspiration of room air after detachment. The washout continues with even, 
regular breaths and no pauses, indicating good quality. The red line indicates the 
approximate finishing point of the washout, where the end-tidal concentration is 
0.005%. It is good practice to continue the washout beyond this point to ensure the 
washout is finished as incomplete washouts cannot be analysed. 
 
Figure 12 - Typical multiple breath washout pattern. SF6concentration reduces with each breath 
  








































Standardised washouts must be conducted to enable quantitative analysis between 
measurements and between research units. Explained in the following paragraphs are 
important standardisation requirements. 
 
Standard concentration of SF6 
The measured concentration of SF6 should always be within the calibration range of 
the analyser. 0.2% is optimal for Innocor washouts. While it does not matter greatly 
what the exact concentration is, large differences in concentration between subjects 
may alter gas viscosity. Each tank of gas supplied by BOC is guaranteed to be within 
5% of the documented concentration. 
 
Documented equipment dead-space 
The dead space of the equipment is removed from the reported estimated lung 
volume. Mouthpieces and filters have documented volumes that can be checked by 
water displacement. The Pneumotach dead space in front of the gas sample capillary 
is also subtracted from the final volume, as all calculations are made at the point the 
gas is sampled. 
Post-capillary dead-space volume, if included in the washout analysis, is subtracted 
from each breath. 
 
Daily flow meter and flow gas delay calibration 
The Innocor flow meter should have calibration documented daily. This ensures 
there are no leaks or other malfunctions in the system. Small errors in flow 
measurements may lead to large errors in volume estimation over many breaths. 
Daily flow calibration delivers known volumes (calibration syringe) over varying 
flow rates. 
There is a discussion of flow gas delay calibration in chapter 8. This process aligns 
flow and gas concentration signals, to take into account time taken for sampled gas to 
reach the analyser. Small errors in signal alignment lead to large volume estimation 
errors(Arieli and Van Liew 1981). Flow gas delay should also be recorded daily to 
detect problems in the gas analyser if the value drifts over time. 
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Mouthpiece and noseclip to minimise gas leak 
The mouthpiece and noseclip ensure minimal leak. They can be uncomfortable 
initially but get more tolerable as the test continues. A nose-clip should always be 
worn, as absence invalidates the measurement due to leaking of unquantifiable 
volumes. 
Sitting posture 
As discussed in detail in a later chapter, posture affects gas volumes and gas 
mixing(Gronkvist et al. 2002). In terms of method development, I noticed that tidal 
volume dropped if subjects slumped or slouched forward. A strict upright sitting 
posture is therefore encouraged in all subjects.  
The method of supporting the Pneumotach is also important. An electrode stand was 
adapted to hold the PNT, with the subject sitting at a table it is easy to maintain 
optimal position. The stand is multidirectional and easily manipulated, making it 
suitable for all sizes of older children. 
In younger subjects, the investigator should encourage sitting posture and support the 
pneumotach and facemask to make sure there is no leak. This picture was published 
by the Institute for Child Health, Great Ormond Street Hospital, London(Aurora et 
al. 2005b). 
  
Figure 13 - example of performing MBW on a young child. Extracted from Aurora et al(Aurora 





Tidal breathing  
An important aspect of multiple breath washout is maintaining a consistent tidal 
volume. When observing washouts in individuals with more variable tidal volumes 
between tests, it was clear that increased tidal volume decreases FRC. As ventilation 
heterogeneity is calculated using FRC, increased tidal volume may increase 
ventilation heterogeneity. 
In initial published MBW studies, researchers recognised the influence of tidal 
volume on gas mixing. If breaths are not large enough to reach beyond the 
respiratory dead space, alveolar gas mixing will not be measured(Engel 1985). Most 
early studies were conducted in adults, developed from single breath vital capacity or 
restricted volume tests. All subjects in these studies were asked to perform 1 Litre 
breaths at all times to reduce variability between subjects and aid alveolar slope 
analysis. This large volume is not practical in children and in those with severe 
respiratory disease.  As an alternative, relaxed tidal breathing is encouraged, 
incorporating adapted protocols to take into account variable tidal volume(Aurora et 
al. 2005b) between subjects. A simple visual tidal volume feedback was designed in 
our department to investigate the benefits and disadvantages of such a protocol in 
terms of washout consistency and acceptability. I found this not to be useful in most 
children, as washouts became complicated by nervousness and difficulty breathing as 
some children found the feedback difficult to use. Therefore, volume feedback was 
not used in any of the paediatric studies. 
 
Detachment of flow-past circuit  
The washout test requires switching from SF6 to air smoothly. Mixing of gas and air 
during inspiration confuses analysis, as mixed re-inspired gas cannot be 
distinguished from equilibrated airway gas at the beginning of the washout. 
Clear switching from flow-past gas to air is achieved by detaching the flow past 
circuit during expiration, when only expired gas is passing over the gas analyser. 
This is difficult to achieve when chest movement cannot easily be seen and in those 
with fast respiratory rates. This is an important skill to achieve when performing 




The Innocor shows a real-time SF6 concentration, however the end-tidal display is 
not given as the value only updates every second. Therefore, the displayed 
concentration taken early in inspiration may be below 1/40
th
 whereas the end-tidal 
concentration is still higher. In addition washout becomes prolonged in advanced 
disease states and the end-tidal concentration may fluctuate around 1/40
th
 for a 
number of breaths. Ending the test early usually invalidates the whole measurement. 
For these reasons, the protocol encourages finishing the washout only when the on-
line display does not rise above 0.002%.   
Experience of MBW in children 
MBW has most recently been developed with children in mind. Despite this, what is 
simple for older children and adults, can be challenging in younger children. Those 
younger than 10 years, in general, have a short attention span and may have 
difficulty in understanding, leading to non-compliance with requests.  
As with all techniques there is an associated learning curve in performing MBW. The 
procedures described above are based on experience with patients attending for 
clinical studies. Prior to this, washouts were performed on colleagues to help practice 
the sequence. My experience has shown that the following important factors 
contribute to a good quality tests in children: 
 
 Testing environment – the room used for testing should be bright and non-
threatening. Familiar posters were put up to encourage conversations and 
rapport. 
 Careful explanation – children may have no prior understanding and can be 
nervous of new experiences. A clear explanation of what is going to happen 
avoids surprises. Attention must be paid to the use of some words (e.g. gas) 
as this may have a particular meaning to them. One 5 year old boy refused to 
perform the test when gas was mentioned.  
Practice with the mouthpiece and noseclip before starting the test was helpful in 
some nervous children.  
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 Posture – slouching or changing posture alters lung volumes. MBW should 
be conducted in a sitting position. A large soft chair may be suitable for 
adults and older children but can be uncomfortable for younger ones (<10 
years). I finally chose a simple wooden chair designed for classrooms with 
some height adjustability (q-learn, CS60281 senior chair, 
www.morleys.co.uk). This encourages children to sit upright and offers no 
ability to slouch. Other chairs (e.g. an adjustable cushioned office chair) were 
too high, deep and moveable so that children were uncomfortable, wriggling 
and swinging during testing. The classroom chair also offers the advantage of 
wipe-able surfaces to comply with infection control guidelines.  
 Distraction – this is an important part of MBW testing. TV or DVDs should 
always be used, no matter the age, as too much attention to breathing rate can 
interrupt tidal flow patterns. This distraction also serves to make the test more 
enjoyable and will divert from what may be frightening pieces of equipment. 
Younger children are especially distractible, and perform tidal breathing very 
well with an engaging cartoon. Obviously, the distraction should be age-
appropriate without encouraging laughing or singing. The most successful 
distraction I use is “The Simpsons”, which has appeal across a wide age-
range, but does not tend to cause laughing due to minimal visual humour. 
 Regular tidal breathing – simple commands can be given during testing to 
encourage even breathing and maintaining a seal around the mouthpiece. I 
observed that too many commands could disrupt tidal breathing by causing 
confusion. 
 Poor flow past detachment - this invalidated many early washouts I 
conducted. When teaching others to perform MBW, this has always been the 
area requiring most attention. Initial confidence eroded when washouts had to 
be discarded. The most common error was detaching the flow-past late in 





 Preparing children too much for the detachment by taking too long or talking, 
can cause deep breaths or pauses as they expect the change. I found that a 
swift timed detachment with no verbal instruction was best. Occasionally, 
children came off the machine at this point thinking the test was over. This 




Multiple Breath Washout is designed to generate data for analysis of airway gas 
mixing. Key components of the technique – tidal breathing and inert gas washout 
from equilibrium to pre-defined end-point – are carefully standardised so analysis 
reveals predictable outcomes, comparable with other studies in other research 
centres. 
This section describes the most common measurements obtained from this technique. 
There is also a description of the analysis process, and alterations made to this in this 
department to improve reproducibility. 
Functional residual capacity 
Functional Residual Capacity (FRC) is a lung volume measurement, obtained from 
inert gas washout analysis. While this is not a measure of ventilation heterogeneity, it 
can be used clinically and is the basis for calculating gas mixing indices. 
In physiological measurements, the lungs are divided into functional compartments. 
This reflects normal circumstances, where full lung capacity is reserved for increased 
respiratory demand, and the lungs do not completely empty with each breath, leaving 
a Functional Residual Capacity (FRC). The FRC is therefore defined as the volume 


















FRC is important, as a standardised measure of lung volume. The gas dilution 
method of assessing FRC may differ from plethysmographic measurements due to 
complete obstruction in some regions will prevent any gas filling in that area. 
Nevertheless, this measurement is important as a basic consistent volume on which 
to base gas-mixing measurements. 
FRC is calculated from the Fick diffusion principle, that (concentration x volume) in 
one compartment is equal to (concentration x volume) when moved to another 
compartment.  
The total amount of gas within the FRC at equilibrium is equal to the (FRC x 
concentration) at the start. The total amount of gas at the end of the washout is equal 
to total amount breathed out, plus the (FRC x concentration) at the end. 
Concentration is continually measured, but the end-tidal concentration of each breath 
represents the concentration within the FRC. 
  
Figure 14 - standard function lung volumes 
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This is a simplified equation used to measure a complex airway tree. Especially in 
disease, it is unlikely that gas concentration is uniform throughout the lungs. The 
end-tidal concentration, measured at the lips, is used as an appropriate measure of 
alveolar gas concentration. 
This calculation also assumes the FRC is constant throughout the test. Calculated 
FRC rises initially with each breath, reaching an asymptote as volumes involved 
increase, reducing error. It is therefore assumed the FRC is more accurate with each 
successive breath. If tidal volume increased, for example, during the test, this may 
reduce the estimated FRC, introducing error into the equation that would not easily 
be detected. Changes within the airways (e.g. mucous clearance due to cough) may 
also alter FRC during the measurement. 
Other techniques use Nitrogen and Helium to calculate FRC. Nitrogen is produced 
from the bloodstream and must be accounted for in the equation. Helium is 
extremely prone to leaks and can result in under-estimation of FRC in prolonged 
washouts. SF6 is completely inert, synthetic and not so prone to leaks, making it ideal 
for prolonged washouts. 
6 init%




total amount SF  (L) at start = FRC  C
total amount SF (L) at end   = V  + (C   FRC)
FRC x C  = V + (C   FRC)
V  = (FRC  C ) - (FRC  C )










Functional Residual Capacity (FRC), Concentration at start of washout (C ), 
Concentration at end of washout (C ), Cumulative volume SF6 expired (V ).
All volumes in litres (L)
V
 
C  - C
Figure 15 - Derived calculation of multiple breath washout FRC 
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Finally, FRC calculated by gas dilution only measures volume connected with the 
airways. Any volume completely obstructed during tidal breathing is not measured. 
There is a documented disparity between gas dilution and plethysmographic FRCs in 
all age groups(Stocks and Quanjer 1995). 
Lung clearance index 
Lung clearance index (LCI) is the most widely used measure of ventilation 
heterogeneity derived from MBW, mainly due to the relative intuitiveness to 
researchers and subjects.  
LCI is defined as: 
 
The number of resting FRC turnovers (TO) required to wash out SF6, 
with tidal breathing, from equilibrium to the pre-defined end-point. 
 
LCI is therefore calculated from the total volume of air breathed out (cumulative 
expired volume, CEV) during the washout, divided by the FRC, measured at the 
same time by gas dilution. The end of the test is conventionally when the end-tidal 
(“alveolar”) concentration reaches 1/40
th
 of the initial concentration(Beydon et al. 
2007). In the case of washouts using Innocor, 0.2% SF6 is washed out until the end-
tidal concentration has fallen to 0.005%.  
 
Cumulative Expired Volume (CEV)
Lung Clearance Index (LCI) = 
Functional Residual Capacity (FRC)  
 
If a normal lung uses tidal breathing to wash out a gas such as SF6, it will take a 
certain number of breaths as the lungs do not completely empty with each breath and 
mixing of gas takes place. What can also be seen from studies in healthy volunteers 
is that it takes roughly the same number of FRC turnovers (TO) to wash the gas out 
whatever the age or size of the subject(Aurora et al. 2005b). Therefore, there is a 
very similar range of normal in all published studies using the same gas. The 
measurement is automatically standardised for lung size, because the denominator in 
the equation is FRC. In disease, LCI increases as a larger number of lung turnovers 
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are required to wash out the gas. As discussed above, this is thought to relate to the 
degree of heterogeneity between parallel lung units. 
LCI is therefore an intuitive, simple measure of overall heterogeneity. A number of 
groups have shown a narrow range of normal that does not change with 
age(Gustafsson et al. 2003a). This is unusual for most physiological tests and may 
increase its application in tracking disease states (e.g. CF) throughout life. The 
concept of the measurement is simple to explain to children and adults, making it 
potentially suitable as a repeatable clinical measurement. 
Multiple cross-section clinical studies, published in the past 10 years, have 
demonstrated increased LCI in patients with cystic fibrosis compared with controls in 
infants from 10 weeks of age up to adulthood(Gustafsson et al. 2003c, Gustafsson et 
al. 2003a, Aurora et al. 2004, A. R. Horsley et al. 2008). Furthermore, these studies 
demonstrated that LCI appears to be more able to detect CF lung disease in children 
and adults than standard lung function (FEV1).  
Only one large study has performed longitudinal LCI measurements(Kraemer et al. 
2005). This showed that LCI deteriorated earlier than FEV1 and other standard 
measures in children aged as young as 6 years old. LCI was also able to discriminate 
between those with and without lower airway Pseudomonas Aeruginosa colonisation. 
Further longitudinal studies are required in children with CF, especially infants 
newly diagnosed by newborn screening. It remains to be seen whether LCI, an 
alternative measure of CF lung disease, is able to track lung disease to allow 
assessment of therapeutic interventions. 
LCI has also been measured in children with asthma. Gustafsson demonstrated that 
LCI was raised in a group of moderately severe asthmatic children, compared with 
healthy controls. LCI in children with asthma is discussed in detail in chapter 4. 
Assumptions and limitations 
LCI is considered to be a measure of global ventilation heterogeneity. However, it is 
not possible from LCI alone to determine at which functional level the heterogeneity 
occurs. LCI is often assumed to be able to detect disease in the small, as opposed to 
medium-sized or large, airways, however this has not been proven. As gas mixing 
takes place in small airways, LCI may be affected by heterogeneity at this level, 
however it could also be that small differences between large units of lung (medium 
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airway branch-points) induce the same pattern of prolonged washout. It is therefore 
inaccurate to state that LCI is a measure of small airway disease. 
LCI measurements assume a constant FRC during testing. Increasing tidal volume, 
for example, will reduce the FRC. As the denominator in the equation is FRC, LCI 
may be artificially raised. Alternatively, larger breaths may actually improve gas 
mixing. It is therefore ideal to maintain as consistent a tidal volume as possible, 
while encouraging relaxed breathing. Average tidal volume and number of breaths 
required to washout are important additional data used to detect reasons for high 
variability or changes between measurements. 
As stated for FRC, LCI does not measure lung regions with little or no gas exchange. 
It is feasible that advanced disease or acute deterioration may cause loss of a section 
of the airway tree. If this region was previously poorly ventilated, there may be a 
paradoxical reduction (improvement) in LCI. Similarly, if acute treatment to improve 
lung function and airway recruitment opens a previously unventilated region, LCI 
may increase (worsen) as this previously unused are is now involved in gas mixing. 
This is an important limitation in our understanding. More clinical studies are needed 
to understand how acute interventions alter gas mixing efficiency. Clinical studies in 
children with asthma and cystic fibrosis, conducted for this thesis, are discussed in 
later chapters.  
 
There is a lack of published longitudinal LCI data in large cohorts. This would 
enable correlation with other measures of disease to understand better the clinical 
significance of increased ventilation heterogeneity. This paucity of data is mainly 
due to a lack of commercially available equipment. There is currently one device 
licensed to perform MBW in all ages. Other devices (including Innocor) have 
advantages and disadvantages but are not widely available without experienced 
technical support. The main aim of this thesis is to validate Innocor for use in 
younger age groups, thus increasing its appeal for large, longitudinal cohort studies. 
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Phase III slope analysis 
Analysis of Phase III (alveolar portion) of each breath has been studied for the past 
50 years(Verbanck et al. 1998, Crawford et al. 1985, Engel 1985). Interest stemmed 
from observations in single breath tests of the sloping alveolar plateau in lung disease 
compared with a stable alveolar concentration in healthy controls. During tidal 
multiple breath washout, the Phase III slope can be seen to steepen in those with 
prolonged washouts, especially cystic fibrosis. Phase III slope analysis seeks to 
quantify this phenomenon and, based on detailed lung model studies, assign changes 
in alveolar slope to distinct functional lung regions. 
Each stage of phase III slope analysis is described, followed by an explanation of the 
resulting ventilation heterogeneity indices. 
  
1. Phase III slope - SIII 
The output of a washout test consists of a gas concentration signal and flow meter 
readings. During each breath, the numerical change in concentration over the 
alveolar phase against volume expired is the Phase III slope. This slope (SIII) is 
measured for every expired breath. An example of numerical slopes plotted against 
time (breath number), taken from a 5 year old healthy control, is shown in Figure 16. 
It is clear from the graph that the phase III slope (absolute change in concentration) 
of each breath falls as the gas is washed out, due to the falling gas concentration. 
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Phase III slope by breath number




























Figure 16 - Plot of breath number vs. phase III slope value. With each breath, phase III slope 
naturally decreases with falling gas concentration 
 
2. Normalised Phase III slope - SnIII against lung turnover 
To allow comparison of slopes over the whole washout, the concentration is 
“normalised” against the mean concentration of the slope of that breath. This 
normalised slope (SnIII) can be compared against breath number, but is normally 
compared against cumulative number of “FRCs” expired - lung turnover. This 
modification allows comparison of the concentration normalised slope against 
different sized subjects with naturally different breath number and washout time 
based on their lung size. The graph below illustrates the plot of the same normal 
washout with the above refinements. The plot of the normalised slope in this patient 
allows comparison of slope values throughout the washout. There is a trend towards 
increasing normalised slope in this patient as the washout progresses. 
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Normalise slope by lung turnover




































Figure 17 - Lung volume turnover (expired volume /FRC) vs. normalised phase III slope. Effect 
of normalisation of phase III slope shows upwards progression as the washout proceeds. 
 
3. SnIII normalised for tidal volume 
Early clinical studies in phase III slope analyses were conducted with adult subjects. 
To simplify comparisons between subjects they were carefully limited to washing out 
gas with 1-litre breaths. This is a large but comfortable volume for most adults even 
with moderate lung disease. The advantage in performing washouts to this standard 
is that a litre is a constant proportion of the FRC and is plotted more easily. Also, 
change in concentration against change in volume does not vary and therefore is 
automatically normalised. 
While a litre is a comfortable volume in most adults, this standard is not possible in 
children and infants. Aurora described the alteration of SnIII analysis to account for 
this(Aurora et al. 2005b). He described a non-linear relationship between expired 
volume and SnIII of the first breath. Multiplying the SnIII of the first breath by the 
tidal volume of that breath removed the relationship. Following tidal volume 
correction calculations became age-independent from 2 to16 yrs. The explanation for 
this may be that different time constants exist in different sized lungs i.e. in smaller 
lungs, a larger proportion of alveolar gas is expired earlier in the breath as lung 
volume increases. The article does not make this clear.  
78 
Performing the 3-stage method above, the overall tidal volume-normalised SnIII is 
plotted against lung turnover over the washout. This, in itself, does not quantify 
ventilation heterogeneity. Further analysis allows washout abnormalities (rising 
phase III slope) to be localised to functional and anatomical regions. 
 
Diffusive- and Convective-Dependent Inhomogeneity 
Based on experimental models, Engel and Paiva described a series of processes that 
interact within the small airways(Engel 1985). As previously described, gas is 
conducted down airways to the gas exchange zone, at which point convection of gas 
(bulk flow) diminishes, to be replaced by molecular diffusion. There is a zone of 
overlap where both processes occur simultaneously, the so-called 
convection/diffusion front, which occurs at or around the entrance to the acinus. 
To attempt to explain the phenomenon of the sloping alveolar plateau originating 
from gas within the acinus, as seen in cadaveric modelling studies, Paiva then 
conducted theoretical mathematical modelling studies to simulate gas mixing in a 
convenient single-branch model. This model shows two trumpets, representing the 
vastly widening overall airway cross-sectional area beyond any one branch at this 
level(Engel 1985). Disease creates asymmetry between parallel units, represented by 












Figure 18 - diagram of 2-trumpet model (adapted from Engel et al
95
), representing a single 
airway branch point, and exponential increase of overall cross-sectional area in subsequent 
branches in the gas exchange zone18. This model demonstrates asymmetry of volume in disease. 
The yellow dots represent gas molecules (relative concentration) 
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When considering gas exchange during multiple breath washout of gas, Paiva 
simulated the relative contributions of convection, diffusion, relative unit volume and 
concentration gradients. At the convection-diffusion front, the interaction of these 
factors explains the rising alveolar slope in asymmetrical lung units. This is termed 
diffusion- and convection-dependent inhomogeneity (DCDI). 
During a multiple breath washout test, there is theoretically complete equilibration of 
gas within all units. As the washout commences, the following processes take place 
in the 2-trumpet model according to Paiva’s modelling. The points below refer to 
Figure 19. 
 
1. Fresh air is inspired and passes by convection to the convection-diffusion 
front. In units of asymmetrical volume, these fronts are at different levels 
indicated by areas of blue shading.  
2. The smaller unit is better ventilated, and gas dilutes more readily, because 
fresh gas has less distance to diffuse. This creates a concentration gradient 
between the parallel units at the end of inspiration. 
3. As expiration commences, the concentration expired is lower than the mean 
concentration because initially gas molecules travel from the larger unit to the 
smaller down the concentration gradient. Only at the end of the breath does 
the concentration rise. This generates a 2-phase concentration change 
(indicated by the volume concentration graph at breath 1). With contributions 
from multiple units there is an alveolar slope at the first breath. 
4. This back-diffusion of gas from larger to smaller unit is opposed by relatively 
larger convective flow out of the larger unit so that the concentration gradient 
remains between the units. 
5. As the next inspiration commences the better ventilation of the smaller unit 
again results in an amplified concentration gradient at the start of expiration, 
leading to a larger change in concentration over the breath. This is seen as a 
steeper alveolar slope at breath 2, represented by the respective volume 
concentration graph. 
6. In subsequent breaths the process continues, but any increased concentration 
gradient is balanced by the decrease in concentration difference between 
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inspired and resident gas as the alveoli are washed out. This is eventually 
balanced by breath 3 or 4 so that the concentration slope still exists but does 
not increase further. A “steady state” exists between inter-unit interactions 
and progressive dilution of gas by inspired breaths(Crawford et al. 1985). 
 
To summarise, the increasing alveolar slope with subsequent breaths, seen during 
multiple breath washout of gas, is contributed to by interactions between parallel 
lung units at the convection-diffusion front (DCDI). After the steady state is reached, 
no further rise is seen and the slope remains constant with subsequent breaths.  
Figure 19 summarises this process. The small volume concentration curves for each 
breath indicate the result from only 2 parallel units. This step change is not seen 
when multiple units of different heterogeneities contribute to the expired breath. At 
the lips, multiple units generate the characteristic alveolar slope. 
 







The rising alveolar plateau seen in disease states during multiple breath washout also 
has a contribution from asymmetry of ventilation between parallel units within 
convection dependent lung regions. Rather than being due to interactions between 
units, as in DCDI, this is due to sequencing of emptying. 
Engel described the behaviour of gas as it is washes out of a simplified 2-
compartment model(Engel 1985). As in the trumpet model above, this represents 2 
parallel units, which could be at any level within the conducting airway region. This 
model is illustrated below (Figure 20), and indicates the simplified concentration 
change seen at the bifurcation of a single airway. The step-change shown is not seen 
at the mouth as multiple units contribute to an overall sloping concentration change 
over each breath. 
 
 
Figure 20 - Convection dependent inhomogeneity shown by sequential emptying of "fast" and 
"slow" lung units 
 
In a completely homogeneous system, gas is distributed and washed out evenly 
between two parallel units as the washout commences. In that situation, the alveolar 
portion will be flat with each breath. If there is a poorly ventilated unit, the 
concentration will remain higher than the well-ventilated one. This poorly ventilated 
unit, which empties later in the breath, will increase the concentration at the end of 
the alveolar slope. This sequencing of parallel units progresses throughout the 
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washout depending on the degree of asymmetry. The conductive contribution to the 
alveolar slope becomes greater as the concentration difference between well and 
poorly ventilated units increases. This progression of the alveolar slope is termed 
convection dependent inhomogeneity (CDI).  
 
Sacin and Scond 
Verbanck et al applied DCDI and CDI concepts to measurement of disease(Verbanck 
et al. 1998, Verbanck et al. 1997). These authors hypothesised that DCDI and CDI 
measurements could be considered independent measurements corresponding to 
airway abnormalities within specific anatomical lung regions. Because the 
convection-diffusion front is thought to be situated at, or near, to the entry to the 
acinus, DCDI was renamed Sacin, or slope progression corresponding to 
inhomogeneity in the acinar region. Similarly, CDI is a measure of inhomogeneity in 
the conductive airways, where convection primarily takes place. This was therefore 
renamed Scond.  
Scond and Sacin are calculated in the following way(Verbanck et al. 1997): 
 Conductive zone inhomogeneity (Scond) contributes to progression of the 
phase III slope throughout the washout.  
 Acinar zone inhomogeneity (Sacin) contributes to progression of the phase III 
slope only in the first 3-4 breaths. 
 The progression of the normalised slope between lung turnover 1.5 – 6 is 
considered to be purely Scond.  
 Sacin is standardised as being the slope of the first breath minus the back-
extrapolated Scond contribution (i.e. Scond x the turnover number of the first 
breath). 
 
Performing multiple breath washout of nitrogen with 100% oxygen, Verbanck et al 
demonstrated a significant increase in CDI (Scond) following histamine provocation 
in both those who had a significant drop in FEV1 and in those who did not. DCDI 
(Sacin), however, did not increase(Verbanck et al. 1997). In another study, Phase III 
slope analysis was performed in patients with Chronic Obstructive Pulmonary 
Disease (COPD). Increased Sacin was linked to measurement of acinar function (e.g. 
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diffusion capacity) and Scond was linked to measurement of conductive airway 
function (specific airway conductance, SGaw)(Verbanck et al. 1998).  
The following example from a key publication(Verbanck et al. 1999) illustrates the 
effect of disease on Scond and Sacin (Figure 21). 
 
Figure 21 - This shows previously published normalised phase III slope values by Verbanck et 
al, averaged over three washouts, from three patients with different respiratory status. The 
dotted line indicates how Scond and Sacin¬ are derived. There is some progression of the slope 
in the healthy control patient, but the asthmatic patient shows an increased progression over 
turnover 1.5 -6 (increased Scond) but a similar Sacin (minus the Scond component of the first 
breath). The patient with COPD, however, shows both a greatly increased offset of the first 




Figure 21 - This shows previously published normalised phase III slope values by Verbanck et 
al, averaged over three washouts, from three patients with different respiratory status. The 
dotted line indicates how Scond and Sacin¬ are derived. There is some progression of the slope 
in the healthy control patient, but the asthmatic patient shows an increased progression over 
turnover 1.5 -6 (increased Scond) but a similar Sacin (minus the Scond component of the first 
breath). The patient with COPD, however, shows both a greatly increased offset of the first 
breath (Sacin) and increased progression over TO1.5-6 (Scond). 
 
Scond and Sacin have also been measured in cystic fibrosis. It is thought that cystic 
fibrosis originates in the small conducting airways, rather than the alveoli or 
proximal airways(Mall et al. 2006). Gustafsson measured Scond and Sacin in 
children (>6 years old) and adults with cystic fibrosis. He showed they were both 
increased compared with healthy controls, indicating involvement throughout the 
airways(Gustafsson 2007). Similarly, Horsley et al published Scond and Sacin 
measurements, performed in our research department, in children (aged >4 years) 
and adults with CF(Alex R. Horsley et al. 2008). Both Scond and Sacin were 
significantly higher in CF patients compared with an age-matched healthy control 
population.  
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These studies may indicate that phase III slope indices are able to discriminate 
between inhomogeneity in the distal gas exchange zone and the more proximal 
conducting airways.  
 
Limitations to Sacin and Scond. 
There are a number of published limitations to the use of Sacin  and Scond. These 
measurements originate from experimental inhomogeneous models, indicating that 
the behaviour of gas during washout can be applied to humans in health and disease, 
with abnormalities in measurements linked to specific anatomical regions.  
Original studies conducted measurements in adults breathing 1-litre volumes with 
strict tidal volume feedback. As previously stated, this is not possible in children, 
leading to the development of tidal volume correction of Phase III slopes(Aurora et 
al. 2005b). Horsley et al also found that 1-litre breaths were difficult for adults with 
moderately to severe CF, inducing bouts of coughing(Alex R. Horsley et al. 2008). 
Tidal volume correction may eliminate the relationship between breath volume and 
Phase III slope over the whole washout, however, the breathing pattern in infants and 
young children can be highly variable(Aurora et al. 2005b). It was highlighted by 
Aurora et al that it has not been shown how Phase III slope indices are affected by 
changes of tidal volume and FRC during the measurement. There is a need for future 
research in this area(Aurora et al. 2005b). 
The assumptions of SnIII indices are that they relate to the stated anatomical regions 
in all situations. It has not been shown whether abnormalities in Sacin seen in patients 
with CF are truly due to acinar inhomogeneity or whether widespread severe airway 
obstruction and structural changes alters the location of the convection-diffusion 
front. 
Scond is calculated from the progression of the Phase III slope, normalised for 
concentration through the early-mid portion of the washout. The mathematical 
alterations to the measurement mean the volume-concentration plot always rises to 
the equivalent of 1 over phase III. The alveolar slope is always preceded by phase I 
and II, meaning there is a maximum possible numerical rise over Phase III. This was 
demonstrated previously by Paiva when describing convection-dependent 
inhomogeneity(Paiva 1975), and confirmed by Horsley et al, who also showed this in 
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adults with moderate to severe CF. The value of Scond reached an asymptote of 
approximately 0.15 with increasing ventilation heterogeneity (LCI)(Alex R. Horsley 
et al. 2008). This had not been clinically demonstrated previously, presumably 
because patients with such severe ventilation heterogeneity had never been tested 
before. There was no linear rise in Scond with advancing lung disease, preventing 
significant correlations being made with other lung function measurements and 
reducing the applicability of Scond in advanced CF lung disease. 
Finally, early experiments compared diffusion of gas in the small airways with gases 
of different densities and diffusivities. It is clear that the values of Scond and Sacin 
may be affected by the different gases and concentrations used between centres,. 
Early studies with nitrogen washouts can not necessarily be compared with SF6. 
Furthermore, different washin concentrations of Sf6 are used by different devices 
(0.2% vs. 4%). The effect of gas diffusivity and concentration may prevent wider use 
of Phase III slope analysis. 
Phase III measurements are technically more complicated and less intuitive than LCI. 
They rely more on controlled even breathing; changes in respiratory rate or volume 
may invalidate results. As described below, data analysis is not standardised, making 
comparisons between research departments difficult. However, the underlying 
principles are potentially important for determining the effect of disease and 




Washout analysis procedure 
Initial analysis of MBW performed with Innocor is done using custom-built offline 
software. This was provided by Professor Per Gustafsson (Goteborg, Sweden). The 
programme is adapted from that used for the mass spectrometer device. Prof 
Gustafsson devises the breath-capture algorithms, with programming done in 
collaboration with Eddie Bergsten, software engineer. This software is available to 
us, with occasional updates to improve performance and ease of use. This section 
describes the software, the analysis procedure and a reciprocal analysis experiment 
performed amongst three researchers. This was to confirm the suitability of our data 
processing standard operating procedure used in a multi-site study. There is also 
discussion of problems encountered during analysis that affect washout accuracy. 
The Innocor device performs no internal analysis. Therefore raw data must all be 
analysed offline. The two elements of breath-by-breath washout analysis are flow 
signal, from which volume is derived, and concentration signal, from which gas 





The washout analysis software was written with testpoint programming software 
(Measurement Computing Corporation, www.measurementcomputing.com). The 
screenshot below shows the layout of the analysis screen. 
 
Figure 22 - Screenshot of washout software 
 
A standard operating procedure (v1.2) has been developed by me with Alex Horsley 
and Clare Saunders (respiratory physiologist, UKCFGTC, London). To ensure 
results generated for a multi-site clinical study were comparable, this SOP deals with 
basic data analysis but also provides guidance for difficult washouts:  
1. The exported Innocor raw data files (.ino) must be altered to select only time, 
flow and gas concentration. A programme produced by Innovision (Innofile 
converter) allows selection of these data, and conversion to a basic text file 
(tab separated values). 
2. This text file is selected using the file button on the Washout screen, loading 
the flow and concentration traces. 
3. The subject name and results filename is entered. 
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4. The flow gas delay value is measured and recorded at calibration, to align the 
flow and concentration signals. 
5. Re-inspired gas can be incorporated into the analysis if required by selecting 
the relevant box (see technical adaptations chapter). 
A sample test is shown here, with the obvious switch to washout (Figure 23). 
 
Figure 23 - end of washin, with switch to washout 
  
6. The portion of the file of interest is the washout. Crop start and end are 
adjusted to focus on this portion. 
7. The flow level to trigger a breath detection can be altered to take into account 
low flows (e.g. infants) or washouts with long breath pauses and small flow 
fluctuations that are not breaths. This adjustment is visual, rather than 
numerical, introducing a degree of subjectivity. 
8. In “settings” the point which the end-tidal concentration is determined can be 
set. Conventionally, we measure from 15 sample points (150ms) back from 
the end of the breath, over an average of 15 sample points. This is reduced in 
younger subjects with shorter breaths. Counting 15 breaths back as also only 
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necessary in the Innocor system as the rising gas signal is speeded. This 
speeding alteration means the end of the breath includes part of the falling gas 
concentration. Counting back prevents underestimation of the end tidal 
concentration. 
9. Once the trace is cropped to include only the washout, the “next” button 
advances one breath at a time. The first breath to be included in the analysis 
is the first expiration after the detachment of SF6, circled below, and 
magnified in the following screen. 
 




Figure 25 – analysis screen showing semi-automated breath capture. 
 
10. It can be seen that the software is capturing inspiratory and expiratory phases 
with 4 points (4 sliders, “Insp-end” and “Exp-start” overlapped). These points 
are defined by a change in flow beyond a pre-determined threshold. As there 
are frequent small fluctuations in flow at the end of breaths, the software 
must determine a minimum flow rate that generates the start or end of a 
breath phase. It is important that the full breath is captured therefore manual 
adjustment of the threshold points is achieved by adjusting the sliders. The 
two numbers underneath each slider are the sample number and flow value. 
11. Once the first breath is identified, the “init value” button is pressed to instruct 
the software to store values and calculate results. 
12. “Next” is pressed repeatedly to capture each breath of the washout. The end 
point (End%) is calculated from 1/40
th
 of the initial value (Init%). Cet% 
refers to the end-tidal concentration. 
13. Each breath is shown in a volume concentration graph. This is used to ensure 
only a single complete breath has been captured, and to aid accurate Phase III 
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slope measurement. It is conventional that the alveolar slope should be 
measured from 65-95% of the maximum concentration of that breath. At low 
concentrations and smaller breaths this may need to be adjusted to visually 
cover the phase III portion. 
14. Once the end tidal concentration is reached, the washout is complete. The 
“results” button is pressed and values are displayed (Figure 26).  
 
Figure 26 – “results” screen after washout analysis. 
 
15. The results of interest are FRC(L) and LCI. These are stored in a results file 
but can be viewed here to ensure consistent results are achieved over three 
washouts. 
 
This procedure is semi-automated, in that breaths are identified according to an 
internal algorithm and washout values calculated and stored. However, because of 
frequent difficulties in washout analysis it is not appropriate to have a completely 
automated programme. The difficulties encountered during washout analysis are 
described later. 
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Once analysis is completed, raw washout measurements require correction for 
equipment dead space and Body Temperature, Pressure, Saturated (BTPS) 
conditions. This is done by adjusting the calculated volumes from the results in a 
spreadsheet. A full description of BTPS correction is given below.  
Analysis development 
Software updates 
Washout analysis software is custom designed and alterations are made by Per 
Gustafsson and Eddie Bergsten, based on our recommendations. Each update has 
allowed greater ease of use in washout analysis, especially in difficult cases. Version 
080415 was specifically developed for infant washouts, allowing adjustment of 
breath detection thresholds. Previous versions detected a breath phase with a fixed 
change in flow beyond zero. As infant flow rates are much lower, often no breaths 
were detected. Ver. 080415 is also able to magnify the flow display. This is a major 
improvement allowing closer infant and adult washout inspection.  
Protocol development 
When analysing washouts it became clear to us (those developing analysis SOP) that 
certain important issues must be addressed for studies in large numbers of subjects 
and those with prolonged washout periods (e.g. well-established CF lung disease). 
Due to the impending CF Gene Therapy Consortium clinical studies, a protocol was 
developed as follows. 
 
1. SF6 washin concentration and starting alveolar gas concentration. 
FRC calculation depends on the difference between starting- and end- alveolar SF6 
concentrations. It can be difficult to completely wash in SF6 to very inhomogeneous 
lungs and minor fluctuations are expected at equilibrium. The difference between 
inspired and expired concentration at equilibrium should be less than 2% (absolute 
change of +/- 0.004%). Even when achieving this, the concentration can drop slightly 
just before detaching so it is important that the true alveolar starting concentration 




2. End of Washout 
The end of the washout is defined as the breath where the end-tidal SF6 concentration 
(Cet%) is washed out to 1/40
th
 of the starting concentration. Clearly, this point will 
probably occur between two breaths. The agreed protocol was to save the 1
st
 breath 
where the Cet% was below 1/40
th
 and end the analysis if the next one is also below 
this value. It was important to realise that in prolonged washouts, the concentration 
can fluctuate around the 1/40
th
 point meaning a number of borderline Cet breaths 
may need to be saved before the end of the washout. Furthermore, small “breaths”, 
caused by swallows or coughs near the end of the washout may prematurely end the 
analysis. Therefore, a minimum breath volume was chosen to end the washout, based 
on calculations by Aurora et al(Aurora et al. 2005b). Those less than 0.4L (8ml/kg in 
children) was chosen as the minimum volume required to count the end-tidal 
concentration at the end of a washout, based on the expected airway and equipment 
dead space. 
 
3. Interruptions to flow 
Volume of expired gas, calculated by integrating flow and gas concentration, can be 
affected by interruptions to flow.  
a. Innocor flow meter re-zeroing. 
The Innocor internal flow meter (as with all Pneumotach pressure transducers) 
converts a pressure signal, converting this to flow based on calibration. Small 
calibration inaccuracies lead to drift in flow over time. Innocor overcomes this 
problem by having a timed reset at regular intervals. This interval can be altered prior 
to testing, but if it occurs during the washout, 1 second of 100ml/sec is inserted in the 
data. The SOP deals with this by ignoring the reset portion, and including as much of 
the breath as possible. The re-zero can also be “flattened” by inserting an average 
flow reading in the raw data file following testing. Either solution is a compromise, 






b. Subject flow interruptions 
Relaxed regular tidal breathing is encouraged throughout the washout, however, 
subjects of all ages frequently exhibit pauses in the middle of, and between, breaths 
that confuse analysis. 
Brief flow pauses trigger the end tidal marker, whereas examination of the gas 
concentration reveals a rise in gas concentration as the breath continues. Prior to the 
beginning and after the end of a breath, brief spikes in flow are often seen. These do 
not represent breaths as there is no rise in gas concentration but the software may 
measure a small expired volume. If the breath is of very small volume (<50ml) or if 
there is no rise in concentration the breath should be skipped. An example of a 
washout with flow interruptions is shown towards the end of this chapter (Figure 30 
Figure 32). 
c. Mis-identification of expiration 
Pauses at the end of inspiration cause mild fluctuations in flow that may be 
interpreted as the start of a new breath. A feature of the software is that between 
breath phases, negative and positive flow is all counted as positive leading to a large 
measured expired volume prior to the true start of expiration. The expiratory start 
marker in this case must be moved to the true breath start. 
 
BTPS correction 
All reported lung volumes should be reported taking into account the changes that 
temperature, humidity and pressure make to gas volumes(Frey et al. 2000b). The 
principle behind this is that inspired gas at ambient pressure, temperature and 
humidity occupies a different volume in the lungs. Hence all volumes are corrected 
and reported at body temperature, pressure saturated (BTPS) conditions, rather than 
ambient conditions (ATP). Expired gas, while being almost at BTPS, tends to have a 
temperature of 30-35
o
C, and is 98% saturated.  
Correction of expired and inspired gas to BTPS is recognised as complicated and 
difficult to standardise. For the expired portion, the correction is small (2.6%, see 
below for equation). For the inspired portion during MBW, only the volume of gas re
‑inspired is of interest, not the full inspired breath. Gas is detected at the beginning 
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of inspiration, then the concentration is zero, as there is no SF6 in the ambient air. As 
inspired volumes are not of interest, only re-inspired gas, the correction would be for 
gas residing in the pneumotach at the end of expiration, gas that is still warmer than 
ambient, and still saturated. As time passes this gas within the pneumotach at the end 
of expiration is cooling and drying, therefore it is difficult to measure the humidity. It 
cannot be assumed to be ambient conditions. 
In addition, there is no need to correct volumes to BTPS when calculating LCI, as 
this is a ratio, and errors in volume are assumed to be proportionally equal on either 
side of the equation. Therefore, only the reported FRC should be corrected. 
 
The initial protocol in our department was derived by Alex Horsley, after discussion 
with other members of the research team.  
                            
         
              
 
 
                                      
 
This equation multiplies FRC proportional to the conversion of ambient air to 
expirate conditions, rather than BTPS. The equation derived was part of the official 
analysis protocol, but was found to have a flaw when looked at again by Dr Nick 
Bell, clinical research fellow at the Western General Hospital, Edinburgh. Dr Bell 
and I discussed a better way of deriving the correction, only correcting expired gas to 
BTPS conditions, ignoring ambient conditions as they do not contribute to the 
condition of expired gas. Nick Bell derived a new equation, converting expirate 
volume to BTPS: 
 
                                          
 
                                                     
 
BTPS volume correction is derived from the following equation: 




       
       
) 
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Where V2 is BTPS volume and V1 is the expirate volume. T2 is BTPS temperature 
(K) and T1 is expirate temperature (K). Pb is the ambient air pressure. Pwv1 is the 
partial pressure of water vapour, derived from a lookup table and dependent on the 
relative humidity of the expired gas. Pwv is the partial pressure of water of BTPS 
gas, at 100% humidity. 
This change in department protocol posed a difficult problem. As the clinical studies 
in chapters 4 and 5 had been completed, I decided not to repeat the analysis, bearing 
in mind the only affected measurement is FRC. LCI is not affected by BTPS 
corrections. Within each study, including others where older data was used, the same 
conversion equation was used. 
This represents an error in analysis, but not affecting the primary outcome of any of 
the studies. 
Intra-test repeatability 
Washout tests are performed 3 times, the mean value of acceptable washouts 
generating the result. The above analysis issues, as well as leaks and true 
physiological variability, can produce outlying unacceptable results. Published 
guidelines state that an FRC value should be discarded if it varies by more than 10% 
of both other values(Beydon et al. 2007). This standard is repeated in a later 
consensus paper (ERJ, in press). 10% is a figure agreed by experts in the field, not 
based on experimental evidence. There was some discussion when preparing the 
consensus statement about the appropriateness of performing 3 washouts when 2 
may suffice, given the time-consuming nature of the test. For the purposes of 
uniformity we performed 3 washouts in all subjects.  
In addition to control on FRC limits, if an LCI differs by more than 20% of both 
others values that washout should be discarded. This was agreed for our SOP, 
recognising that some washouts can be greatly prolonged because of a change in 
breathing pattern or physiological variability in advanced disease. Accidental 
deviation from washin or washout protocol can cause variability if washin is 
incomplete or washout is ended prematurely. This usually means the washout is 
discarded. 
98 
Finally, there may high variability between all 3 washouts despite visible technical 
accuracy. This exceptional situation may allow an average of all 3 still to be 
accepted. 
As will be seen in the subsequent chapters, the above variability rules result in 
discarding approximately 30% of washouts. In reality, while 3 washouts are 
performed, 2 is the minimum for analysis. There is no clear evidence base behind 
discarding washouts based purely on variability. In the absence of this evidence the 
current agreed standards are the only way to compare data across different centres. 
Future studies may provide a better way to decide on washout acceptability. 
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Reciprocal data analysis  
The results of the following study were presented in the form of an electronic poster 
at the European Respiratory Society International Conference 2007(Macleod et al. 
2007). The first 3 authors (Macleod, Horsley, Saunders) were involved in conception 
and execution of the study. 
Background 
The explanation of data analysis procedure and standardisation protocols is important 
if results performed between sites, by different researchers, can be compared(Stocks 
et al. 2000). In preparation for planned multi-site clinical studies (CFGTC) using the 
Innocor device to perform MBW measurements in patients with Cystic Fibrosis, and 
standard operating procedure was developed and tested to ensure inter-site 
consistency.  
To validate the above standards, this experiment compared analysis of washouts 
across the 3 sites in question. Subjects with moderate to severe respiratory disease 
were selected as most likely to have prolonged and complex washouts and multiple 
examples of flow disruptions from patients.  
Aims 
To assess agreement of the standardised data analysis protocol, minimising variance 
during multi-site studies. 
Methods 
To compare results using the standardised analysis protocol, data were selected from 
washouts performed by 3 different researchers in a selection of subjects with CF 
from 3 respective study sites (Royal Brompton Hospital, London; Western General 
Hospital, Edinburgh; Royal Hospital for Sick Children, Edinburgh). Three washouts 
were selected from each subject, attending on one occasion as part of a separate 
clinical study; one which involved patients with CF attending on three separate 
occasions at the time of a respiratory exacerbation. All patients attended prior to 
starting and immediately following antibiotic therapy, with one more visit 2-5 weeks 
after completing antibiotics.  
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All washouts, performed in triplicate at each visit, were analysed independently by 
three researchers. Researchers are numbered 1,2 and 3. Mean results were calculated 
from three acceptable washouts independently by each researcher, with acceptability 
defined as in the above detailed methods explanation. Washouts were discarded 
where FRC differed by more than 10%, or the LCI differed by more than 20%, of 
both other washouts. 
Washout results were analysed by calculating mean differences and 95% limits of 
agreement of FRC and LCI measurements between centres in pairs(Bland and 
Altman 1986). Bland Altman Plots were constructed to identify error between 
researchers in pairs. Analysis of variation compared mean values between three 
centres together. A p-value less than 0.05 is considered statistically significant.  
Analysis and graphical presentation was performed on Minitab statistical software 
(Minitab, USA). 
Results 
10 patients were selected, from 3 different sites. Nine completed all three visits and 
one completed only two visits. Twenty-nine washout triplicates were therefore 
available for analysis. One triplicate was deemed unsuitable for analysis as we were 
unable to select at least two washouts within 10% of each other.  
 



















[12 – 43] 
Mean (SD)FEV1 %predicted 
[range] 
52.99 (14.01) 
[37.8 – 86.8] 
Mean (SD) FRC 
[range] 
2.24 (0.50) 
[1.66 – 3.35] 
Mean (SD) LCI 
[range] 
14.17 (1.07) 
[10.13 – 18.02] 
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Table 4 - Basic patient demographics 
 
Boxplots below (Figure 27) show the similarity of FRC and LCI measurements 










Comparing pairs of researchers in turn, the mean differences in FRC and LCI are 
shown in  
Table 5. The maximum difference in mean FRC was 330ml (12% of the mean 
value). The maximum difference in LCI was 0.99 (6.6% of the mean value).  
  
  
site 1 vs. site 2 
mean difference  95% limits of agreement 
FRC (L) 0.004 (-0.17 - 0.18) 
LCI (cev/frc) -0.005 (-0.61 - 0.60) 
  
 
site 1 vs. site 3 
mean difference 95% limits of agreement 
FRC (L) 0.001 (-0.08 - 0.08) 
LCI (cev/frc) -0.041 (-0.76 - 0.68) 
  
 
site 2 vs. site 3 
mean difference 95% limits of agreement 
FRC (L) -0.003 (-0.15 - 0.15) 
LCI (cev/frc) -0.040 (-0.40 - 0.32) 
 
Figure 27 - comparison of mean FRC and LCI values calculated from 10 washout triplicates by 3 
researchers. Box shows median line, with interquartile ranges. 
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Table 5 - Mean differences and limits of agreements. Sites compared against each other in turn. 
 
To illustrate effect of magnitude of measurement (degree of abnormality) on 
difference between researchers, the following Bland-Altman plots were constructed 
(Figure 28Figure 29). These plot average measurement between 2 researchers for 
individual subjects against the mean of these 2 measurements. If the difference in 
measurements increases with higher or lower values, there may be a systematic bias. 




































Figure 28 - comparison of mean FRC measurements between researcher 
(site) pairs. Individual plots are the average of paired measurements 
against the difference. Mean bias and 95% limits of agreement are shown 





Figure 29 - comparison of mean LCI measurements between researcher 
(site) pairs. Individual plots are the average of paired measurements 
against the difference. Mean bias and 95% limits of agreement are shown 
by the horizontal lines 
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There was no evidence of overall systematic bias between researchers, although the 
95% limits of agreement for FRC measurement pairs were higher when comparing 
researcher 2. This is not consistent, however, as when comparing LCI values, limits 
of agreement are higher when comparing researcher 1.  
Comparing all 3 researchers by analysis of variation (ANOVA), there was no 
statistical difference (p>0.05). Importantly, this is not an adequate test for detecting 
differences between the same measurements performed by different researchers. It is 
included for completeness. 
Conclusion 
This small reciprocal study was designed to test a written MBW analysis protocol in 
preparation for a multi-centre observational study (see chapter 7). When comparing 
results of washouts in patients with CF, taken during a respiratory exacerbation, there 
was no evidence of systematic bias between researchers following the same protocol. 
While 95% limits of agreement were variable between researcher pairs, the 
differences in measurements were small. A maximum difference in FRC 
measurements of 300ml is rather high, but is an obvious outlier, looking at the 
Bland-Altman plot. 
The patients in question were difficult to test. During an exacerbation LCI is likely to 
be raised from the baseline(Horsley et al. 2007) and therefore the washout period is 
longer. Also, patients are less well, and are likely to cough more or to feel effects of 
breathing through a device if slightly short of breath. This results in more episodes of 
shallow breathing, pauses and aborted washouts. These washouts are challenging to 
analyse as decisions must be made about which breaths to include and which to 
discard when very small. Very shallow breathing does not ventilate beyond the 
anatomical dead space and therefore does not contribute to LCI, although the CEV 
rises. Examples of irregular breathing patterns are shown in Figure 30-Figure 32.  
106 
 
Figure 30 - Example of pause in breathing early in washout. This subject has paused during 
expiration, creating a spike with no gas washout. 
 
Figure 31 - Another example of erratic breathing shows a disrupted expiration and inspiration 
causing a small spike in gas concentration which is not a real breath 
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Figure 32 - This example shows very erratic breathing. Breaths are hard to capture accurately, 
leading to variability in defining the end of the washout. 
 
This study was an attempt to validate a written analysis protocol, and results indicate 
close correlation when washouts are analysed by different researchers. The 
researchers were blind to the others’ results until analysis was complete. In terms of 
equipment validation this is a strength of this study. It could be assumed that all 
researchers involved in writing a protocol will analyse the data in the same way, 
however this study shows that even with frequent erratic breathing and prolonged 
washouts the final results are very similar. 
The patients were selected from an existing cohort and non-randomly. These subjects 
are therefore not representative of a wider population. This does not compare results 
before and after use of the protocol, and there is no attempt to test the protocol in a 
new set of researchers. A weakness of this study is that the protocol was written 
based on local experience and understanding of the test. There is no published article 
that explicitly details how washouts should be analysed. Indeed, many existing 
articles are in younger populations where the problems of advanced lung disease, 
exacerbations and prolonged washouts are not present. It is hoped the pending 
European Respiratory Journal “state of the art” document, due to be published in late 
2012 will contain adequate detail to allow groups to analyse data in the same way. 
This will enable accurate comparisons between studies using different equipment and 
research personnel. 
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Learning points and contribution to thesis 
This study is important in validating the Innocor system. In proposing Innocor as a 
suitable MBW device for multi-centre studies, data analysis between researchers is 
crucial. In preparing for the CFGTC “run-in study” (chapter 7), we used this data 
sharing and reciprocal analysis strategy to harmonise our analysis protocol. This 
helps to ensure everyone involved in analysis is fully taught and increases confidence 
in multi-centre data. 
This study helped us as a research team to standardise the analysis protocol. As each 
step was discussed we were able to refine the technique and change parts that were 
not logical or sensible. In terms of this thesis, all the following chapters use the 
standardised protocol. The analysis protocol used by the CFGTC is under review, as 
automated software is now available. This changes many of the analysis steps, and 
allows swift comparison between different analysis methods. As this was only 
developed towards the end of this thesis, no automated software has been used in the 
thesis studies. 
Chapter conclusion 
This chapter has discussed the following topics: 
 Physiological basis behind MBW measurement 
 Differing method between devices 
 Innocor specifications and comparison with different systems 
 Innocor MBW equipment 
 Data analysis and MBW indices of lung disease 
 Standardisation of MBW analysis 
 
This chapter has described in detail the multiple breath washout technique and 
derived ventilation heterogeneity indices. This builds upon previously published 
work in other institutions, as well as work completed in this department. As many of 
the concepts have been newly developed following experience in new populations 
(i.e. children in health and disease), there are no definitive evidence-based guidelines 
to follow. It is therefore important to understand the underlying pulmonary 
physiology and the resulting effects of disease prior to conducting measurements in a 
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novel device such as Innocor. Experience with MBW using Innocor has led to 
publication of local data analysis guidelines. These take into account the difficulties 
associated with MBW measurement in challenging populations – children and those 
with advanced lung disease. Clinical studies published in this thesis use the above 
methods and guidelines to validate Innocor in paediatric populations. As mentioned 
above, BTPS proved to be a problematic standardisation. The change in the official 
departmental method for BTPS correction was partly due to an oversight, and also 
due to poor application of scientific principles. It is important to recognise again that 
the primary outcome (LCI) was not affected by BTPS correction. 
Development of a standardised method is important to be able to compare results 
between research sites. This method was successful in a comparison of washout 
analysis in adult CF patients between 3 researchers. Use of Innocor in a variety of 
clinical studies has highlighted areas of good performance, as well as limitations. 
Studies in novel population have also raised important questions about the 
physiological basis of standard washout indices in subjects with advanced lung 
disease. 
Particularly in the area of phase III slope analysis, only limited populations have 
been studied previously. Analysis in children and adults with moderately severe CF 
lung disease has introduced important questions about the underlying assumptions 
behind Scond and Sacin. This is a challenge to the wider research community and 
may stimulate important discussions, leading to improvements. The MBW technique 
is simple and the basic measurements are intuitive to subjects and researchers. 
Development of standardised equipment and analysis methods is less simple. 
Consideration of equipment specifications, BTPS correction, effect of lung disease 
on washout accuracy and data analysis standardisation is an important part of 
Innocor validation. When aiming to adapt and validate Innocor for use in younger 
children and infants, all of these considerations have been re-visited and are 
discussed in the next chapters. This continued validation has the aim of 
demonstrating accuracy and suitability of Innocor for use in younger children and 
infants. This is important because the increasing interest in detecting and tracking 





Chapter 3 - Introduction to clinical studies in older 
children 
Introduction 
The main aim of this thesis is validation of the Innocor device for use in children. At 
the beginning of this project, the Innocor device had already been adapted for use in 
adults and Alex Horsley, clinical research fellow for the UK CFGTC, was 
conducting some clinical studies. A small series of lung model experiments led by 
him showed that Innocor may be suitable for use in children as young as 5 years of 
age(A. R. Horsley et al. 2008).  
At the time of starting my project, no children (<17yrs) had performed Innocor 
washouts. Approximately 5 children performed MBW to establish suitability of 
equipment prior to commencing the studies in this thesis, however the data were not 
used. 
Clinical studies in age-specific healthy and disease populations allow comparison 
with other published data, and contribute to the understanding of lung physiology in 
airways disease. In terms of change in measureable lung function over time; many 
factors such as age, lung volume, disease progression, and physiological variability 
contribute to within-subject differences. LCI has the advantage of a stable reference 
range throughout life, and detecting change over time does not have to incorporate 
age and lung volume related factors.  
As described in the main introduction, a growing volume of evidence supports the 
use of MBW in paediatric research(Robinson et al. 2009b). Clinical studies using 
Innocor are compared to published data, with the aim of validating Innocor for use in 
this age-group. In addition, examining the sensitivity of LCI to airway changes – 
induced short-term effects and longitudinal change – allows us to hypothesise on the 
suitability of Innocor LCI to wider research and clinical practice. 
This introductory section aims to show how chapters 4 to 7 contribute to the larger 
topic of equipment validation. Whilst they are all clinical studies in their own rights, 
they also demonstrate a number of important validation principles, which will be 
summarised afterwards. The most basic over-arching question when considering 
equipment validation is: how accurately do Innocor MBW indices distinguish disease 
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from health, and how can this disease be measured over time on multiple occasions 
in large populations? 
Validation aims 
The validation principles to be answered in chapters 4 to 7 are listed in Table 6 
        Key Validation Questions 
General Issues  Is the Innocor device acceptable to children? 
 Does the presence of lung disease affect test acceptability? 
 How well-suited is Innocor to larger studies with minimal 
expert guidance? 
Healthy Controls  Does Innocor use in healthy children demonstrate expected 
reference values? 
 Do individual values and calculated reference ranges change 
over time when measured in the same subjects? 




Asthma  In children with well-controlled asthma (mild disease), can 
LCI using Innocor demonstrate latent disease? 
 Can the use of short-term intervention in asthmatic 
demonstrate the sensitivity of LCI to airway changes? 
Cystic 
Fibrosis 
 Can Innocor LCI detect airway disease in children with CF? 
 How variable are the results compared with healthy controls 
both within- and between- subjects? 
 Can active manoeuvres – physiotherapy and change in 
posture – induce LCI sensitive airway changes? 
 How repeatable are measurements in children with CF 
compared to healthy controls? 
 How sensitive is LCI to longitudinal change in disease as CF 
progresses? 
Table 6 - aims of clinical studies 
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Contribution to thesis 
The methods in the chapters that follow all refer to chapter 2, which describes the 
Innocor device and the multiple breath washout technique. Therefore, the methods 
section within each chapter is short and specific to that study. These chapters are also 
written as distinct articles, discussing contributions to the current scientific 
knowledge, as well as relevance to the thesis as a whole. The clinical chapters 
showing the contribution to thesis aims are show in Table 7. 
 
















on LCI in 
children with 
CF 
Children with CF  Detection of CF airways disease with LCI compared 
with healthy controls 
 
 Change in measurements following induced airway 
manoeuvre (physiotherapy) 
Effects of 
posture on LCI 





 Change in measurements after change in posture 
  Change in measurements after change in posture 
Children with CF  Sensitivity of LCI to postural change and effect of 
disease on magnitude of change 
Longitudinal 
change in LCI 





 Long-term variability of LCI and effects of disease on 
long term measurements 
Children with CF 
 Sensitivity of LCI to longitudinal change in disease 
severity  –  independent of underlying variability 





Chapter 4 - Multiple breath washout in children with 
well-controlled asthma and healthy volunteers 
Introduction 
Asthma is a common paediatric condition, with a variable course in childhood. 
Recently published evidence indicates the presence of clinical phenotypes, relating 
broadly to age at onset, presence or absence of atopy and length of time with 
symptoms(Stein et al. 1997, Goksor et al. 2006, Silvestri et al. 2003, Kiley et al. 
2007, Sears et al. 2003). Whilst symptoms are controllable with treatment leading to 
minimal symptoms in many cases, there is evidence that some symptom-free 
individuals have ongoing evidence of airway obstruction and inflammation(van den 
Toorn et al. 2001, Warke et al. 2002).  
Asthma severity is conventionally assessed by spirometry (FEV1) and symptom 
control. Recent evidence suggests FEV1 may be insensitive to airway obstruction in 
the small airways, leading to some with normal lung function and well-controlled 
symptoms but ongoing airway inflammation. This may be associated with the 
development of airway remodelling, leading to the observed increased decline in 
lung function in symptom-free adults with a previous diagnosis of asthma compared 
with disease-free individuals(Edwards et al. 2003). 
Current opinions suggest that spirometry is able to detect airway obstruction and 
reversibility in the medium to large airways, but may be insensitive to subtle changes 
in the distal airways (Macklem 1998, Gustafsson 2005). As previously stated in this 
thesis, young children also have difficulty in performing spirometry as it requires 
cooperation and learned techniques. Ventilation Heterogeneity, measured by Lung 
Clearance Index, is a sensitive and repeatable measurement suitable for use in 
children, and is increasingly recognised by research groups as a measure to detect 
and track lung disease in CF.  
At the time of planning this study, LCI had not been similarly studied in children 
with asthma. Since then, a  study in adults with asthma measured ventilation 
heterogeneity before and after treatment with inhaled corticosteroids, which 
demonstrated residual ventilation heterogeneity (measured by Scond and Sacin) 
independent of inflammation(Downie et al. 2007). It was postulated that this 
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abnormality represents airway remodelling, although there was no direct link made 
with bronchial biopsy results. This is important to those conducting MBW studies, as 
abnormalities in ventilation heterogeneity may be surrogate measures of subtle 
airway wall changes (remodelling). Downie et al suggested that ventilation 
heterogeneity in adult asthmatics is independent of airway inflammation(Downie et 
al. 2007), such that fraction of exhaled nitric oxide (FeNO), a commonly used 
measure of asthma control, may not be able to detect changes associated with airway 
remodelling.  
Only one study has previously assessed ventilation heterogeneity in children with 
asthma(Gustafsson 2007).  LCI and FEV1 improved post bronchodilator, but 
remained significantly different from controls. Children in this cohort had a low 
baseline FEV1 and hence would not be considered well controlled by current 
standards. No study had measured ventilation heterogeneity in children with well-
controlled asthma to look at subtle abnormalities, possibly not detected by 
spirometry. The majority of children with asthma have well-controlled and stable 
disease. It is expected that children who have an improvement in FEV1 following 
bronchodilator may have a similar change in LCI. In addition, given the increased 
sensitivity of LCI compared with FEV1 in other disease states, LCI may be a more 
suitable measure of asthmatic airways disease, given its ability to detect changes in 
smaller airways, than FEV1. 
 
The aims of this study of LCI in asthma were:  
 Measurement of ventilation heterogeneity in children with well-controlled 
asthma attending out-patient clinics, compared with FEV1 and FeNO.  
 Assessment of acute response after administration of inhaled bronchodilator.  
 To obtain the first MBW measurements in a healthy control paediatric 
population using the Innocor device. 
 
The study was designed in conjunction with Alex Horsley, who completed a similar 
study in adult patients. Abstracts of the data I collected were presented as a poster at 
the American Thoracic Society International Conference, 2007 and as an oral 
presentation at the British Thoracic Society Winter Meeting 2007. The data were also 
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published in Thorax in 2009(Macleod et al. 2009). Healthy volunteer data were also 
used in other publications for which I am an author(A. R. Horsley et al. 2008, Alex 
R. Horsley et al. 2008). 
 
In addition to the clinical research applications, this study is an important part of the 
wider theme of Innocor validation. The research questions this chapter addresses are 
as follows: 
 Do the measurements obtained in healthy control children and adolescents, as 
well as those with disease, correspond with previously published data?  
 Is Innocor an acceptable system for studies in this age-group and may it have 




Asthmatic patients, aged 5-16 years, were recruited from those attending the Royal 
Hospital for Sick Children specialist asthma clinic. Age-matched healthy volunteers 
were recruited from patients attending for follow-up of stable upper-limb fractures as 
well as children of hospital staff.  
Inclusion criteria were:  
Children with asthma 
1. Known asthma diagnosed by a consultant respiratory paediatrician.  
2. No previous history of severe asthma requiring admission to intensive care. 
3. No increase in symptoms or any exacerbation requiring increased use of 
inhaled bronchodilator or systemic steroid treatment in the four weeks prior 
to testing.  
Healthy volunteers 
1. No history of recurrent wheeze, pertussis or tuberculosis.  
2. No previous diagnosis of asthma or previous use of asthma medication. 
3. No prematurity (<34 completed weeks gestation). 
4. No neuromuscular weakness or bone disease likely to affect respiration.  
5. No congenital cardiac disease requiring medication.  
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Study design 
Patients with asthma attended on two separate occasions one week apart. All patients 
took normal preventer medication on the day of testing but were asked to withhold 
short-acting beta2 agonists for six hours prior to testing.  
Each visit consisted of completing multiple breath washout (MBW) and standard 
spirometry before, and 20 minutes after, inhaled salbutamol (200mcg metered dose 
inhaler (MDI), Allen and Hanburys, GlaxoSmithKline (GSK), UK) or placebo 
(propellant only MDI, Allen and Hanburys, GSK, UK). In addition, fraction of 
exhaled nitric oxide was measured at each visit after the first spirometry assessment 
(Figure 33). 
 
Both salbutamol and placebo were delivered via standard spacer (Aerochamber plus, 
GSK, UK). MDIs were blinded by covering and labelling. An extra covering was 
used to disguise the difference in size and weight of placebo and active MDIs. 
Labelling was done in private by an independent person. Code was sealed in an 
envelope, with un-blinding only after washout analysis was complete. 
Patients were administered salbutamol or placebo in a randomised, double blind 
manner, with the alternative intervention given at the second visit to ensure 
variability in tests was valid. Salbutamol and placebo MDIs were masked by an 
independent person. Order of intervention was determined by sealed, sequentially 
numbered, opaque envelopes, also prepared independently of the study team. 
Healthy volunteer subjects did not receive any intervention and simply attended on 




Figure 33 - Summary of study protocol 
Multiple breath washout 
MBW was conducted as per the method described in chapter 2. In children with 
asthma, three washouts were completed both before and after salbutamol or placebo. 
6 washouts in total. Healthy volunteers completed 3 washouts in total. 
A mouthpiece was used throughout. Most children were able to hold the whole 
mouthpiece inside their mouth. Occasionally, younger children could only complete 
washouts holding the inner part of the mouthpiece with their lips. This pragmatic 
solution for children with smaller mouths did not greatly alter the equipment dead 
space but occasionally caused visible leaks. Therefore careful observation was 
needed. 
LCI, FRC, Scond and Sacin are all quoted as the mean of at least two reproducible 
measurements out of three washouts. As a quality control measure, washouts were 
excluded if the measured FRC differed by more than 10% from both other 




Spirometry (Easyone, nnd, Sweden or Micromedical, UK) was performed according 
to ARTP guidelines('Guidelines for the measurement of respiratory function. 
Recommendations of the British Thoracic Society and the Association of Respiratory 
Technicians and Physiologists'  1994). Measurements were performed standing up, 
without a noseclip, to conform the protocol to that used in adults. A noseclip is 
recommended in more recent guidelines(Miller et al. 2005b). Three reproducible 
measures (defined according to ERS/ATS standards(Miller et al. 2005b)) were 
required for a satisfactory result, with the best of three recorded. This definition 
ensures results are reproducible, with each FEV1 and FVC required to be within 
150ml of one another (or 100ml if FVC< 1litre). 
Standard deviation scores (z-scores) were calculated from the reference population 
residual standard deviation(Rosenthal et al. 1993).  
The Easyone is now a widely used device even in children. In published studies it 
has performed well in comparison to standard respiratory lab devices in children 
aged 5 years and over(Mortimer et al. 2003, Coates 2005). It does not have a visual 
incentive display, as is common in paediatric devices, in the standard setup. This is 
an option with additional software but was not purchased for this study. 
 
Exhaled nitric oxide 
Fraction of expired Nitric Oxide (part per billion) was measured using the online 
NioxMino analyser (Aerocrine, Sweden). This device requires the child to breathe in 
to full vital capacity through a mouthpiece, then to breathe out steadily against 
resistance. A single acceptable measurement was performed with flow rate 
50 +/- 5ml/s, exhalation time 6seconds, according to ATS standards('ATS/ERS 
Recommendations for Standardized Procedures for the Online and Offline 
Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 
2005'  2005). An upper limit of 20ppb is considered abnormal. 
This manoeuvre can be difficult to perform for some children. No display is given to 
the child with the Niox Mino. A light is shown but regulation of expired flow, 




Data were analysed using Minitab version 14 statistical software (Minitab Inc., 
USA).  
Data are presented as mean and standard deviation unless otherwise stated. Student’s 
T-test for parametric data and Mann-Whitney Test for non-parametric data were used 
for comparison of groups and effect of treatment. Correlations between two measures 
were assessed with Pearson’s correlation coefficient. Non-parametric paired 
comparisons were analysed using the 2-sample Wilcoxon Signed Rank Test. 
P values less than 0.05 were considered significant. 
Ethical approval  
Prior approval was given by the Lothian Research Ethics Committee (REC: 
06/S1104/29) and Lothian NHS Research & Development. 
Summary of analysis 
 Description of population demographics. 
 Comparison of measurements in healthy volunteers and children with asthma. 
 Correlation of LCI with other measurements. 
 Comparison of change following salbutamol vs. placebo. 





Thirty-one patients (mean age 10.6 years, range 5-15) and 29 healthy volunteers 
(mean age 11.1 years, range 5-16) were recruited. Five asthmatic patients withdrew 
after one visit (two suffered exacerbations and three were unable to find time to 
return).  
All patients were taking regular inhaled corticosteroids at the time of testing. 
Treatment regimens according to BTS/SIGN guidelines for asthma 
management('British guideline on the management of asthma'  2003) are shown in 
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Table 8. 58% of patients had evidence of atopy (positive skin-prick testing to 
aeroallergen with a history of hay fever and/or eczema). 
 
BTS/SIGN management step Regimen % 
Step 2 regular inhaled corticosteroids 200-
400mcg/day 
6% 
Step 3 regular inhaled corticosteroids 200-
400mcg/day with long acting ß2 
agonist (LABA) or Montelukast   
68% 
 
Step 4 regular inhaled corticosteroids 
>400mcg /day +/-  LABA or 
Montelukast 
26% 
Table 8 - Distribution of management regimes of children with asthma 
Baseline data 
Patient demographic characteristics and baseline measurements from the first 
attendance in the study are shown in Table 9. Groups were matched for age, sex and 
height. Mean (SD) baseline FEV1 z-score at the first visit was not statistically lower 
in the asthmatic patients compared with controls (-1.09 (1.28) vs. -0.70 (0.88), 
p=0.16). Both groups were within the normal range (+/- 1.96SD). There was also no 
difference in median [range] FeNO (ppb) between asthmatics and controls (14 [5 – 
300] vs. 18 [3 – 50], p=0.63).  
Mean (SD) baseline LCI was higher in the asthmatic group than controls at visit 1 
(6.69 (0.91) vs. 6.24 (0.47), p=0.02) indicating greater overall ventilation 
heterogeneity. There was a trend towards higher  Scond in the asthma group, though 
this was not significant (0.026 (0.02) vs. 0.017 (0.02), p=0.06). There was no 
difference in Sacin between the groups (0.14 (0.02) vs. 0.12, (0.06) p=0.23). There 
was no statistical difference in mean tidal volume, FRC or dead space (Fowler 
method) to tidal volume ratio (Vd/Vt). 
There was no correlation between age and either LCI, Scond or Sacin in healthy 
volunteers or asthmatics. Increased LCI did not correlate with increased steroid dose 
or BTS step of asthma treatment. 
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ICS, inhaled corticosteroid. LABA, long-acting beta2 agonist  
*Mann-Whitney non-parametric test. 
Table 9 - Subject characteristics and baseline measurements at first visit 
 Healthy Controls 
Asthmatic Patients at 








Mean age (yrs) 
[range] 
11.1 
[5 - 16] 
10.6 
[5 - 15] 
0.54 
Sex (male/female) 18/11 17/14  
Atopy +ve skin prick 
testing to 
aeroallergen 
- 58%  
Eczema - 16%  
Hay fever - 71%  














Mean (SD) FEV1 z-score 
[range] 
-0.69 (0.88) 
[-2.64 – 1.28] 
-1.09 (1.28) 
[-4.00 – 1.82] 
0.16 
Mean (SD) LCI (CEV/FRC) 
[range] 
6.24 (0.47) 
[5.14 – 7.05] 
6.69 (0.91) 
[5.49 –  9.46] 
0.02 
Mean (SD) Scond, Vt corrected       
[range] 
0.017 (0.02)  
[-0.03 – 0.06] 
0.026 (0.02) 
[-0.01 – 0.09] 
0.06 
Mean (SD) Sacin Vt corrected 
[range] 
0.12 (0.06) 
[0.02 – 0.29] 
0.14 (0.02) 
[0.05 – 0.40] 
0.23 
Mean (SD) Tidal Volume (L) 
[range] 
0.55 (0.24) 
[0.19 – 0.99] 
0.45 (0.17) 
[0.23 – 0.80] 
0.07 
Mean (SD) FRC (L) 
[range] 
2.14 (1.02) 
[0.80 – 4.51] 
1.91 (0.78) 
[0.85 – 3.82] 
0.31 
Mean (SD) Dead Space to Tidal 




[0.13 – 0.37] 
0.27 (0.05) 
[0.17 – 0.36] 
0.89 
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At visit 1, pre-intervention, there was no correlation between LCI and FEV1 z-score 
in asthmatic patients (r
2
 = 0.11, p=0.08). Figure 34 shows relationship between 
baseline FEV1z-score and LCI. While some subjects have a low FEV1 and normal 
LCI, others have a raised LCI with normal FEV1. 
 There was a significant correlation between LCI and Scond (r
2
=0.41, p<0.001) but not 
between LCI and Sacin (r
2
=0.11, p=0.07). This relationship between LCI and Scond 
was maintained at each time point on both visits. There were no significant 
correlations between FeNO and any of the measured physiological variables.  
Baseline FEV1 vs LCI in children with asthma and
healthy controls































Figure 34 - Baseline characteristics FEV1 vs. LCI in children with asthma and healthy controls. 
Dotted lines indicate limits of normality. LCI limit calculated from mean +1.96SD of healthy 
control population. 
 
To assess repeatability of measurements in asthmatic patients, within subject 
coefficient of variation (within subject standard deviation divided by population 




Following salbutamol administration there was a significant increase (6%) in mean 
(SD) FEV1 z-score (-1.26(1.25) to -0.93(0.23), p=0.03) indicating additional 
reversibility despite patients having optimal control (no recent exacerbations and no 
increase in symptoms). No change was seen post-placebo (-1.04(1.14) to -0.97 
(1.17), p=0.5). There was no significant change in mean LCI, Sacin or Scond following 
either salbutamol or placebo (p>0.05). (* Significant difference in post-salbutamol value 
compared with healthy controls (p=0.01) 
Table 10No significant differences 
Table 11)  
Mean (SD) FEV1 z-score after salbutamol did not differ significantly from healthy 
controls (-0.93 (0.23) vs. -0.69 (0.88) p=0.38). Mean (SD) post-salbutamol LCI 
remained significantly higher than controls (6.64 (0.69) vs. 6.24 (0.47), p=0.01) 
indicating residual overall ventilation heterogeneity despite improvement in FEV1. 
Compared with controls, there was no difference in post-salbutamol Scond (p=0.54) or 
Sacin (p=0.33). (* Significant difference in post-salbutamol value compared with healthy 
controls (p=0.01) 
Table 10). 
 Healthy controls Asthmatic 
pre post p (post vs. pre) 
Mean (SD) FEV1 z-score -0.69 (0.88) -1.26 (1.25)                                                                                                                                                                                                                                         -0.93 (0.23) 0.03 
Mean (SD) LCI 6.24 (0.47) 6.82 (1.04) 6.64 (0.69)* 0.12 
Mean (SD) Scond 0.017 (0.02) 0.027 (0.02) 0.020 (0.04) 0.19 
Mean (SD) Sacin 0.12 (0.06) 0.12 (0.06) 0.14 (0.10) 0.45 
* Significant difference in post-salbutamol value compared with healthy controls (p=0.01) 




pre post p (post vs. pre) 
Mean (SD) FEV1 z-score -1.036 (1.14)                                                                                                                                                                                                                                         -0.97 (1.17) 0.45 
Mean (SD) LCI 6.69 (1.01) 6.71 (1.23) 0.83 
Mean (SD) Scond 0.033 (0.03) 0.033 (0.02) 0.90 
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Mean (SD) Sacin 0.14 (0.09) 0.16 (0.12) 0.46 
No significant differences 
Table 11 - Measurements before and 20 minutes after placebo 
 
Discussion 
In this study, children with well-controlled asthma had significantly higher LCI than 
controls, indicating abnormal gas mixing despite normal FEV1. Scond correlated with 
LCI at all time points, suggesting this abnormality may be located in the conducting 
airways (Scond) as opposed to the acini (Sacin) although the trend towards a difference 
in Scond between groups did not reach statistical significance (p=0.06).  
In patients with ongoing inhaled corticosteroid therapy and high level of asthma 
control, salbutamol administration only minimally improved FEV1, as is to be 
expected in a well-controlled asthmatic population such as this. Despite this, post 
salbutamol mean LCI did not change and remained significantly raised. This raises 
the suspicion that LCI may be able to detect airways disease that does not respond to 
salbutamol, and is not detected by FEV1. 
This is the first study to show evidence of ventilation heterogeneity in well-
controlled asthmatic children with normal FEV1. The residual abnormality did not 
appear to reflect persisting inflammation or bronchospasm as FeNO was normal, and 
heterogeneity persisted after salbutamol administration. It is possible therefore that 
LCI may at least partially reflect structural airway changes, consistent with previous 
observations made by bronchoscopic biopsy in children with asthma(Saglani et al. 
2007, Sonnappa et al. 2011). My observational study was obviously unable to 
directly link ventilation heterogeneity with independent evidence of structural airway 
changes. Given the difficulty in performing these invasive measurements, we can 
only hypothesise as to the cause of this residual ventilation heterogeneity. 
Measurement of Airway Hyperresponsiveness (AHR), if measured, may also have 
provided further evidence of airway remodelling to support our hypothesis. If we had 
recruited pre-school children, we may have been able to determine the influence of 
age and length of time with wheeze on ventilation heterogeneity. This was not 
possible due to lack of validation of the Innocor system in younger children. 
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In adult asthmatics, ventilation heterogeneity has been demonstrated to correlate with 
AHR, independent of airway inflammation measured by exhaled nitric oxide(Downie 
et al. 2007). In a similar study in adults with mild asthma reported by Verbanck et al, 
Scond and Sacin were measured before and after salbutamol. As in our study, there was 
evidence of ventilation heterogeneity in the conducting airways but not in the 
acini(Verbanck et al. 2003). The persistently raised Scond, following salbutamol, 
reinforces the suggestion of non-bronchodilator responsive disease in the small 
conducting airways of well-controlled asthmatic patients. The elevation of Scond was 
greater in both of these studies than we have seen. This may be due to poorer 
asthmatic control compared to our patients, or longer duration of asthma, leading to 
greater progression of airway structural changes. Gustafsson demonstrated elevated 
LCI and Scond in a Swedish population of moderately severe asthmatic children, with 
a greater improvement in both of these variables than we have observed(Gustafsson 
2007). Compared to the current study, however, these patients had a lower baseline 
FEV1 (77% predicted) and a higher mean LCI (>8).  
Inflammation is an important component of asthma. When exhaled nitric oxide or 
sputum eosinophil count are used to titrate inhaled steroid doses in adult asthmatics, 
better control can be achieved with fewer exacerbations and an overall lower steroid 
dose than treating using symptoms alone(Green et al. 2002, Smith et al. 2005). 
Similarly in children (6-18 years), using FeNO as the basis to increase or decrease 
inhaled steroid dose resulted in improved AHR and fewer exacerbations than those 
treated by symptoms alone(Pijnenburg et al. 2005).  The abnormality in LCI we 
detected in the current study appears to be independent of airway inflammation, as 
FeNO was normal and did not correlate with LCI.  
These findings are important because current treatment is normally decided by 
standard lung function (FEV1) and FeNO. If these measures are unable to detect 
abnormalities related to progressive structural changes, it will be impossible to assess 
the efficacy of future treatments, targeted to managing airway remodelling. 
Therefore this study may enable other groups to begin development of novel 
treatment strategies aimed at preventing long-term lung function decline in children 
with asthma. Such treatments are only just being trialled in larger populations, and 
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involve targeted treatment of inflammatory proteins (IgE, IL-13). Data on longer 
term outcomes are awaited. 
Critique of above conclusions 
An alternative interpretation of the above results is that LCI is actually insensitive to 
mild asthmatic airways disease as most patients had normal results. Only 6 patients 
had an abnormal LCI, compared with 7 with an abnormal FEV1. LCI did change in 
those with abnormal baseline results, not constituting an overall significant result. All 
the others had normal results and therefore no room for improvement. 
This point is illustrated in Figure 35 below. This chart plots paired results (pre and 
post salbutamol) in asthmatic individuals, joined by a line. The progression is from 
pre to post in the direction of the arrow. If both FEV1 and LCI improved, the arrow 
would move down and right, as is the case in a few individuals. It is also clear that a 
number of individuals have changes in FEV1 indicating reversibility, but no change 
in LCI. While this results an overall increase in FEV1, there is no overall change in 
LCI. 
 
Figure 35- paired FEV1 vs. LCI in children with asthma following salbutamol administration. 
Pre to post measurements progress in the direction of the arrow. 
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To respond to this criticism, it is necessary to consider the fundamental principles of 
ventilation heterogeneity. LCI is thought to be a global measure of ventilation 
heterogeneity. As a disease of both the small and central airways(Hamid et al. 1997), 
there is interest in LCI as more appropriate measure of asthma, able to detect overall 
ventilation heterogeneity. As previously stated, FEV1 is a measure of airway 
resistance at flow limitation in only the medium airways. Therefore LCI is likely to 
be better-suited, especially in those with well-controlled asymptomatic disease. This 
cannot be proved by this study. 
While there are few patients with abnormal results, this may highlight the 
heterogeneity of the disease – so called asthma phenotypes. This study did not aim to 
select different phenotypes therefore conclusions are speculative. It could be that 
those with higher LCI, despite having the same level of control as others, represent a 
different phenotype. LCI did not change in the majority of patients, and remained 
raised compared with controls. Therefore the question arises: is it most likely that, if 
LCI is able to detect subtle residual disease even in this heterogeneous group and 
there was no overall change in LCI after salbutamol, this is because of lack of 
reversibility, rather than lack of sensitivity of the assay?  To begin to answer this 
question, it is necessary to follow a well-controlled cohort, controlling for phenotypic 
features, to track progression of this abnormality over time. In addition – despite the 
complexity and invasiveness of such a study – pairing LCI results with 
bronchoscopic biopsy features would confirm the hypothesis that LCI is able to track 
these progressive structural airway changes. 
Learning points and contribution to thesis  
This was the first study conducted in children using the Innocor MBW system. While 
the technique is simple for children to perform, quality control issues needed to be 
learned. These issues have previously been described in chapter 2. 
If repeating this study, it would be important to take into account the effect of one 
measurement on another. FeNO was consistently performed after spirometry despite 
ATS/ERS recommendations stating that forced expiration may affect 
FeNO('ATS/ERS Recommendations for Standardized Procedures for the Online and 
Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric 
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Oxide, 2005'  2005). This was an oversight in the study design, although on 
reviewing the literature there is conflicting evidence of the effect of Spirometry on 
FeNO(Gabriele et al. 2005, Kissoon et al. 2002). Notwithstanding this, FeNO was 
always performed after spirometry in this study and any bias is constant. 
 
While still falling within the normal range, the mean(SD) FEV1 z-score of the 
healthy control group is lower than expected (-0.69(0.88)). All were Caucasian and 
within the age-range of the reference population(Rosenthal et al. 1993). There are 3 
possible explanations for this. 
1. The reference population is different to the healthy control group 
This is unlikely given that the reference population was a British Caucasian group.  
2. Differences in method meant lower FEV1 than expected 
ERS/ATS guidelines recommend the use of a noseclip(Miller et al. 2005b). No 
noseclip was used in this study, which may have lowered the mean FEV1. 
3. Lack of experience 
All healthy control children completing spirometry were naïve to the technique. This 
may have contributed to poor quality results. Lack of operator experience (all 
measurements were conducted by me) may have meant children were not all 
encouraged adequately to achieve flow limitation. Contrary to this hypothesis, there 
was no relationship between subject number (R
2
 = 0.03) or age (R
2
 = 0.00003) and 
FEV1 z-score.  
 
The above factors (particularly the lack of noseclip) may have affected FEV1 
measurements in this population. While this prevents comparisons between other 
healthy populations and is not ideal, both asthma and healthy groups were measured 
according to the same standards. Therefore, they can be reliably compared. 
 
This first study conducted in children using Innocor was important in establishing the 
validity of subsequent studies. As a novel device for MBW in children, the suitability 
of the Innocor patient interface (mouthpiece and noseclip) and comparison of 
normative values with other devices is of particular interest. Innocor is simple to use, 
and did not require any servicing throughout the study. There were instances of 
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equipment malfunction (such as unexpected computer operating system re-boot, and 
accidental compression of the nafion sample tubing), but these were easily remedied. 
In this study, all children were able to perform MBW to a satisfactory standard, with 
3 washouts being completed in 69% of occasions. Children were easily distractible 
using cartoons. Performing 6 washouts with a waiting period was tiring for some 
younger ones. With encouragement a good seal was maintained throughout the 
washin and washout periods. 
A number of studies have been completed in normal populations, similar in size to 
this. A simple table of mean (SD) LCI using Innocor, compared with other SF6 
devices is shown below (Table 12).  
Publication Device, SF6 
concentration 
n Mean [range] or 
(SD) age (yrs) 
Mean (95% CI) 
LCI 
This study 
(Macleod et al. 2009) 
Innocor, 0.2% 29 11.1 [5-16] 6.24 (0.47) 
     
Horsley et al 
(A. R. Horsley et al. 2008) 
Innocor, 0.2% 48 33 [19-58] 6.7 (0.4) 
     
Aurora  
(Aurora et al. 2005a) 
Mass Spec, 4% 30 4.31 (0.84) 6.89 (0.44) 
Aurora  
(Aurora et al. 2004) 
Mass Spec, 4% 33 11.3 (3.1) 6.45 (0.49) 
Gustafsson  
(Gustafsson et al. 2003a) 
Mass Spec, 4% 28 11.4 [3-18] 6.33 (0.43) 
Aljassim  
(F. Aljassim et al. 2009) 
Mass Spec, 4% 18 18 [17-18] 6.50 (0.45) 
Gustafsson  
(unpublished) 
Mass Spec, 4% 44 41.1 (10.3) 6.6 (0.5) 
Table 12 - comparison of recent publications. Healthy control adults and children. Adapted 
from Robinson et al(Robinson et al. 2009b) 
 
Reassuringly, the results from this study were very similar to other published studies. 
While the basic setup of the mouthpiece and pneumotach was very similar, the 
concentration of SF6 used in mass spectrometer studies was 4%. This suggests that 
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gas concentration (with changes in viscosity) does not influence LCI, certainly in 
healthy subjects. The obvious conclusion from this is that results from Innocor and 
mass spectrometer studies can be compared. 
 
In addition to reassuring normative results, this study provides evidence of increased 
sensitivity of LCI to residual airways disease in well-controlled asthmatic children. A 
clinical application of this would be in measuring and tracking changes in lung 
function over time in a larger population. This would only be possible in a large, 
multi-centre cohort. Innocor is likely to be more suited to this than a mass 
spectrometer for reasons already highlighted elsewhere. 
Finally, this study allows us to make a power calculation for future interventional or 
observational studies in asthmatics. A change in LCI of 1 could be considered a 
meaningful change, based on the standard deviation of the population. Based on this 
study, a sample size of approximately 8 in each group would be able to detect a 




Chapter 5 - Effects of airway clearance physiotherapy 
on ventilation heterogeneity in children with CF 
Introduction  
Chest physiotherapy is widely used for airway clearance in children and adults with 
Cystic Fibrosis. Improvements in survival of CF patients in the past 40 years are 
attributed, in part, to the introduction of effective airway clearance techniques. 
Despite a lack of robust empirical data to support this, recommendations currently 
state that airway clearance techniques should be introduced at the time of CF 
diagnosis (Konstan et al. 1994, Armstrong et al. 2005, Khan et al. 1995, Dakin et al. 
2002a, Rosenfeld et al. 2001), but daily physiotherapy is time-consuming, adversely 
affecting compliance(Arias Llorente et al. 2008). A Cochrane Intervention Review, 
conducted to assess the evidence for the benefits of chest physiotherapy in CF, 
showed no long-term benefits. The only consistent outcome was a short-term 
improvement in mucous transport(van der Schans et al. 2000). In addition, no 
eligible studies showed a benefit in terms of improvements in lung function over the 
short or long term.  
The lack of data recommending regular physiotherapy in CF may be because FEV1 is 
relatively insensitive to acute change, especially in those with mild or stable lung 
disease. Forced expiration at flow limitation, thought to detect an overall increase in 
airway obstruction in medium-sized airways, may not be appropriate to detect early 
CF airway disease in small to medium sized airways. Ventilation heterogeneity (LCI) 
is likely to be more able to detect acute changes after an intervention such as chest 
physiotherapy. This study seeks to test this hypothesis.  
 
CF lung disease is characterised by excess mucous production as a result of chronic 
infection and inflammation. Airway clearance is a fundamental treatment 
recommended universally for prevention of the long term consequences of 
destructive properties of retained mucous(Flume et al. 2009, Bradley et al. 2006). 
Most previous interventional studies have used FEV1 as the main functional outcome 
following physiotherapy. Only 2 studies have so far measured lung clearance index 
before and after physiotherapy. One aimed to demonstrate that airway clearance does 
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not influence the short term variability of LCI in the clinical setting, rather than to 
prove a therapeutic benefit(Fuchs et al. 2010). There was no significant mean change 
in LCI following physiotherapy, suggesting it does not matter whether MBW is 
performed before or after physiotherapy. Another study used a measure of ventilation 
heterogeneity (single breath helium washout) to measure effects of physiotherapy in 
a small number of patients with cystic fibrosis(Darbee et al. 2004). Following 
positive expiratory pressure manoeuvres in 5 patients, the average gas mixing 
improved, indicating airway clearance had some positive effect on the function of the 
lungs. 
Airway clearance techniques aim to move mucous proximally, to allow 
expectoration. Recommended techniques involve one, or a combination of, 
percussion, high frequency oscillation and postural drainage. Self-administered 
techniques that are popular with patients use thoracic pressure, rather than external 
forces, to mobilise mucous. Many patients use mechanical devices to increase 
expiratory resistance, provide oscillations or give non-invasive ventilatory assistance. 
Techniques are often combined and no one technique is recommended universally.  
 
Theoretically, physiotherapy should be moving mucous proximally, resulting in 
changes in lung volume, however previous studies have not shown changes in FRC 
following airway clearance. Airway clearance should also have an effect on lung 
clearance index, where movement of mucous leads to changes in ventilation 
heterogeneity.  
The primary aim of this study was:  
 To assess the ability of MBW, compared with FEV1, to detect a change in 
lung function following airway clearance physiotherapy in children with CF 
(active cycle of breathing technique, ACBT).  
The hypothesis stated that following ACBT, there would be an improvement in 
ventilation heterogeneity compared with those who performed paired measurements 
without intervention, due to clearance of retained airway mucous. This small study 
contributes to an understanding of how ventilation heterogeneity changes following 
an acute intervention. In contrast, large numbers would be required to provide 
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definitive evidence supporting or refuting the current standard recommendation of 
regular chest physiotherapy in CF.  
 
The secondary aims of this study are of importance to the thesis as a whole: 
 To compare short term change in LCI in disease states with and without an 
intervention 
To assess Innocor performance in a therapeutic study with multiple repeated 
measurements in one visit. Those with CF can have elevated LCI values and 
prolonged washout duration, which may amplify errors in the system. Previous 
studies have measured LCI in CF, but few have recorded short-term repeatability and 
acute response to interventions. This study therefore also aimed to demonstrate the 
suitability of Innocor for repeated prolonged washouts in those with measureable 
lung disease.  
 
This study was designed and conducted in parallel with a similar protocol for adult 
patients with CF. The protocol for children was written with Elaine Dhoueib, 
Paediatric Physiotherapist at the Royal Hospital for Sick Children, Edinburgh. 
Results were submitted for a MSC in Physiotherapy qualification (Queen Margaret 
University, Edinburgh). 
All data analysis and statistics for this study were performed by me.  
 
Methods 
This randomised interventional study recruited children (5-17 years) with CF 
attending two clinical centres at the Royal Hospital for Sick Children, Edinburgh. 
Subjects attended on one occasion and were randomised to perform MBW and 
spirometry before, and immediately after, physiotherapy intervention (ACBT) or a 
30-minute waiting period. 
All patients repeated MBW and spirometry immediately after the intervention, with 
an additional 2 MBW repeats, 1 and 2 hours after that. For a summary of the study 













Figure 36 - Study flow chart 
 
Active cycle of breathing technique (ACBT) 
Active Cycle of Breathing was chosen because it is the technique children were most 
familiar with, and is recommended and taught by physiotherapists as standard care in 
the local hospital clinic. ACBT was supervised by a qualified physiotherapist or 
trained research nurse. Patients all received training prior to the study.  
A brief description of ACBT is given here: 
Children completed 20 minutes of standardised ACBT according to a locally agreed 
standard operating procedure, based on CF Trust guidelines. A set of 3 deep breaths 
with an inspiratory hold, followed by 1-2 forced expiration “huffs” at mid to low 
lung volume, was repeated 3 times. Patients were lying down throughout, and 
completed this process in supine, left and right lateral positions. 
 













Multiple breath washout 
MBW was performed and analysed as per standard operation procedure discussed in 
Chapter 2. Three repeat measurements were taken, with mean calculated, at all time 
points. 
Spirometry 
All patients performed standard spirometry, while sitting, immediately after MBW 
without a nose clip, (Easyone handheld spirometer, ndd, Switzerland). The highest 
value of 3 acceptable manoeuvres was defined according to ERS/ATS guidelines. 
Reference values were provided by recently published all age equations(Stanojevic et 
al. 2008). 
Statistical analysis 
Data were analysed using Prism software (GraphPad Software Inc., CA, USA). A 
t-test, or non-parametric equivalent where appropriate, was used to analyse 
differences between groups. Mean vs. difference before and after (Bland-Altman 
plot), with 95% limits of agreement was used to compare change in measurements 
following physiotherapy with those who waited. Paired measurements with a similar 
interval in healthy volunteers were not available; therefore, the limits of agreement 
between the first and third washouts, spaced approximately 30 minutes apart during 
normal testing in adults only, were chosen as an equivalent. These measurements 
were taken from a suitable healthy control population recruited for the clinical study 
in chapter 4. 
No power calculation was possible at the time as there were no data on the short term 
variability of LCI in CF.  
Ethical approval 
Ethical approval for this study was granted by the Lothian Research and Ethics 
Committee (REC 06/S1103/66).  Patients and parents, where appropriate, were 
provided with detailed information, and signed an informed consent form prior to 





18 patients with cystic fibrosis (median age 11.8, range 7-17) were recruited to the 
study, and randomly assigned (random number) to receive physiotherapy (n=10) or 
wait (control, n=8). 29 healthy control subjects (mean age 11.5, range 5-16) were 
used as a comparison group, recruited for the previous study (chapter 4) to complete 
one set of washouts on a single occasion. Three children were unable to complete all 
four time points due to time constraints, however paired measurements before and 
after the intervention were obtained in all patients. 
All patients completed measurements during periods of clinical stability. This was 
defined as no recent exacerbation or increase in respiratory symptoms requiring extra 
antibiotic courses in the 2 weeks prior to testing. 
Baseline measurements 
Baseline measurements and demographics for all patients are shown in table 13.  
Results are presented as the randomised CF groups (physiotherapy and wait) 
compared with healthy controls. There was no difference in mean (SD) FEV1 z-score 
in either the physiotherapy or wait group compared with healthy volunteers 
(-0.56(2.75) and -1.05(2.20) respectively vs. -0.60(0.88), p>0.05). Mean(SD) LCI, 
however, was higher in both CF groups (physiotherapy and control) compared with 
healthy volunteers (7.36(2.90) and 7.17(1.42) vs. 6.24 (0.47), p=0.047 and p=0.004, 
respectively. See Figure 37.  
Mean (SD) functional residual capacity (z-score) did not differ between either CF 
group and healthy volunteers (p=0.58 and p=0.14 respectively). Scond was 
significantly higher in both CF groups compared with healthy controls (0.061 (0.028) 
and 0.078 (0.030) vs. 0.016 (0.013), p<0.0001). This relationship was only seen in 
Sacin measurements in the group receiving physiotherapy (0.19 (0.065) vs. 0.12 







 Cystic Fibrosis Healthy Control 
 Physio Wait  
N 10 8 29 
Sex (m/f) 7/3 5/3 18/11 
Median [range] age (yrs) 14 [7 - 17] 11 [7 - 17] 11 [5 - 16] 
Mean (SD) height (cm) 144.9 (18.61) 142.4 (11.4) 148.2 (19.1) 
Mean (SD) FEV1 z-score -1.05 (2.86) -1.54 (1.92) -0.81 (0.97) 
Mean (SD) FRC z-score 3.37 (4.04) -0.35 (1.46) 1.49 (2.94) 
Mean (SD) LCI (cev/frc) 7.36 (2.90)* 7.17 (1.42) † 6.24 (0.47) 
Mean (SD) Sacin Vtadj 0.19 (0.07) † 0.15 (0.13) 0.12 (0.064) 
Mean (SD) Scond Vtadj 0.061 (0.03) ‡ 0.078 (0.030) ‡ 0.016 (0.013) 
Significant difference to healthy controls * p<0.05, † p<0.01, ‡ p<0.001 
Table 13 - Comparison of baseline measurements between intervention and no intervention 



























































Figure 37 - Baseline measurements compared with healthy control 
population 
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Response to physiotherapy 
After completion of ACBT, there were no significant differences in any 
measurements, compared with those who waited. This applied at all 3 
post-physiotherapy time points. Neither were there any significant mean changes 
from zero. To summarise these data, mean(SD) absolute changes (with % change 
where relevant) are shown by time point in  
No significant differences (p>0.5) 
Table 14. It can be seen that mean changes are very small; however the variability of 
change is relatively high. Especially with FRC, coefficient of variability (CV%) on 
the measurements immediately following physiotherapy was higher than the wait 
group (9.3 vs. 4.8). This suggests a trend towards increased change in lung volume 
following physiotherapy compared with waiting; however, the change is not 
consistent in one direction, and did not continue in the subsequent measurements. 
Change in LCI at all time points for both groups is illustrated in Figure 38. This 
demonstrates greater fluctuation of LCI in the physio group but no overall group 
differences. 
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Change in LCI following intervention



















Figure 38 - Change in LCI following physiotherapy compared with wait group.  
 
No significant differences (p>0.5) 
Table 14 - Mean change in measurements following physio and in waiting controls. 
 Mean(SD) change from 
baseline - Immediate 
Mean(SD) change from 
baseline – 1 hour 
Mean(SD) change from 
baseline – 2 hours 
 Physio Wait Physio Wait Physio Wait 
FEV1 z-score 0.16(0.62) -0.28(0.49) -- -- -- -- 
FRC 0.02(0.57) -0.02(0.12) -0.20(0.44) -0.01(0.16) -0.01(0.10) -0.01(0.16) 
FRC % change 3.35(16.77) 0.14(0.15) -6.02(11.04)  0.50(12.50) 0.15(6.47) -0.81(10.77) 
LCI 0.14(0.56) -0.03(0.47) 0.34(0.41) 0.02(0.48) 0.23(0.73) -0.28(0.83) 
LCI % change 2.63(9.07) -0.83(5.61) 5.47(7.26) 0.48(6.60) 4.44(14.76) -3.04(11.03) 
Sacin -0.014(0.06) -0.021(0.06) -0.023(0.05) -0.030(0.08) -0.025(0.05) -0.041(0.14) 
Scond 0.007(0.02) 0.006(0.02) 0.012(0.03)  0.006(0.02) 0.021(0.03)  0.007(0.02) 
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There was no consistent correlation between change in LCI and change in FEV1 z-
score, Scond or Sacin. There was, however, a significant correlation between change 
in LCI and change in FRC. This is summarised in Table 15. It is expected that 
change in FRC would result in a concurrent change in LCI (FRC being the 
denominator when calculating LCI). However, despite both positive and negative 
changes in FRC, there is not always an associated “mathematical” change in LCI, 
e.g. fall in FRC does not necessarily correspond to a rise in LCI (CEV/FRC). This 
indicates a more complex picture. This will also be discussed. 
 
 Change from baseline 









 * p 
Physio 0.69 0.003 0.49 0.02 0.05 0.65 
Wait 0.79 0.5 0.76 0.005 0.36 0.12 
*Pearson’s correlation coefficient 
Table 15- Correlation between change in LCI and change FRC 
Discussion 
In this study, neither LCI, FRC, Sacin, Scond and FEV1 changed consistently 
following ACBT compared with baseline and control. While there was evidence of 
greater absolute change in those receiving physiotherapy compared with those who 
waited, the difference was not significant. Furthermore, change was not in one 
direction. Change in LCI did not correlate with change in FEV1 and was not limited 
to those with a higher LCI or lower FEV1.  
Fuchs et al have recently measured short-term reproducibility of MBW 
measurements in healthy control children and adolescents(Fuchs et al. 2009). This 
showed an acceptable co-efficient of variability (CV%) of LCI after 1 hour. FRC 
reproducibility is not quoted in this paper. The same research group has published a 
study measuring LCI and FEV1 before and 1 hour after physiotherapy or waiting in 
young people with CF. This was with the aim of determining to what extent 
performing physiotherapy before LCI and spirometry affects the results. This is 
obviously very similar to our study, although their aim is more concerned with test 
quality control in a clinical setting rather than airway physiology. Again, minimal 
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changes in LCI were seen following physiotherapy, which confirms the results we 
have collected. Table 16 compares data from these papers against those collected 
before and 1 hour after physiotherapy. No data are available from these articles about 
intra-individual, between test reproducibility of FRC. 
Both previous studies have shown similar results. CV% is low (<5%) after 1 hour, 
even after 30 minutes of physiotherapy. CV% is higher post physiotherapy compared 
with those who waited, and it is also clear from this paper that the 95% limits of 
agreement are wider in those who did not receive physiotherapy, compared with 
those who did. We have confirmed the findings of Fuchs et al(Fuchs et al. 2009). 
  This chapter Fuchs et al  
post physiotherapy 
in cystic fibrosis  






Post physiotherapy n=10 4.71 (3.7) n=16 4.6 (3.1) 
4.2 (3.7) 
Post wait n=8 3.56 (3.0) n=11 2.6 (2.1) 
Table 16 - Comparison with published MBW data. Coefficient of variability (CV%) of LCI 
measurements in individuals with CF before and 1 hour after physiotherapy or wait, and 1 hour 
apart in healthy individuals. 
 
The marginal average changes in ventilation heterogeneity seen here are similar to 
those seen in a similar study by Neil Woodhouse and Jim Wild et al, 
Sheffield(Woodhouse et al. 2009). This group have developed inhaled 
Hyperpolarised Helium-3 MRI as a non-ionising method of imaging ventilated lung 
volume. This study measured lung volumes followed by spirometry before and 30 
minutes after physiotherapy in 9 individuals, comparing results with paired 
measurements in 5 controls. There were no significant changes in volume and 
spirometric measurements, however higher variability was seen in those performing 
physiotherapy compared with the control group. 
 
To attempt to explain these findings, I will discuss the effect of airway clearance on 
mucous in the lungs, and how this may affect ventilation heterogeneity. 
Physiotherapy is considered to be an effective way of clearing mucous from the 
airways in CF. This study attempted to test a simple, regularly used airway clearance 
technique (ACBT) to see its effect on ventilation heterogeneity. There seems to be a 
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hypothetical connection between mucous obstruction and ventilation heterogeneity, 
and therefore measurable change. It was thought that this change could be measured 
more sensitively with LCI rather than FEV1, because LCI is thought to measure 
global ventilation heterogeneity involving small as well as medium and large 
airways, rather than the flow limitation in the medium airways with FEV1. LCI is 
also more able to detect subtle lung disease, and therefore may be more sensitive to 
acute change. This was seen after bronchodilator use in CF and asthma in a 
previously published study by Gustafsson(Gustafsson 2007). 
 
CF is a complex airway disease, with a dynamic balance of factors influencing 
airway patency, as seen in an inhaled Hyperpolarised Helium-3 MRI study. Mentore 
et al demonstrated increased ventilation defects per image (VDI), i.e. the number of 
areas with no gas entering, after physiotherapy in patients with CF first treated with 
inhaled salbutamol(Mentore et al. 2005). While the baseline VDI measurements 
correlated with lung function (spirometry) there was only a weak correlation (r = -
0.13) between change in VDI and change in FEV1. This sheds some light on the 
processes underlying the results seen in our study. It appears that more regions of 
lung are blocked off after physiotherapy, however the authors admit that the scoring 
system exaggerates mild defects and dampens severe defects. It may be that very 
subtle differences result in a large increase in VDI. In addition, any de-stabilising 
effect of salbutamol on airway smooth muscle tone was not discussed. While a 
reduction in VDI was seen after the pre-physio salbutamol dose, the effect of smooth 
muscle relaxation could result in exaggerated changes after physiotherapy because 
smooth muscle is no longer involved in maintaining a balance of airway patency in 
parallel lung regions. 
 
In this study, physiotherapy may have increased blocked off areas of lung by shifting 
mucous proximally as is proposed by Mentore et al. Simple shifting of mucous 
proximally would result in a reduction in FRC, but overall changes in our study were 
marginal, implying no effect or rather parallel processes of conflicting changes. It is 
somewhat disappointing not to be able to report results with clear conclusions. There 




There are limitations to this study that may have contributed to the inconclusive 
results.  
1. Study power. 
With 8 subjects in 1 group and 10 in the other, only large and consistent changes in 
LCI will be detected. It is clear that this study is underpowered to answer the primary 
aim of the study. The results, however, are important in informing similar studies. 
Without clear statistical conclusions, any comments made here are essentially 
speculative. It is important to learn from the following study limitations in order to 
design future interventional studies in a complex airway disease such as CF. 
 
2. Contribution of spirometry to variability in “wait” group. 
Those patients who waited, rather than performing physiotherapy, did complete 3 
forced vital capacity manoeuvres following the first sequence of MBW. While this 
was brief, and allowed comparison with previous studies, there is concern that these 
manoeuvres may have disrupted airway obstruction and at least partially cleared the 
airways. A solution to this would have been to perform FEV1 at some point after the 
MBW manoeuvres (e.g. 2 hours), or not at all in those who waited. 
 
3. ACBT not enough to clear on this occasion 
ACBT was chosen as a familiar technique to most patients. This is the preferred 
method in the clinical centres involved in the study. It is assumed that one 30-minute 
session of ACBT will result in significant clearance. All subjects were clinically 
stable at the time of testing, and may not have had “clearable” obstructions (i.e. 
mucous). A large proportion of both physiotherapy and wait subjects (32% and 39%) 
had baseline LCI results below the upper reference limit. This suggests minimal 
baseline heterogeneity and little potential for improvement. Therefore, ACBT on one 
occasion, in these patients, may not have been enough to alter ventilation 
heterogeneity significantly.  
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An alternative method could have chosen those being treated for an exacerbation. 
Measuring acute changes in those with more active airway disease, and presumably 
increased mucous, may have produced results that were more impressive but less 
applicable to understanding the effect of daily physiotherapy to lung function. 
 
4. Multiple parallel factors influencing change in ventilation heterogeneity 
The primary aim of ACBT, in the absence of efficient mucociliary clearance, is to 
move mucous proximally allowing expectoration or swallowing. If mucous is 
completely cleared from a lung region, it would be assumed that ventilation 
efficiency would improve as overall heterogeneity is decreased. It may not be so 
simple. The following diagrams (Figure 39) seek to illustrate possible mechanisms 
for the minimal overall changes we saw following ACBT in this study. 
The basis for these diagrams is that LCI measures ventilation heterogeneity, i.e. 
differences between washouts of parallel lung units. A simplified 2-compartment 
model, as described by Paiva and Engel(Engel 1985), proposes a model of well- and 
poorly-ventilated compartments. These compartments could exist at any airway 
level, but are probably most important at small-airway levels where CF airway 
disease is thought to begin. As stated in Chapter 2, the well-ventilated compartment 
washes out first, as inspired fresh air is preferentially distributed. Later, the poorly 
ventilated compartment washes out, requiring a larger overall number of lung 
turnovers to washout the SF6 to the end-point. In this model, I have added a further 
compartment. It is completely closed during tidal breathing and therefore does not 
contribute to LCI during the 3 washouts of any one test. This corresponds to a known 
trapped gas volume in CF, shown by the differences between washout and 
plethysmography FRC(Hulskamp et al. 2006, Morris et al. 2001, Stocks and Quanjer 
1995). I propose this “virtual volume” may be altered to greater or lesser degrees 
because of the postural changes and forced expiratory manoeuvres (“huffs” and 
coughs) during ACBT. Significant changes in FRC were not seen in this study, and 
no measure of trapped gas was made to confirm or refute this hypothesis. A 
reduction in FRC, as the denominator in the LCI equation (CEV/FRC), may cause a 
mathematical rise in LCI but the lack of consistent strong correlations between 
change in FRC and change in LCI indicate a more complex picture. A reduction in 
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lung volume does not automatically result in an increased LCI, because there is less 
lung volume to be washed out so that the CEV also decreases. Changes in volume 
following physiotherapy are probably in those lung regions most affected by disease. 
Therefore, the diseased components will contribute less to the washout. While LCI is 
a ratio, the numerator and denominator are not independent of each other. 
 
To further discuss the dynamic changes within the lung following physiotherapy, 
Figure 39 shows a simplified 3-compartment model prior to, and following, chest 
physiotherapy. Green represents the well-ventilated compartment (no obstruction), 
yellow is poorly ventilated (some obstruction), and red is completely obstructed (i.e. 
not ventilated at all during tidal breathing). 
Following ACBT, one of 3 scenarios is proposed.  
1. LCI may decrease if obstruction is cleared from the partially obstructed 
region (previously yellow), decreasing heterogeneity. The closed region (red) 
is unchanged.  
2. Alternatively, LCI may increase if mucous is partially cleared from the 
previously closed region (red), increasing overall heterogeneity. 
3. The 3rd scenario is a mixed picture, with both 1 and 2 occurring in parallel. 
This seems most likely as these processes are multiplied throughout the lung 



































Figure 39 - Three-compartment model illustration proposing complex interactions of parallel 




Learning points and contribution to thesis 
This study raises important learning points relevant to the main theme of the thesis: 
In planning the study, we used a standardised protocol, but did not factor in the effect 
of one measurement on another. It would have been wiser, in retrospect, to avoid 
spirometry (or at least 3 full forced expiratory manoeuvres) until after the post 
intervention MBW was completed. The study was underpowered, and future short-
term interventional studies should take this into account. In addition, recruiting 
young people with stable CF increases the likelihood that one short term intervention 
will have no effect on stable airway disease. 
 
LCI is already recognised as a promising technique for detection and tracking of CF 
lung disease and is better able to detect disease than FEV1. This study suggests, 
however, that it may not be able to assess the effectiveness of acute interventions in 
CF without recruiting large numbers of patients. This may be due to the insensitivity 
of the assay, or the complexity of factors influencing global ventilation heterogeneity 
in the CF lung of even clinically stable individuals. The 3-compartment model I 
propose seeks to explain interactions of complex factors following ACBT in a 
simplified way. This is in no way a conclusive model, as this study was not designed 
to answer this question. 
 
Finally, the Innocor device, used over 2 hours in each patient, performed well. There 
were no incidents of technical faults or random measurement errors seen. The 
measurements took place in another department of the hospital, with only stair 
access. The moving each day and setting up did not appear to destabilise the analyser 
or flow meter. This helps to validate Innocor as a robust, reliable device capable of 
regular and prolonged use without advanced technical support. There is therefore 
potential for use in a clinical setting once software and hardware validation has been 
completed in all ages. 
 
This study does not have clear conclusions on the acute effect of physiotherapy on 
lung function in CF, mainly due to underpowering. Physiotherapy may have complex 
short-term effects on ventilation heterogeneity, which are not reflected in a 
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conclusive overall change. Conversely, one session of physiotherapy may not be 
enough to produce measureable change in children with stable CF lung disease. This 
is an important finding in terms of planning future clinical studies. In assessing long 
term change in a cohort of patients, the effect of the timing of daily physiotherapy is 
unknown, therefore should be kept constant at each time point.  This 




Chapter 6 - Effects of posture on LCI and FEV1 in 
health and disease 
Introduction  
MBW is suitable for all ages to perform. Recent guidelines have focussed attention 
on younger age groups, primarily because of a paucity of longitudinal data tracking 
the progression of cystic fibrosis. Generally, infants perform MBW while supine, but 
in older children (>2 yrs) and adults, MBW is performed sitting. This may cause 
difficulties in longitudinal studies tracking changes in children from infancy to 
childhood, as it would not be clear whether any progression in lung disease was due 
to true lung changes or simple methodological alterations. Therefore, for lung disease 
to be tracked in this way, the effect of a change in posture should be examined.  
Previous studies have documented changes in lung function in infants, children and 
adults whilst supine. Lung volume (FRC, Vt and FVC) is reduced in individuals 
when changing from sitting to lying supine(Gustafsson 2003, Moreno and Lyons 
1961). In a study of healthy adult male volunteers, changing from sitting to supine or 
prone posture resulted in a fall in FEV1 and FRC(Vilke et al. 2000). In a study of 
children with asthma and healthy controls there was a fall in FRC on lying, but no 
clear effect of the presence of airway disease on the magnitude of the fall. In the 
same paper, peak expiratory flow rate (PEFR) also fell in those with asthma, but not 
healthy controls(Greenough et al. 1991). No published studies have performed the 
same experiment in children with CF. 
A few studies have looked at the effect of change in posture on ventilation 
heterogeneity parameters(Gronkvist et al. 2002, Cortese et al. 1976, Grönkvist et al. 
2002, F Aljassim et al. 2009, Gustafsson 2003). Mostly these studies have been using 
phase III slope analysis, rather than LCI. Only one has involved children with cystic 
fibrosis(F Aljassim et al. 2009). In this study (currently presented only as an abstract) 
there was reduction in FRC and increase in LCI in older children, but importantly not 
in infants.  In another study by Professor Gustafsson, FRC decreased after changing 
to supine posture from sitting in children with asthma and healthy controls. A greater 
than 20% reduction in FRC was seen, but there was no significant change in LCI in 
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either group. As CF has a different disease process to asthma, the results of that study 
do not necessarily translate to other conditions.  
An important implication of a decrease in lung volume and function with supine 
posture is the connection between this and sleep disordered breathing. A number of 
studies have reported hypoxaemia in infants, children and adults with CF, even in the 
presence of stable lung disease(Villa et al. 2001, Bradley et al. 1999, Francis et al. 
1980, Tepper et al. 1983). It is suggested this may be due to reduced respiratory drive 
while asleep, leading to lower tidal volume and impaired ventilation. Simulating the 
sleep posture while awake to assess the effect on lung function may shed light on an 
explanation for sleep disordered breathing in CF. The changes after altering posture 
may be the same as those occurring at night, however it is important to recognise that 
additional sleep-related effects due to changes in upper airway patency and 
respiratory drive will not be measured.  
This study had the following primary outcome: 
 Effect of change in posture from sitting to supine on lung volume (FRC), 
ventilation heterogeneity and spirometry (FEV1) in healthy controls and 
children with CF 
Secondary outcomes were: 
 Correlation of posture-related changes in FRC and LCI to change in 
spirometry 
 Effect of Disease (CF) on posture-related changes in lung volume and 
ventilation heterogeneity compared with healthy controls. 
 
This is an important study for the following reasons:  
1. When validating Innocor for use in younger children, the effect of a change in 
posture must be taken into account. In the scenario of repeated measurements 
over time, some children might perform tests lying down on one occasion, 
then sitting up. If there is a change in LCI only due to change in posture, this 
may affect the interpretation of results. The study presented by Professor 
Gustafsson’s group(F Aljassim et al. 2009) showed no change in FRC in 
infants (when changed from supine to sitting) however there was a reduction 
in older children. No overall change in LCI was recorded in either infants or 
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older children. This may mean that there is no concern about following young 
children over time even if there is a change in posture. There may however be 
important methodological differences between Professor Gustafsson’s study 
and the standard Innocor setup that negated the effect of the change in 
posture. This will be discussed later. 
2. This thesis as a whole considers the wider physiological basis of ventilation 
heterogeneity. A number of studies have shown a change in FRC with change 
in posture, but the effect of a change in FRC on LCI has not been fully 
explored. This study, similarly to other studies in this thesis, aims to apply a 
standardised change in the respiratory system, and measure the effect of this 
on gas washout efficiency. It is hoped that this chapter will provide important 
information on how lung disease affects LCI, and how LCI and FRC interact 
in health and disease. 
This study was conceived and designed by Dr Steve Cunningham and myself. It 
started as a medical student project but continued beyond the student project period. 
Chantal Ellis, then a 3
rd
 year medical student, was involved in the study design 
discussions and assembled the paperwork for ethical committee and R&D 
application. The study protocol was written by Chantal, with supervision and advice 
from Dr Steve Cunningham and me. 
Method 
Patient selection 
Children with cystic fibrosis and healthy volunteers were recruited to complete all 
measurements on a single day. Children with CF were recruited from those attending 
the RHSC and Stirling Royal Infirmary paediatric CF clinic. A letter was sent 
inviting them to take part with the relevant parent and child information sheets. A 
follow up phone call was made after at least one week to make an appointment date 
with willing participants. Healthy volunteers were largely recruited from the previous 
healthy volunteer group (chapter 4) and a proportion from children of hospital staff. 
Again, an invitation was made by letter with relevant information sheets. The follow 
up phone call or e-mail made a date with willing participants. 
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Inclusion and exclusion criteria 
Healthy volunteers were selected as in the previous study (chapter 4). They were to 
be healthy, without chronic respiratory history and in the age-group shown. Children 
with CF were clinically stable, defined as no exacerbation requiring antibiotics in the 
4 weeks preceding the testing date. They had mild to moderate lung disease (FEV1 
>40%), characteristic of this age-group. Those with severe lung disease were 
excluded as it was thought the tests may be too difficult to perform and there was 
little experience with this particular population. Those with a significant co-
morbidity that may have confounded the results (previous prematurity, 
neuromuscular or congenital cardiac defect) were also excluded. 
Measurements were performed by myself, Chantal Ellis (4
th
 year medical student), 
Kay Riding (research nurse), Debbie Miller (research nurse) and Dr Helen Sheridan 
(clinical research fellow) between October 2008 and May 2011.   
Inclusion criteria  
Healthy volunteers 
(a) Children aged 5-16 years. 
(b) No history of respiratory disease. 
(c) No significant medical history. 
(d) Non-smoker. 
 
Children with Cystic Fibrosis 
(a) Children aged 5-9 years. 
(b) Confirmed diagnosis of cystic fibrosis (positive sweat test or genetic testing). 
(c) Clinically stable – no recent exacerbations (requiring antibiotics) in preceding 4 
weeks. 




(a) Any past history of: recurrent wheezing episodes, pneumonia, cystic fibrosis, 
pertussis or tuberculosis. 
(b) Previous diagnosis of asthma or taking anti-asthma medication. 
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(c) Previous hospitalisation for respiratory infection. 
(d) Born before 34 weeks gestation. 
(e) Neuromuscular weakness or bone disease likely to affect respiration. 
(f) Congenital cardiac defects requiring treatment. 
 
CF paediatric patients 
(a) FEV1 < 40%. 
(b) Recent chest exacerbation requiring antibiotics (in past 4 weeks). 
(c) Born before 34 weeks gestation. 
(d) Neuromuscular weakness or bone disease likely to affect respiration. 
(e) Congenital cardiac defects requiring treatment. 
Study design 
This study has a simple design. MBW and FEV1 were performed whilst sitting up, 
then lying down. It was felt that to allow time for airway changes to take place, there 
needed to be a 30 minute period of lying before repeat measurements were taken. 
The study protocol is summarised in Figure 40. The sequence was identical for CF 
and healthy control groups. 
Prior to commencing the measurements, a brief patient history was taken to ensure 
inclusion and exclusion criteria were adhered to, with details of CF treatment and 





























Figure 40 - study protocol summary flowchart 
Statistical analysis 
Basic washout data were analysed according to methods described earlier in this 
thesis, with results tabulated using a standard spreadsheet (Excel 2007, Microsoft, 
USA). Mean LCI, FRC, Vt and CEV were taken from 3 washouts. Individual 
washouts were excluded if FRC values differed by more than 10% of the next nearest 
result. FEV1 values were converted to z-score using a spreadsheet plugin. Data for 
this are published in Stanojevic et al (Stanojevic et al. 2008), with the plugin 
available from www.growinglungs.org. Mean baseline (sitting) results were 
compared between children with CF and healthy controls using the Student’s t-test. 
Paired sitting and lying results were also compared using a paired Student’s t-test. 
Statistical calculations were performed using Prism version 4 (Graphpad software, 
USA). 
Ethical approval 





Twenty children with cystic fibrosis (median age[range] 7.5[5.1-14.8] years) were 
recruited, and analysed along with data from twenty-one healthy volunteers (median 
age[range] 11.8[5-17.8] years). Data from two children with CF were excluded as 
measurements on lying were too highly variable to be acceptable. Mean baseline 
sitting measurements in these 2 children were not extreme compared with the rest of 
the group (FEV1 z-score -1.49 and -1.92 respectively, LCI 5.22 and 7.22 
respectively).  
Baseline measurements 
Mean basic information and baseline sitting measurements are shown below for the 
subjects included in the final analysis. Mean(SD) FEV1 z-score was lower and LCI 
was higher in children with CF compared with healthy controls (-1.39(1.5) vs. -
0.21(0.9), p<0.01 and 8.28(2.2) vs. 6.23(0.4), p<0.0001). Importantly, mean FEV1 




Figure 41), 6 (33%) children with CF have raised LCI (>7.4) but normal FEV1z-score 
(>-2). This indicates, as has previously been shown (chapter 4), that LCI appears to 
detect more abnormality in children with CF than FEV1.  
Mean %predicted FRC was similar between groups. Both Tidal volume and 
cumulative expired volumes were the same between groups, but because of height 

































Cystic fibrosis  
(CF) 
 
p (HV vs. CF) 
Number 21 18  
Sex (m/f) 13/8 7/11 
Median Age (yrs) 
[range] 
11.8 
[5.0 - 17.8] 
7.6 
[5.1 – 14.8] 
    
Mean (SD) Height (cm) 147.2 (22.4) 129.1 (17.4) <0.01 
Mean (SD) FEV1 (L) 2.50 (1.1) 1.36 (0.5) <0.005 
Mean (SD) FEV1 z-score -0.21 (0.9) -1.39 (1.5) <0.01 
Mean (SD) FRC (L) 1.87 (0.9) 1.15 (0.4) <0.01 
Mean (SD) % pred FRC 101.0 (21.1) 98.79 (19.5) ns 
Mean (SD) LCI (cev/frc) 6.23 (0.4) 8.28 (2.2) <0.0001 
Mean (SD) CEV (L) 11.69 (5.4) 10.04 (5.3) ns 
Mean (SD) Vt (L) 0.48 (0.2) 0.40 (0.1) ns 
Table 17 - Baseline (sitting) measurements from healthy volunteers and children with CF. Mean 
(SD) values shown with between group comparison in the right hand column  














Figure 41 - Comparison of baseline (sitting) FEV1 z-score and LCI in children with CF (red) 
and healthy controls blue). Dotted lines indicate limits of normality: -2SD below reference 
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population mean for FEV1 and greater than 7.4 for LCI (based on previous local, as well as 
international data using other devices). 
Table 18 - Change in measurements after change in posture in healthy volunteers and children 
with cystic fibrosis. Symbols show level of significance within groups:  * p<0.0001, † p<0.005, § 
p<0.01, ‡ p<0.05, 
ns
 not significant.  Significant differences between groups are shown in the 
right-hand columns.  
Change in measurements with posture 
There was a significant mean change in FEV1, FRC, LCI and CEV in healthy 
volunteers and children with CF. Only CF patients showed a significant change in 
tidal volume when supine, with a mean fall of 11% (50ml). There was a similar 
change in FEV1 and LCI (p>0.05), however while between group variance in FEV1 
was similar, there was a significantly greater variance in change LCI, indicating 
greater changes (positive and negative) in LCI in those with CF compared with 
healthy volunteers. There was a greater fall in absolute and %predicted FRC in 
healthy controls than those with CF. There is also a dissociation between change in 
FRC and change in LCI (CEV/FRC) as those with CF demonstrated a greater mean 
rise in LCI (although not significant). Intuitively, if reduction in FRC is the sole 
contributor to change in LCI the above would not be seen. 
The magnitude of change in CEV and Vt cannot be compared between groups as 
both are growth related values. The observation that Vt changes significantly in 
children with CF, but not in healthy controls is still an important finding, however. 
Figure 42 below shows the association between change in FEV1 z-score and change 
in LCI. In healthy volunteers there is a reduction in FEV1 and increase in LCI, but 
 Mean [95% CI] difference after change in posture  HV vs. CF 
 





FEV1 (L) -0.21 [-0.3 –  -0.1]* -0.12 [-0.2 – -0.04]§
 
 no no 
FEV1 z-score -0.67 [-1 –  -0.4]* -0.37 [-0.9 –  -0.03]‡  no no 
FRC (L) -0.60 [-0.8 –  -0.4]* -0.30 [-0.4 –  -0.2]*  p=0.002 p=0.002 
%pred FRC -31.4 [-37.5 –  -25.3]* -24.2 [-28.3 –  -20.9]*  p=0.03 p=0.049 
LCI (cev/frc)  0.29 [0.1 – 0.5]†
 
 0.64 [0.2 – 1.1]‡  no p=0.003 
CEV (L) -3.29 [-4.3 –  -2.3]* -1.81 [-2.7 –  -1.0]†  p=0.02 no 
Vt (L)  0.01 [-0.05 – 0.06]
ns 
-0.05 [-0.08 –  -0.02]†  p=0.09 p=0.007 
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not to the extent of becoming abnormal. The graph suggests that in those with a 
raised LCI, there is a greater change (in both directions) in LCI following change in 
posture. Because of the numbers involved it is not possible to perform sub-analysis, 
but the greatest change in LCI appears to be in those children with a moderately 
raised sitting value, rather than in those with the poorest lung function. Performing 
Pearson r correlation, there is no association between change in FEV1 and change in 
FRC, LCI, CEV or Vt, following change in posture. 
This is illustrated in Figure 43. Average LCI (sitting and lying) in each subject is 
plotted against magnitude of change on the y axis. This is an approximation of the 
Bland-Altman plot, with bias and 95% limits of agreement of change in LCI (mean 
change +/- 1.96*pooled standard deviation) with the solid and dotted lines on the Y-
axis. The dotted line on the x-axis indicates the upper limit of normal LCI. The 
greatest change in LCI is mainly limited to 6 (33%) of subjects with CF and a 
moderately raised LCI. This change is not consistent as there are 2 others with 
moderately raised LCI and no change. A minimum change in LCI is seen in subjects 
with CF with a normal LCI and healthy controls. This indicates that the presence of 









Figure 42 – Effect of change in posture on children with CF (red arrows) and healthy volunteers 
(blue arrows). Direction of change is indicated, as is association between change in FEV1 z-score 
and change in LCI. Direction towards the top left, indicates worsening of both LCI and FEV1. 
 
Figure 43 - Modified Bland-Altman plot showing magnitude of change in LCI based on average 
value. Y-axis lines show bias and 95% limits of agreement, with x-axis line showing upper limit 
































































To investigate associations with change in LCI, correlations calculations (Pearson r) 
indicate that change in LCI after lying did not correlate with change in FEV1 z-score, 
FRC, CEV or Vt in healthy volunteers. In children with CF, change in LCI only 
weakly correlated with change in CEV (R
2
 = 0.27, p=0.03) and did not correlate with 
change in FEV1 z-score, FRC or Vt. 
Conclusions 
This study shows that the effects of change in posture, measured by LCI, are 
different between healthy controls and those with lung disease. In both groups of 
children, FRC and FEV1 fell and LCI rose after 30 minutes of supine posture 
compared with sitting. Importantly this change was significantly more variable in the 
children with CF than healthy controls; with the greatest individual changes limited 
to those with measurable lung disease (raised sitting LCI) compared to those with 
normal baseline measurements. Change was not in one direction, in that LCI both fell 
and rose beyond the 95% limits of agreement of healthy volunteers. 
This is the first study to show such results, and has implications for the use of LCI in 
young children where measurements are generally performed supine. In the scenario 
of following longitudinal change in lung function in infants, those who progress over 
time from lying to sitting to perform the test may have a disproportionate change in 
lung function from one test to another, depending on the extent of lung disease 
present. It may be hard to interpret to what extent this is a worsening in lung 
function, limiting the clinical application of the test. 
Previous studies have shown that change in posture reduces resting lung volume 
(FRC). The increased effect of supine posture on LCI in those with a raised LCI has 
not previously been demonstrated. It is not clear why Aljassim et al demonstrated no 
change in LCI in children with CF(F Aljassim et al. 2009), whereas we have shown 
the opposite. In another paper by the same group, LCI did not rise in asthmatic 
children or healthy controls following a more prolonged supine period (1 
hour)(Gustafsson 2003). Professor Gustafsson uses a standard operation procedure 
that is slightly different to that described in chapter 2. He distracts all subjects with a 
cartoon or film, but in older children he displays tidal volume targeting. This 
information is from discussion with him about general MBW principles, rather than 
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from the published article, where no mention is made of tidal volume targeting. It 
may be that with targeted tidal volume breathing, any disruption of supine posture to 
ventilation heterogeneity is negated by compensating with deeper breathing, 
although this does not explain why in our study healthy volunteers saw a rise in LCI, 
and no change in tidal volume. Respiratory rate was not measured in this study, and 
may be another compensatory measure for disruption to ventilation. 
In our study, LCI did not change as a function of reduced FRC. Also, there was a 
reduction in tidal volume in those with CF, but not in healthy controls. The only 
association with rise in LCI, was increase in CEV, and only in children with CF. 
Interestingly, FRC and CEV both fell more in the healthy control group than CF. 
This suggests that there are intra-airway differences in disease groups compared with 
healthy controls that cause a fall in tidal volume, presumably due to airway collapse. 
The presence of airway inflammation and alterations in airway architecture 
(bronchiectasis) may contribute to a reduction in airway muscle tone which leads to 
increased airway collapse following a reduction in resting lung volume upon 
adopting supine posture.  
Study limitations 
This study is limited in that it did not set out to investigate respiratory effort or 
minute ventilation. It is not clear why there are differences between CF and healthy 
groups, and a further study involving detailed respiratory rate and minute ventilation 
measurements would help to understand the relationship between supine posture and 
resultant changes in breathing pattern. Larger numbers would be able to investigate 
whether degree of ventilation heterogeneity leads to increased changes following 
change in posture. 
 
A criticism of the observation that the greatest changes in LCI were seen in those 
with moderately raised LCI, is that intra-test variability is higher in this group 
anyway. Therefore even without a change in posture, there would be a bigger intra-
test positive or negative change in LCI. Importantly, in those with the highest LCI 
values, where test variability would be expected to be highest, there was minimal 
change following supine posture. Also, correlating sitting and lying intra-test 
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variability (CV%) with between posture variability showed no association (p>0.1). 
There was also no association between sitting LCI and between-posture variability 
(p>0.1).  
Studies of sleep hypoxaemia and disordered breathing in children and adolescents 
with CF postulate that increased airway resistance with supine posture, increased 
V/Q ratio, and decreased respiratory drive contribute to impaired 
oxygenation(Tepper et al. 1983, Villa et al. 2001). This appears to occur mostly 
during deep (REM) sleep. A reduction of tidal volume in deep sleep due to decreased 
muscle activity reduces resting lung volume, thereby increasing airway closure and 
decreasing V/Q ratio, leading to desaturation. In this study we have simulated 
sleeping posture but while awake. We have still seen an overall increase in LCI in 
healthy control subjects as well as those with CF. The greatest changes were seen in 
CF patients with measurable lung disease. An increase in ventilation heterogeneity 
after changing to supine posture may go some way to explaining why hypoxaemia 
occurs in children with CF. This study indicates that it may be gravity-dependent, as 
well as sleep related factors, which lead to desaturation during sleep. With a future 
carefully designed study, LCI may prove to be an important measurement to help 
decide which patients are at risk of sleep-induced hypoxaemia, as sleep studies are 
complex and time-consuming to perform. 
Learning points and contribution to thesis 
In conclusion, care should be taken when interpreting MBW results in young 
children over time, as posture may contribute disproportionately to a rise in LCI in 
those with lung disease, compared with those with normal values. This is important 
in research and future clinical use. While there is only one published longitudinal 
study in CF involving younger age-groups(Kraemer et al. 2005), it is expected that 
with wider use, more groups are ready to publish data in larger populations over 
longer periods of time. These data should be interpreted with posture taken into 
account. 
This study is also important for the wider themes of this thesis. Previous chapters 
have already demonstrated that Innocor shows promise as a tool for detecting and 
tracking change in lung disease over time in children with lung disease. This study 
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matches previous lung function and posture studies, in that a decrease in FRC was 
seen. Increased ventilation heterogeneity (interregional) is also previously 
documented in healthy men(Gronkvist et al. 2002). This study used LCI as a measure 
of overall heterogeneity, and there was a mean increase in healthy control and 
disease groups. There was a bigger increase in the CF group although this did not 
reach statistical significance. Variability (sitting vs. supine) was greatest in those 
with moderate lung disease. LCI measured with Innocor appears able to detect 
posture-related changes within the airways. 
This study was the first to use trained nursing staff and another clinical research 
fellow to perform the washouts. The additional staff were trained locally after 
observing many washouts and becoming familiar with the equipment. Because my 
post as clinical research fellow came to an end during the study, most of the CF 
patients were tested by other staff. There was no visible difference between their data 
and mine, in terms of washout quality. No more washouts were discarded following 
the change in operator. While occasional technical support was required from me, it 
was mainly due to software issues, rather than analyser issues. To restate the main 
reason for Innocor validation, Innocor is a more compact, robust, affordable 
alternative to a mass spectrometer. It is also simpler to operate, as demonstrated by 
this study. A mass spectrometer operator needs to attend a formal training session to 
be able to use this equipment. While adequate formal training is essential in the 
context of a larger multi-centre study, it is clear from this study that good quality 





Chapter 7 - Longitudinal change in LCI in children 
with progressive lung disease. 
Introduction 
This chapter describes a large clinical study conducted on behalf of the UK CFGTC. 
While the work of this group does not contribute to the central theme of this thesis, it 
is for reasons of completeness and general interest I have included much of the 
descriptive information about the “Run-in Study”. The findings of this study have 
much to contribute to the central thesis aims. It would not have been possible to 
obtain these data without the consortium initiative. The following describes some 
background to the CF gene therapy “run-in” study.  
In 2001, the CFGTC was established to investigate and develop agents for use as 
pulmonary gene therapy for Cystic Fibrosis. In the first 5 years of the consortium, 
essential basic scientific work established the principles of gene therapy for cf – a 
plasmid containing a genetic code for CFTR, and a non-viral vector to carry the 
plasmid into the airway cells. Despite the large number in the past 17 years, clinical 
trials of gene therapy have so far been limited to a small numbers of patients 
measuring a cellular or electro-chemical response(Griesenbach et al. 2009) . Positive 
results from these studies have stimulated progression from basic to clinical science. 
Instead of only assessing cellular responses alone, a clinical benefit must also be 
elicited.  
In CF the most commonly quoted clinical outcome is survival. Fortunately for 
younger patients this end-point is many years in the future as overall life expectancy 
is increasing. Either the trial of treatment would need to be very prolonged, or the 
follow up period set far in the future. This incurs a lot of expense and very slow 
progression of scientific knowledge. In recent years, the response to the difficulties 
of measuring slow disease progression has been to investigate surrogate markers of 
long term outcomes. The ideal assay is simple and repeatable, representing a true 
assessment of disease progression, and how a new intervention has influenced this 
severity 
The CFGTC conducted the tracking study in 2006. This study recruited adults and 
adolescents with CF during a respiratory exacerbation. Measurements were 
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performed at the beginning, end and 2 weeks after a course of intravenous 
antibiotics. A main aim of this study, in addition to collection of valuable data on 
assay variability, was development of the best available surrogate assays relevant to 
CF in adolescents and adults,  individuals most likely to receive Gene Therapy in 
future trials. Given that these assays were complicated to set up, perform and 
analyse, the tracking study provided an opportunity to practice in a real clinical 
research situation. Assays in this project were selected to measure all aspects of CF 
lung disease – lung function, inflammation, structure, infection, symptoms and 
quality of life/ daily functioning.  
In 2008, the Run-in study commenced. Using data and experience from the tracking 
study, assays were selected if tolerable to patients and most likely to detect a change 
following treatment with gene therapy. They needed to be reproducible and 
repeatable in real CF patients. One of these assays is Lung Clearance Index. I was 
employed by the CFGTC in 2006 primarily to recruit and retain paediatric patients to 
this long-term study in Edinburgh. 
This chapter briefly describes the Run-in study method, but will only concentrate on 
MBW and spirometry results performed in children and teenagers recruited by me, as 
other assays were not managed by me, and have not yet been completely analysed. 
Many assays will be listed, but not explained as results are not presented here. The 
run-in study will in due course progress to a clinical trial of gene therapy, and 
recruitment from those who completed the run-in study has begun at the time of 
writing this chapter. 
In the context of this thesis, the whole run-in study is of limited importance. 
However such a study assesses the practicalities of using Innocor in a long-term 
study in larger numbers of subjects, i.e. how robust the equipment is, and how 
acceptable it is to patients. In addition, data from the run-in study is able to assess 
how well LCI detects change in lung function compared with FEV1. These are some 
of the first data to measure longitudinal change in ventilation heterogeneity (LCI) in 
young people with CF. In another important study which helps to inform the run-in 
study, Kraemer et al previously published annual clinical and lung function data in 
142 children and adults with CF (aged 6 to 20 years)(Kraemer et al. 2005). They 
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demonstrated that LCI, along with FRCpleth and MEF50 had the steepest slope of 
progression over time. FEV1 progression was least steep.  
Scientific basis for inclusion of LCI in the run-in study 
Previous clinical studies measuring LCI in CF have mainly been limited to single 
measurements or very short term change, with some groups beginning to collect 
longitudinal data(Robinson et al. 2010, Robinson et al. 2009a, Gustafsson et al. 2008, 
Kraemer et al. 2005, Aurora et al. 2004, Fuchs et al. 2010, Riedel et al. 2009). In 
developing LCI as a potential assay in future gene therapy trials, sensitivity to 
change over the planned gene therapy trial needs to be estimated. LCI must therefore 
be able to measure the slow, gradual decline often seen in CF, the rate of which is 
highly variable between patients. A complicating factor is how acute events such as 
exacerbations contribute to this. For this reason the run-in study was designed to 
perform serial measurements over time, in clinically stable individuals. The 
hypothesis was that if a predictable change in LCI is seen over time (12-18 months), 
repeatable between visits, and correlating with change in other assays (e.g. structure, 
function, symptoms), then it may be suitable for detecting a halt in decline, or even 
improvement following repeated doses of inhaled gene therapy.  
As stated previously, LCI is thought to be a global measure of ventilation 
heterogeneity, contributed to by airway changes in the small to medium airways. If 
CF lung disease progresses from the small to medium airways, LCI is intuitively 
more likely than FEV1 to be a more suitable assay. 
Prior to starting the run-in, the results of which are not complete at the time of 
writing this chapter, the proposed broad selection criteria for the future gene therapy 
trial were: 
1. Those in which CF lung disease is severe enough to measure with the 
available assays. 
CF begins in infancy with early evidence of airway inflammation(Armstrong et al. 
2005, Armstrong et al. 1997, Armstrong et al. 1995). The earliest changes appear to 
be only evident in invasive broncho-alveolar lavage studies, or on CT scan, with 
associated radiation risks with repeated measurements (de Jong et al. 2006, 
Armstrong et al. 2005, Dakin et al. 2002a, Dakin et al. 2002b, Gustafsson et al. 
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2008). Most other tests are normal, and remain so until late childhood. Because LCI 
appears to detect mild or early airway disease, it was added to the list of assays for 
the run-in study and gene therapy trial.  
2. Those in which lung disease is not so severe that there is too great a barrier to 
inhaled gene transfection. 
Mucous biolayers and inflammation cause thickening of the wall between air and 
cells. In advanced disease it may be that this barrier is too thick, rendering 
transfection of the inhaled gene product unsuccessful(Griesenbach et al. 2006). The 
obvious caveat to this is that a “no signal” result from a gene therapy trial may be 
due to lack of availability of the product due to intra luminal barriers to transfection, 
or simply no response because the product is defective. 
The consortium summarise those patients with measureable disease, which is not too 
severe for successful transfection of inhaled therapy as the “can deliver, can 
measure”. 
It is likely that those in the adolescent age-group will be those in the “can deliver, 
can measure” group. Intuitively it makes sense to treat those earlier in the disease to 
get the most benefit. However, concerns about the ethical propriety of recruiting 
young children to the first multi-dose gene therapy trial resulted in a minimum age of 
12 years for the first multidose trial. For the run-in study, children as young as 10 
were recruited with the realisation that the run-in will take 18 months to 2 years to 
complete. 
Chapter aims 
This chapter uses FEV1 and LCI data from all paediatric patients in the Run-in Study 
at the Edinburgh RHSC site as these are measurements I performed and analysed. 
The primary aim is to: 
 Assess the sensitivity of LCI measured using Innocor compared with FEV1 
on multiple occasions over 18 months in cystic fibrosis lung disease.  
Secondary aims are: 
 Long-term reproducibility of LCI measurements performed using Innocor on 
healthy controls. 
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 Suitability of Innocor for larger clinical studies. In particular, how robust is 
the equipment, and how acceptable is the test to children with lung disease? 
Methods 
The protocol for the run-in study was assembled by a large team of experienced 
clinical and laboratory researchers over many months. My role was refining the 
protocol for the LCI in children, along with Dr Alex Horsley, the clinical research 
fellow responsible for recruitment of adult patients. While I had some input to the 
assay order, timing of testing, protocol writing and data analysis, this is not my study 
and apart from the MBW assay, the protocol is not mine. The following is a 
description of the methods for the run-in study, but in addition there are important 
data from healthy volunteers that were not part of the run-in study. These children 
were recruited initially as part of other studies included in this thesis, and the study 
protocol was my responsibility. 
Children with CF 
According to inclusion and exclusion criteria, paediatric patients in centres local to 
Edinburgh were invited to take part in the run-in study, with the added information 
about the forthcoming gene therapy trial. Local centres were identified where 
travelling time to the study site (Royal Hospital for Sick Children, Edinburgh) was 
deemed acceptable. Four clinical sites were contacted: Edinburgh (Royal Hospital for 
Sick Children), Glasgow (Royal Hospital for Sick Children, Yorkhill), Stirling 
(Stirling Royal Infirmary) and Dundee (Ninewells Hospital). Together with 
responsible consultants and specialist nurses, families were identified who fitted the 
inclusion criteria. Information was sent out, with the option of a telephone discussion 
regarding the details of the study. A slightly different approach was chosen at each 
site, depending on the responsible consultants’ preferences. Some preferred to select 
families they thought would be suitably interested and motivated. Other centres 
preferred to be as equitable as possible, giving all eligible families the opportunity to 
opt in. 
Interested families returned the invitation and a date was set for the first visit, after 
checking inclusion and exclusion criteria. Patients were considered recruited at the 
time of commencing the first study visit. 
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Visits were estimated to take around 3 hours. 2 visits could take place per day, with 
time in-between to clean the room and ensure low risk of cross-contamination of 
colonised bacteria.  
Parallel recruitment of adult patients from Scotland took place at the Western 
General  Hospital, and because some assays required laboratory staff support, only 2 
days per week were allocated as paediatric study days, with a total of 4 possible 
study visits per week. A 16 week lead-in time was built in to the study timetable for 
completion of all first visits. Therefore, the maximum possible number of paediatric 
patients in the Royal Hospital for Sick Children was 64; however it was clear that 
many appointments would need to be changed at the last minute because of 
exacerbations and other variations to management affecting the strict stability 
criteria. Therefore flexibility was built into the timetable to allow the freedom to 
change appointments if patients were not able to attend. 
The run-in study was conducted over 18 months, with patients attending 4 times over 





 visit was 12-15 months. The study was conducted over 3 sites – the Royal 
Brompton Hospital, London (paediatric and adult), and the Western General Hospital 
(>16 years) and Royal Hospital for Sick Children (RHSC), both in Edinburgh. 
Patients were recruited with the following inclusion and exclusion criteria (taken 
from the study protocol): 
Inclusion 
1. Cystic fibrosis confirmed by a combination of clinical symptoms/ signs and 
sweat test, genetic analysis or nasal potential difference measurements.  
2. Forced expiratory volume in 1 second (FEV
1
) > 40% of predicted values.  
3. Clinical stability at entry defined by:  
a. Not on any extra antibiotics (excluding routine, long-term treatments) 
for the last 2 weeks.  
b. No increase in symptoms such as change in sputum production/ 
colour, increased wheeze or breathlessness over the last 2 weeks.  
c. No change in regular respiratory treatments over the last 4 weeks.  
4. Aged 10 years and above. 
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5. Written informed consent from patient (aged 16 years and above) or parent if 
younger child; assent from child where appropriate.  
6. Permission to inform GP of participation in study.  
 
Exclusion 
1. Current participation in any other interventional clinical trial.  
2. Infection with Burkholderia cepacia complex organisms or MRSA unless 
local infection control guidelines can be adhered to. 
3. Awaiting/ referred for or post-lung transplant.  
4. Chronic day-time oxygen requirement.  
5. Previous spontaneous pneumothorax unless patient has had a subsequent 
pleurodesis.  
6. Recurrent severe haemoptysis.  
7. Current smoker (will be assessed by measuring urinary cotinine level or 
exhaled CO prior to study entry).  
8. Significant comorbidity including:  
a. Moderate/ severe CF liver disease (varices or significant, sustained 
elevation of transaminases: (ALT/ AST>100 IU/l).  
b. Significant renal impairment (serum creatinine > 150 μmol/l).  
c. Significant coagulopathy.  
9. Receiving 2nd line immunosuppressant drugs such as methotrexate, 
cyclosporine or intravenous immunoglobulin preparations.  
10. Pregnancy. 
 
Therefore, these criteria were designed to select those with confirmed CF, and were 
likely to select those with measureable lung disease, without being too severe to be 
able to benefit from the treatment in a subsequent gene therapy trial. 
Assays performed at each visit are shown below. A detailed description of each test 
is not provided, as results are not available for this chapter. It is shown here only as 




Table 19 - Full schedule of gene therapy run-in study 
Test Assays Visit  
1 
Visits  




Sputum expectoration Microscopy and culture 
Inflammatory assays 




    
Blood tests Standard clinical biochemistry 




    
Exhaled Breath Condensate pH, nitrite and ammonia     
Urine Research inflammatory assays     
Quality of Life 
Questionnaire 
Standardised Questionnaire 
    
Multiple Breath Washout LCI 
FRC 
    
Shuttle Walk Test Modified 6-minute walk test     
Hypertonic Saline Sputum 
induction 
If no spontaneous sample 
obtained 
    
High Resolution CT scan Various scored items      
 
Additional interim measurements 
Pedometer Steps taken each day in the week prior to testing 
Weekly Spirometry (Piko-6 
handheld spirometer) 
FEV1  and FVC (FEV6) performed on the same day, weekly 
between measurements 
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The study was designed to perform the assays at a time of clinical stability. To 
ensure this was the case, a standard phone questionnaire was conducted with each 
patient or parent approximately 1 week prior to each visit. The stability criteria 
shown below refer to the week prior to the visit, except the last question relating to 
routine medication: 
 No new courses of iv or oral antibiotics  
 No fever greater than 38oC (temperature was asked to be taken with “tempa-
dot” thermometer whenever fever suspected) 
 No unscheduled absence from school or work due to CF illness 
 No increased cough 
 No major change in sputum volume or consistency or change in chest 
symptoms 
 No increased shortness of breath 
 No new haemoptysis 
 No other clinical issues that may affect the measurements 
 No change in routine respiratory medication in previous 3 weeks 
 
If there were any stability issues, the appointment was re-scheduled for 3 weeks later, 
and stability re-checked. The sequence of questions was not a validated technique, 
but was formulated to make sure patients adhered to inclusion and exclusion criteria, 
and to allow the best comparison of results between visits. 
Only spirometry and MBW data are presented in this chapter, therefore the methods 
of other measurements are not described. Spirometry and MBW data were collected 
at every visit, according to methods described in chapter 2.   
MBW was performed using Innocor to collect flow and gas concentration data for 
calculation of FRC and LCI. The setup and analysis was identical to that described in 
Chapter 2. 
FEV1 was performed using the EASYONE device (ndd, Switzerland) as described in 
previous chapters. Measurements were performed standing, without a noseclip. 
Subjects were asked to inhale to full vital capacity, and then forcefully exhale 
without a pause to residual volume. As previously described, 3 good quality forced 
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expirations were performed at flow limitation, according to ERS criteria; with the 
highest FEV1 value dictating which manoeuvre to select. 
Healthy control population 
To assess long-term reproducibility of measurements in healthy controls, data from a 
cohort recruited to 2 previous clinical studies were analysed. In 18 cases, the same 
healthy children were recruited to the asthma study (chapter 4) and posture study 
(chapter 6). As measurements in these studies were completed approximately 24 
months apart, this is a convenient sample to study. 
This represents a retrospective analysis and would not be valid if there were changes 
to the test standards or equipment during this time. Importantly, the same MBW test 
protocol was used for the asthma, posture and run-in studies – that outlined in 
chapter 2. Similarly, FEV1 was performed to the same standards in each study. 
Statistical analysis 
Measurements were expected to fluctuate over time due to natural variability and 
temporal changes in gas mixing (to be thought of as random variation). The purpose 
of this analysis is to assess the ability of LCI to detect longitudinal change in CF lung 
disease compared with Spirometry (FEV1), independent of these fluctuations. For 
this purposes of this chapter, this change is thought of as true progression in disease 
over time, although this implies that random variability is reversible, and underlying 
disease progression is not. With this major limitation in interpretation in mind, the 
following statistical analysis was performed. 




 measurements is the most basic way to 
assess these data. The null hypothesis is that the overall change in LCI and FEV1 
over 18 months (4 measurements) is no greater than two standard deviations from the 
baseline measurement. 




 measurements are not influenced by 





Analysis of variation (ANOVA) allows analysis of more than 2 measurements to see 
if an observed difference is likely to be greater than that expected from random 
variability, and is a ratio of within and between test variability(Altman and Bland 
1996). 
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To assess the reproducibility of measurements in health controls, within-subject 
variability of LCI measurements (Coefficient of variability, CV%) is measured 
between 2 visits, similarly spaced. Variability of FEV1 z-score measurements is also 
assessed, although CV% is not appropriate in this case due to the distribution of 
values around zero.  
FEV1 and height z-scores are taken from published normal populations(Freeman et 
al. 1995, Stanojevic et al. 2008), using Microsoft Excel plug-ins to calculate values 
(www.growinglungs.org.uk). %predicted FRC is taken from an age-appropriate 
reference population(Stocks and Quanjer 1995). 
This study as a whole was powered with the gene therapy trial in mind. No statistical 
power calculation was done. A maximum of 100 patients were able to be recruited to 
the future trial, and to take into account attrition and future exclusions from the trial, 
twice as many were recruited to the run-in study. In the paediatric arm of the study in 
Edinburgh, the maximum number able to be recruited was 36, given the manpower 
and time taken to complete each visit.  
Ethical approval 
The complete run-in study was approved by the Kings College Hospital Research 
Ethics Committee (07/Q0703/78). Data from patients in this study were taken for 
inclusion in this chapter. 
Results 
34 paediatric patients (median age 12.3 [range 10-17] years) were recruited to the 
run-in study and completed the first visit. Basic demographic information is shown in 
Table 20. One child was not eligible following visit 1 because of Cepacia growth in 
induced sputum. One subject did not complete v3 and v4, and one did not complete 
visit 4, because they were too old and had moved to the adult CF service. Two 
further subjects did not complete v4 because unable to attend due to exacerbations 
and breaching stability criteria. Therefore, 29 patients (88%) have complete 
Spirometry and MBW data for 4 visits. Data are included for all 34 patients in the 
following tables and graphs. 
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18 healthy control subjects (median age 19.2 [range 5 – 16]) are included as a 
convenient control to assess long-term reproducibility of MBW measurements in 
children. 
  Run-in Study Healthy controls 
Number  34 18 
    
Male/female  22/12 12/6 
    
Median age (years) 
[range] 
 12.3 
[10 – 17] 
10.2 
[5 - 16] 
    
Median height (cm) 
[range] 
 152.0 
[137 – 184] 
146.0 
[118 – 180] 
    
Median height z-score 
[range] 
 -0.17 
[-2.3 – 3.1] 
0.86 
[-1.5 – 2.7] 
    
Mean (SD) FEV1 z-
score 
[range] 
 -1.62 (1.3) 
[-5.4 – 0.5] 
-0.82 (1.1) 
[-3.1 – 1.3] 
    
Mean (SD) FRC (L) 
[range] 
 1.99 (0.6) 
[1.3 – 3.7] 
2.01 (1.1) 
[0.8 – 4.5] 
    
Mean FRC % predicted 
[range] 
 98.54 (17.7) 
[69.7 – 128.4] 
111.7 (21.4) 
[74.0 – 145.7] 
    
Mean LCI (cev/frc) 
[range] 
 9.02 (1.8) 
[6.7 – 14.2] 
6.39 (0.55) 
[5.3 – 7.4] 
Table 20 - basic demographic information. CF and healthy control groups 
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In this CF population Mean (SD) LCI (9.02(1.8)) was significantly higher, and FEV1 
(-1.62 (1.3)) was significantly lower, than healthy controls (6.39 (0.6), p<0.0001 and 
-0.82 (1.1), p=0.03).  
27 patients (80%) had abnormal LCI (>7.4) at baseline. 13 patients (38%) had 
abnormal FEV1 (<-2). These cross-sectional data demonstrate that increasing age 
appears to be associated with abnormal LCI and FEV1 (Figure 44 Figure 45).  
 
 
Figure 44 - Baseline (visit 1) LCI measurements by age 
 
Figure 45 - Baseline (visit 1) FEV1 z-score measurements by age 
 
Comparing baseline (visit 1) FEV1 and LCI measurements, most either have both a 
normal FEV1 and LCI, or abnormal FEV1 and LCI. 14 subjects (41%) have an 
abnormal LCI but normal FEV1, whereas only one with a normal LCI had a 















































marginally abnormal FEV1. Figure 51 shows baseline FEV1 vs LCI. There is a 
significant correlation between these measurements (R
2
= 0.41, p<0.0001).  
 
Figure 46 - baseline FEV1 standard deviation score vs. LCI in children with CF 
Comparison of CF with healthy controls – long-term change and 
reproducibility 
 Run-in subjects  Healthy controls  
Number 29  18  
 Visit 1 Visit 4 t-test Visit 1 Visit 2 t-test  
Median Age (yrs)  
[range] 
12.3 
[10 – 16] 
13.4 
[11 – 17] 
 10.1 
[5 – 16] 
12.3 
[6 – 18] 
 





[10.6 - 16.3] 
  
22.2 
[16.3 – 31.8] 
 
Mean (SD) LCI 
[range] 
8.96 (1.9) 
[6.7 – 14.2] 
9.14 (2.1) 
[6.1 – 15.5] 
p=0.38 6.39 (0.6) 
[5.3 – 7.4] 
6.31 (0.5) 
[5.3 – 7.0] 
p=0.57 
Mean (SD) FRC 
[range] 
1.97 (0.6) 
[1.3 – 3.7] 
2.10 (0.7) 
[1.3 – 4.5] 
p=0.049 2.01 (1.1) 
[0.8 – 4.5] 
2.20 (0.9) 
[0.9 – 4.1] 
p=0.048 
Mean (SD) %pred. FRC 
[range] 
97.90 (17.8) 
[69.7 – 126.5] 
92.86 (15.8) 
[71.2 – 136.8] 
p=0.07  111.75 (21.4) 
[74.0 – 145.7] 
129.5 (30.6) 
[81.4 – 181.3] 
p=0.01 
Mean (SD) FEV1 z-score 
[range] 
-1.56 (1.3) 
[-5.2 – 0.5] 
-1.85 (1.4) 
[-5.5 – 0.1] 
p=0.09 -0.83 (1.1) 
[-3.1 – 1.3] 
-0.24 (1.0) 
[-2.9 – 1.3] 
p=0.05 
Table 21 - Comparison of CF subjects with healthy controls. First and last measurements in 
both groups are compared. Significant differences (students t-test) are shown in bold (p<0.05).  
Baseline (visit 1) FEV1 vs. LCI

















Table 21 shows how measurements change over time. There is a significant change 
in FRC, which is to be expected in growing lungs. There is a rise in %predicted FRC 
in healthy controls, with a trend towards a fall in CF. There is a trend towards a rise 
in FEV1 z-score in healthy controls (p=0.05), with a slight fall in CF patients 
(p=0.09), although neither reach statistical significance. Importantly, there is no 
significant change in LCI in either group. 
 
Analysing change in LCI and FEV1 in healthy controls shows that LCI performs 
well. Variability (CV%) within subjects over 2-3 years is <5%. This is illustrated in  
Figure 47 and 48. FEV1 z-score does appear to increase over the time period in 




Figure 47 and 48 illustrate the direction and variability of change in healthy controls over time. 
 
 
Figure 47 and Figure 48 - LCI and FEV1 z-score at 2 time points plotted against age in years. 
This chart shows change in individual LCI over time in healthy controls. The arrow shows the 
direction of change. In one subject only one FEV1 result was available due to technician error 
(indicated by a dot) 
Longitudinal change in LCI and FEV1 in children with CF 
Performing One-way Analysis of Variation (ANOVA) shows a significant increase 
in LCI at timepoint 3. There is no significant change in FEV1 at any timepoint (Table 
22). Performing ANOVA for trend however, shows no significant change in LCI 
over the 4 timepoints (p=0.2) whereas FEV1 has a significant, if small, trend over the 
time period (slope -0.06, p=0.03). In this population, therefore, there is an overall 






































V2 V3 V4  1-way ANOVA 
for trend 
p 
Number 34 33 32 29 
 
 
       
Mean (SD) FEV1 z-score -1.62 (1.29) -1.55 (1.51) -1.75 (1.74) -1.85 (1.36) 
 0.03 
Mean (SD) LCI 9.02 (1.83) 9.30 (2.40) 9.62 (2.04)* 9.14 (2.11)  ns 
 
Table 22 - Mean FEV1 z-score and LCI values over 4 visits in children with CF. There was a trend 
towards a decline in FEV1 over the time period. * significant increase in LCI only at this timepoint 
(1-way ANOVA, p=0.02). 
 
Figure 49 illustrates the complexity of overall trend in LCI and FEV1. The top plots 
show the overall change from v1 to v4. The bottom plots show the degree of 
variability of measurements over the 4 timepoints, illustrating the importance of 
multiple repeated measures to detect a significant change, independent of period 
“random” fluctuation. 
 
Figure 49 - Change in FEV1 z-score and LCI. Top plots draw line between 1st and 4th 
measurements. Bottom plots connect all 4 measurements to show inter-visit variability 
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The plots above aim to illustrate the variability of FEV1 and LCI measurements 
between visits. Despite patients being tested at a period of clinical stability, defined 
by the locally developed criteria, there is still a great degree of fluctuation of values 
(mean [SD] CV% of within-subject LCI over 4 visits = 8.95[5]). This highlights the 
inherent difficulties of performing lung function tests in CF. Drawing a straight line 
between visit 1 and visit 4, ignoring the measurements in-between may 
underestimate the significance of a change. 
An alternative analysis strategy is to look at all FEV1 z-score values plotted against 
LCI in individuals (Figure 50). A linear regression line is drawn using the 4 values 
from each individual, so that the overall trend can be seen. No direction is indicated 
in this plot, but an association is seen where lines follow upper left to lower right 
direction (increased in LCI with fall in FEV1 z-score), or vice versa (decrease in LCI 
with rise in FEV1 z-score). Lines which follow a perpendicular trajectory to this 
indicate a dis-association in overall trend. In this scenario, there is overall a weak 




Figure 50 - FEV1 plotted against LCI at each timepoint (individual points not shown). A linear 
regression line drawn for each subject shows an association between change in FEV1 and LCI. 
Direction of change not indicated in this graph. 
Finally, a comparison of average monthly change in FEV1 vs. LCI shows that 25 
(75%) subjects demonstrated an average rise or no change in LCI over 4 visits. FEV1 




















 linear trend in FEV1 z-score 
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expected average fall, or no change, in FEV1 z-score. Most subjects show an 
associated change in both measurements, as illustrated below  
Figure 51), however some show a rise in LCI, with an associated rise in FEV1. None 
showed a fall (improvement) in LCI with a fall (worsening) in FEV1.  
 
Figure 51 - Average change in FEV1 vs. average change LCI per month. Indicating the 
association between average change in measurements. 
Conclusions 
Lung clearance index in children with CF is higher than healthy controls, and LCI 
appears to be more able to detect lung disease than FEV1, in that abnormalities were 
detected in more subjects.  
Baseline measurements showed a cross-sectional trend towards increased LCI and 
decreased FEV1 z-score in older children. This trend has previously been reported by 
Aurora et al (Aurora et al. 2004), (Figures 52 - 53). Their study from 2004 was 
conducted in 22 children with CF and age-matched healthy controls aged 6-16 years. 
Those with CF had an increased LCI and, importantly, only 1 child with CF had a 
LCI value within 2 standard deviations of the healthy control mean. This study, with 
others by the same authors, generated a great deal of interest in the scientific 
community for LCI as a marker of CF lung disease. This marked distinction between 
healthy control and disease populations is not commonly seen in physiological 
measurements, but the run-in study data do not show the same clear difference. There 
are a number of possible explanations for this that have relevance for this study, as 
well as future studies in CF. 

























































The population chosen for the run-in study was defined as those with mild to 
moderate CF lung disease (FEV1 ≥40% predicted). In addition, measurements were 
only performed while clinically stable, according to clinical criteria. Finally, those 
with Cepacia colonisation – associated with increased decline in lung function – 
were excluded. Subjects in the Aurora et al study were recruited opportunistically 
from outpatient clinics and in-patients, and therefore were not controlled for 
exacerbations or changes in treatment. Patients in the run-in study were tested at least 
4 years after those in the Aurora et al study. In a different population with different 
treatment this may explain some of the disparity in the cross-sectional data. 
There was a significant trend of decreasing FEV1 over the 4 timepoints, whereas LCI 
did not change. Average direction of change in FEV1 matched that of LCI in all but 6 
(18%) patients. In these 6 cases, there was an improvement in FEV1, but with an 
increase (worsening) in LCI.  In no cases did LCI improve where FEV1 worsened. 
Figures 52 and 53 - data from Aurora et al 2004, showing cross-sectional association 
between increasing age and worsening lung function. No effect of age in healthy controls. 
Clear distinction between disease (CF, black symbols) and healthy controls. 
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Therefore, this indicates that LCI may be measuring an aspect of airways disease 
also measured by FEV1, but that it may also be measuring a different aspect of 
airways disease (possibly medium to small airways disease). These data are unable to 
examine this, therefore this can only ever be speculation. 
In healthy controls, LCI did not change after 2-3 years. Reassuringly, results are very 
reproducible (CV <5%), adding to the validity of the changes seen in those with CF. 
There appears to be a trend for increased FEV1 z-score over time, which did not 
reach statistical significance in this cohort. It cannot be proved from these data what 
this related to. There may be inaccuracies in the z-score algorithms or simply better 
results due to improved subject technique on the second occasion, even though FEV1 
is effort independent at flow limitation. 
The results presented here were conducted as part of a large clinical programme 
leading to a clinical trial of pulmonary gene therapy for CF. The other data have not 
yet been analysed and are not presented here. This study will yield important 
information for selection of patients for the future trial but also contributes, as a 
stand-alone study, to the understanding of CF as a progressive airway disease.  
The data presented support the use of LCI as an outcome measure for a trial of gene 
therapy. LCI seems to be measuring, in part, a similar aspect of airway disease as 
flow-limitation spirometry. Measurements change slowly in this population, as may 
be expected. LCI is able to detect change in measurements over time. More frequent 
measurements over a longer period of time would help in understanding the reasons 
for fluctuations in in measurements in clinically stable individuals. Other data 
collected as part of the run-in study – e.g. weekly home FEV1 measurements, 
inflammation measurements, exercise capacity or infective colonisation – will also 
contribute to this. These data have not yet been analysed. 
LCI is proposed as a surrogate marker of CF disease progression. It is assumed that 
CF progresses (i.e. gets worse) over time but also there are periods of poorer lung 
function (e.g. an exacerbation) that responds to treatment (e.g. antibiotics). It can be 
difficult to separate these two elements if measurements are taken without 
controlling for exacerbations or changes to treatment. These were controlled for in 
the stability criteria check prior to testing. 
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In using these data to plan for a gene therapy trial there are multiple aspects 
complicating the analysis. CF is a highly heterogeneous condition, in that there are a 
variety of severities, with variable progression within severity levels based on a 
number of factors (e.g. pseudomonas colonisation or number of exacerbations). All 
patients over the 18 month time period had episodes of poorer health. There were 
changes to medication, exacerbations, new interventions and presumably variable 
adherence to prescribed therapy. Because there is no guarantee that the initial 
measurement represents the true disease state at that point, independent of periodic 
fluctuations, a line cannot be drawn between visit 1 and visit 4 without including 
observed fluctuation over that time period. Additional measurements taken during 
the run-in visit – symptom scoring and inter-visit FEV1 measurements – will help to 
distinguish  fluctuations from “true change”, but were not available for this thesis. 
Learning points and contribution to thesis 
Concerning the aims of this thesis, the run-in study provided a great deal of 
information on the utility of Innocor in a larger clinical study, as there are important 
practical considerations when validating a lung function device.  
During the run-in study, Innocor was used for approximately 360 washouts. It did not 
require extra servicing during this study, and there were no technical problems that 
meant the test couldn’t be performed, or where the validity of the results was in 
doubt. Innocor is also portable in that the self-contained flow meter and analyser can 
easily be transported to another site. The limitation to this is transporting the 
pressurised gas tank, as this is bulky and subject to a number of health and safety 
regulations. There is obviously the possibility of having gas tanks available in 
multiple locations. 
To perform the test to the highest standard, ensuring adequate washin and washout, 
one complete manoeuvre can take up to 20 minutes. Performing 3 is obviously time-
consuming. MBW was one part of a long series of tests in the run-in study, taking 
over 3 hours to complete. This may have implications for the use of MBW in some 
studies, depending on the number of other assays being performed. The MBW test 
was acceptable to all subjects who took part in the study. It was obvious that the 
washin period causes a dry mouth, and this is worse in those with advanced disease 
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because of prolonged washin time. Other than that, the test is simple, if boring, to 
perform. Distraction in the form of an appropriate video was all that was required. If 
this test was to be performed on a regular basis, there may be some compliance 
issues, which were masked in this study by the novelty of the test and the increased 
motivation of being part of a Gene Therapy project. 
In summary, this chapter describes a large clinical study, however only analysing a 
small portion of data. Innocor performed well during this long study period with a 
relatively large number of patients and no technical concerns. The results are largely 
consistent with previously published work. LCI is higher in CF compared with 
healthy controls, and appears more able than FEV1 to detect mild to moderate lung 
disease. LCI measured during periods of clinical stability increased over the study 
period despite high variability between time points. Concerning the wider thesis 
question of Innocor validation, this chapter adds strength to the argument that MBW 
using Innocor is able to accurately estimate and track ventilation heterogeneity in 





Chapter 8 - methods II: Innocor hardware 
modifications for use in young children and infants 
Introduction 
The first part of this thesis has described the validation of Innocor for older children 
and adults. Building on previous work carried out by Dr Alex Horsley, adult clinical 
research fellow, I was able to set up the equipment for use with older children (≥5 
years). The methods and clinical studies contributing to the wider theme of Innocor 
validation have already been described. 
A further question that arose from these initial studies was whether the perceived 
limitations to the Innocor system that prevented its use in younger children and 
infants could be overcome to allow studies to be conducted in this age-group. The 
following section of the thesis concerns this important validation question. 
 
As explained in previous chapters, Innocor is a promising technology for MBW 
measurements. It has the following advantages over similar equipment (e.g. A mass 
spectrometer): 
 Ease of use 
 Portability 
 Relative affordability 
 Relatively high gas analyser signal to noise ratio 
 
There are concerns over the limitations to Innocor that may invalidate its use in 
young children and infants, the age group in which many feel there is greatest 
potential application. The main limitations are: 
 Slow analyser response time 
 High gas sample flow rate 
 
These concerns were raised following discussion with experienced researchers, who 
used MBW equipment on a regular basis. Information from detection and tracking of 
disease progression from infancy to adulthood is of interest to research groups and 
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clinicians. If the above limitations to the Innocor device cannot be resolved, 
invalidating its use in children less than 5 years, there will be only limited future 
research and clinical relevance. For MBW measurements conducted on Innocor to 
become accepted in the wider academic world, these specific concerns needed to be 
resolved. 
 
This chapter describes the Innocor technology in detail, and how the above 
limitations contribute to error in MBW measurements conducted in infants and 
young children. There is a description of work completed previously by Dr Horsley, 
as part of his PhD thesis, to provide background to the current experiments.  
 
Section 1 - Background and previous research 
Initial Innocor modifications 
The standard “off the shelf” Innocor setup is not designed for MBW measurements. 
Its licenced purpose is to measure flow and exhaled gas concentration during 
exercise testing. While there are similarities between multiple breath washout and 
non-invasive cardiac output measurement – washout of gas is followed in both cases 
– the equipment requirements and data analysis process are different. 
Initial investigation in previous research revealed the following factors that 
prevented use in MBW testing. 
 The flow meter has a large equipment dead space (Figure 54) to allow 
automatic switching between gas and air supplies. This is appropriate for 
exercise testing as large tidal volumes are expected. During resting tidal 
volume breathing this large dead space may introduce error unless accounted 
for 
 The large dead space risks accumulation of CO2 with prolonged testing. This 
risk increases in younger patients with smaller tidal volume 
 The gas sampling capillary placement is optimised for automation of re-
inspired gas tests including switching from test gas to air with a valve system. 




Figure 54 - Standard Innocor rebreathing valve unit (RVU) with connections.  
1 gas sample line, 2 flowmeter, 3 respiratory bacterial/viral filter, 4 mouthpiece, 5 rebreathing 
bag, 6 breath-by-breath port, 7 rebreathing port. Total equipment dead space approx. 130ml. 
Taken from Innocor user manual(Innovision 2005-05) (COR-MAN-0000-001-IN / UK, May 
2005). 
 
To resolve the initial problems with the standard setup and to increase similarities 
with other centres performing MBW measurements, a replacement low deadspace 
screen pneumotach was chosen instead of the standard Innocor Pneumotach to 
measure flow. Consistent with the MBW setup seen at other centres a sample 
capillary was sited inside the pneumotach using a metal needle(Gustafsson 2005, A. 
R. Horsley et al. 2008, Morris et al. 2001, Aurora et al. 2005b). 
To establish the principle of Innocor in MBW measurements and to begin validation 
of the device, Horsley and Gustafsson also conducted a series of studies on the 
Innocor device in adults [unpublished data]. The device was initially tested against 
the mass spectrometer to confirm its ability to accurately estimate gas concentration 
and breath volume during tidal breath tests. A series of washouts was performed, 
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simultaneously collecting Innocor and mass spectrometer gas concentration signals. 
When the signals are overlaid there appeared to be a close match, although 
calculations of expired and inspired gas volume showed large differences. The 
expired SF6 volume was 4% less when measured through the Innocor. Inspired 
concentration was also greater when measured by Innocor. 
Data comparing results with The mass spectrometer were also collected from adult 
washouts at a faster respiratory rate (~30/min). It was shown that at lower breathing 
rates normally seen in adults the two devices are comparable. However, it was 
observed that while the signals overlap well, additional error was introduced at 
slightly raised respiratory rates. The error may also be greater in disease states 
because of longer washout duration. This was not studied. 
 
To confirm stability of the concentration measured by the internal Photoacoustic Gas 
Analyser (PGA), the signal was tested at low SF6 concentration. High signal to noise 
ratio is also required throughout the concentration range measured during the 
washout and this was confirmed(A. R. Horsley et al. 2008). Most other devices use 
4% SF6, out with the Innocor upper range. For simplicity 0.2% to 0.005% was 
chosen as this was the range used in the standard Innocor exercise manoeuvres and 
the signal is linear. In addition, there is reduced gas consumption. Data from these 
experiments were published by Horsley et al(A. R. Horsley et al. 2008). 
Building on Dr Horsley’s experiments, I began to assess Innocor 
 
Why does slow rise time lead to error in expired gas volume 
estimation? 
Despite high gas signal quality and simple setup for MBW testing on Innocor, the 
method of gas analysis is slow compared with the mass spectrometer. The speed of a 
gas analyser is quantified as the rise time or response time after a step-change in gas 
concentration. A graphical representation of the effect of signal response after a 
sudden step change in concentration is delivered to two different simulated devices is 
shown in  
Figure 55. A step change is the actual change in concentration if a sudden flow of gas 
at maximum concentration is delivered to the analyser. All devices lag behind this 
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step change to a greater or lesser degree. In this illustration it can be seen that the 
simulated machine with the fast response reaches the peak concentration earlier than 
the other, closely representing the true step change. The slow analyser has increased 

















Innocor has an approximate signal rise time (10-90%) of 160ms. The standard rise 
time of the mass spectrometer equipment is 80ms. This slow Innocor SF6 signal 
response causes error in volume measurements (e.g. FRC) through additive effects 
on estimated gas volume.  
Net expired gas during a breath by breath test is calculated in the following way: 
 
                                                   
 
Re-inspired gas is that which is left in the equipment at the end of each breath.  
A slow rising gas concentration leads to underestimation of expired volume. This 
error is not cancelled out by overestimation of the falling gas concentration, as may 
be expected. Slow falling gas concentration adds to the error as flow is reversed 
max
Expected and measured gas concentration

















Figure 55 - simulated step-change in gas concentration with the output response from 2 








during inspiration. Underestimated expired volume is thus further reduced by 
overestimation of reinspired gas volume. The final net estimated FRC is therefore 
greatly underestimated due to additive errors in both inspiration and expiration(Arieli 
and Van Liew 1981).  
 
This error in gas signal response was initially investigated in this department (A. R. 
Horsley et al. 2008). It was clear then that the response time (time for signal to rise 
from 10-90% of full concentration) is slower than A mass spectrometer (160ms vs. 
80ms) and that this contributed to error in volume estimation during washout tests. 
The initial research question posed by Alex Horsley to resolve this is given here: 
 
Given the effect of slow rise time on gas volume estimation, can the SF6 signal be 
manipulated to improve signal response time, and therefore the accuracy of MBW 
tests? 
 
This first question was addressed in the initial validation steps, but is revisited in my 
thesis when considering Innocor for use in younger children (<5 years) and infants. 
Children and infants pose a considerable additional problem when considering 
analysis of exhaled breath, as expired volume is low and expiratory time is short. The 
options below were proposed by Dr Horsley. I have included them as an introduction 
to further Innocor modifications, and also because I worked with Dr Horsley on the 
initial Innocor validation for use by the UKCFGTC. 
Early improvement proposals 
Option 1 - mathematical correction of the SF6 signal to improve 
the rise time.  
The principles behind this originate from earlier studies conducted primarily in CO2 
analysers(Sasse 1985, Schena et al. 1984, Block and McDonald 1992, Linnarsson 
and Lindborg 1974, Arieli and Van Liew 1981).  In a key paper by  Arieli and Van 
Liew, mathematical formulae were applied to gas signals to improve signal response 
time(Arieli and Van Liew 1981). Because concentration curves tend to follow 
predictable mathematical sigmoid forms, a formula that steepens this rise has the 
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effect of increasing the estimated expired gas volume. Arieli et al conducted a 
modelling study that generated timed step changes in gas concentration while a mass 
spectrometer measured the gas concentration. Also, syringe breaths were delivered to 
simulate human breaths. A conclusion of this study was that to optimally correct for 




 order correction should be 
applied to the gas concentration signal as this improved the estimated gas volume 
experimentally. Errors of as much as 4% in gas volume were seen with an unaltered 
signal; however this was reduced to less than 0.5% with optimal mathematical 
correction. Error in volume estimation was reduced with larger breaths (1.5L vs. 
0.5L). Arieli and Van Liew also found that, while matching the change in flow with a 
later point in the rise to maximum gas concentration (>50%) improved the error in 
unaltered gas signals, matching to an earlier point in concentration rise (20%) 
improved the error in mathematically optimised signals. The recommendation is that 
a mathematical alteration including an adjustment in flow gas delay compensation 
reduces signal error. 
 
Assumptions to be made when mathematically altering concentration signals are: 
 The concentration curve is sigmoid and can be manipulated without 
compromising signal quality. A high signal to noise ratio needs to be 
maintained for data analysis. 
 The measurements after a sudden step change in gas concentration are 
equivalent to the more gradual changes seen in washouts. 
 The Innocor internal signal processing does not already have filtering or 
signal altering. Further mathematical modification would greatly increase 
noise in the signal. 
 
Horsley applied first and second order manipulation to washout signals and 
compared this against a mass spectrometer signal. The first order correction did not 
make a great difference to expired gas volume and the second order produced 
excessive noise making analysis of washouts impossible [unpublished data, Alex 
Horsley].  
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A concern with mathematical manipulation such as this is that it is not physiological. 
The true rise in gas concentration in human washouts with each breath is not a step-
change because of phases of airway emptying. Therefore mathematical manipulation 
may simply be introducing a cosmetic improvement without actually improving 
accuracy in real washout situations. Arieli and Van Liew also state that the 
measurement error seen in these published studies is greatly dependent on flow rate 
past the sample capillary. At higher flow rates in “real” breaths, any error may 
change due to faster rise or fall in concentration.  
 
Internal Innocor signal processing 
When considering if the Innocor gas signal should have mathematical alteration, a 
missing consideration of Dr Horsley’s investigations was that the Innocor analyser 
already applies a first-order mathematical “speed-up” filter to the gas concentration 
signal. Further alterations, in addition to the internal Innocor signal processing, 
introduced additional error and excessive noise This issue was discovered some time 
later by me, and confirmed by Knud Pederson at Innovision..  
 
Conclusion 
In conclusion, it is felt that to improve the Innocor signal for infant washouts, 
mathematical altering of the signal is not appropriate. While the principles of 
speeding the signal may seem to improve the response of the equipment, this may be 
purely cosmetic. Mathematical filter speeding sacrifices signal quality, potentially 
leading to poorer representation of the concentration curve over the whole breath. 
The improvements demonstrated by Arieli et al were not in infant washouts. Any 
recommendations based on simulated washouts would need to be conducted using 
infant lung parameters. 
Finally, signal speeding is not possible with the current Innocor setup. Removal of 
the signal filter would have to be performed by the device manufacturers. 
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Option 2 - speeding of the Innocor signal to align it to the mass 
spectrometer signal.  
Given the difficulties associated with mathematical signal correction, an alternative 
solution to the problem of slow signal rise was investigated and subsequently 
adopted into the Innocor MBW setup. As the Innocor signal lags behind The mass 
spectrometer due to slow rise time, and the signal is aligned to the flow at calibration, 
it was appropriate to left-shift the Innocor signal relative to the flow. For the rising 
gas signal, this has the effect of matching the change in flow with a later point in the 
SF6 rise, as suggested by Arieli and Van Liew(Arieli and Van Liew 1981). 
Conventional signal alignment matches change in flow with 50% rise or fall in gas 
concentration as this recognises that gas concentration rises or falls as a function of 
“spreading” within the sample tubing. The alternative “equal area” technique aligns 
the zero point in flow with the 50% of the area under the signal curve. Both attempt 
to measure the true rise in gas signal, whilst compensating for error during transit of 
gas. The equal area technique is thought to be more accurate as gas concentration 
does not necessarily rise linearly during tidal breathing. However, since gas signal 
alignment is concerned only with spreading of the gas signal, it is reasonable to 
conclude this spreading is linear. 
Signal speeding improves underestimation of expired gas volume by aligning the 
zero flow point later in the rising or falling gas signal – once the concentration is 
80% (rather than 50%) of max. This increases the measured volume of expired gas 
on the rising SF6 portion of each breath.  
Using comparison washouts from the Innocor and The mass spectrometer (see 
above), the calculated Innocor FRC using this speeding method was very close to the 
mass spectrometer FRC [unpublished, A Horsley]. This was repeated using a model 
lung, and measuring known “FRC” volumes with the speeded signal alignment(A. R. 
Horsley et al. 2008). This method was therefore validated for use in humans 





1. The effect of slow rise time may be influenced by respiratory rate and breath 
volume 
A number of published papers have shown that expired gas volume estimation in 
breath tests is actually greatly influenced by respiratory rate and breath 
volume(Arieli and Van Liew 1981, Linnarsson and Lindborg 1974, Tang et al. 2005, 
Brunner and Westenskow 1988). Brunner et al, in particular, showed that when step-
changes in concentration are delivered, respiratory rates or 40bpm caused a 7% error 
in estimated volume and rates of 60bpm resulted in errors of 16%(Brunner and 
Westenskow 1988). Therefore, it may be that adjusting signal alignment is not 
accurate when considering infant washouts. 
 
2. Reinspired gas volume cannot be measured 
Speeding the gas signal improves accuracy only in the rising gas portion. Re-inspired 
gas is the small volume residing in the equipment dead space that is breathed back in 
at the start of inspiration. In a low dead-space system the re-inspired gas volume is 
low but must be taken into account in infants otherwise FRC will be overestimated. 
With the modified MBW setup, the SF6 sample capillary was sited close to the end of 
the pneumotach. This has the effect of minimising (negating) the volume of re-
inspired gas. The volume of pneumotach space re-inspired with each breath is 
approximately 5ml and with adult and older child tidal volumes of greater than 
200ml, this volume is negligible and is ignored in volume calculations as proposed 
by Dr Horsley. It is not clear, however, whether there is increased error in this 
system as the tidal volume reduces in younger children. At lower tidal volumes seen 
in infants (20- 75ml) this 5ml volume cannot be considered negligible.  
Summary of early Innocor validation 
Previous experiments have shown that Innocor, despite being designed for a different 
physiological test, was able to accurately estimate lung volumes in adults and older 
children. Simple modifications to the gas signal alignment (signal speeding) 
compensated for slow gas analyser response. This method was devised based on 
previously published comparing Innocor against the current MBW standard device 
(mass spectrometer). As a result, data published in healthy control adult and older 
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child populations showed very similar results to other populations measured using 
different equipment(A. R. Horsley et al. 2008, Aurora et al. 2004, Gustafsson 2007, 
Gustafsson et al. 2003a). 
 
Despite the improvements to the Innocor and reassuring experimental and clinical 
data from adults and older children, there is much less confidence in this modified 
Innocor setup for use in infants and younger children (<5yrs): 
 
1. At faster respiratory rates (>30/min), the slow response of the analyser may 
greatly under-estimate the cumulative expired volume, with a possible 
increased error in patients with lung disease as more breaths are required to 
washout the SF6 in less efficient airways. 
2. The post-capillary dead space re-inspired with each breath may not be 
negligible and should be taken into account during cumulative expired 
volume calculation. This means signal speeding cannot be applied in this age 
group. 
 
When considering solutions to these problems, there is high risk of including 
multiple errors if all aspects of the equipment are not fully investigated. It can be 
seen from these summarised problems, for example, that overestimation of re-
inspired gas and underestimation because of slow analyser response may in fact 
cancel each other out in the results. This could lead investigators to consider 
equipment highly accurate if not investigated rigorously. This equilibrium of errors 
may not be balanced throughout all ages and may be affected by the presence of 
disease. Operating a system with two potentially large errors is therefore 
unacceptable if they cannot be quantified in-vivo. Further validation must therefore 
recognise sources of error and correct accordingly. 
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Section 2 – basis for Innocor hardware modification for infant 
washouts 
Innocor limitations in children 
The above Innocor problems were carefully considered for this thesis from basic 
principles, aiming to extend the use of Innocor to younger children. A lower limit of 
5 years prevents detection and tracking of early lung disease in infancy without using 
a different device in younger age groups.  
Intuitively, it is expected that the most accurate validation involves comparing 
Innocor directly with a mass spectrometer device in young children and infants. In 
preparation for this in-vivo comparison validation in young children and infants, a 
series of initial lab-based in-vitro experiments was conducted to resolve the main 
concerns about the Innocor equipment. 
This section describes investigations into further Innocor modifications, and the 
justification behind them prior to in-vivo mass spectrometer comparison. Advice for 
this was given by Innovision, the manufacturers of Innocor. Some direction was 
offered regarding hardware modifications, but Innovision was unable to alter the 
software or fundamentally change the assembly. This is presumably due to 
regulations surrounding CE European safety marking and wider company marketing 
policy.  
All the following work was led, and conducted by me in the Department of Child 
Life and Health, Edinburgh. 
Basic breath by breath gas analysis principles 
This chapter has already stated the limitations of the Innocor system, particularly the 
lack of confidence about its lower age limitation. These concerns are primarily about 
the relatively slow gas analyser response time and the position of the gas sample 
capillary that eliminates the need for analysing re-inspired gas in the current “adult” 
setup. 
There are limited data on which to draw evidence for an upper signal rise time limit 
that prevents use of any particular gas analyser for MBW in young children. An 
official ERS statement document, published in 2007, contains comprehensive 
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information on many different lung function techniques(Beydon et al. 2007). This 
was in response to the increased use of these techniques with very few equipment 
and analysis standards. One chapter, written by Professor Gustafsson details the use 
of MBW equipment, quoting 100ms as the acceptable upper rise time limit. It is from 
this statement that Innocor is judged to be “too slow” for MBW in small children and 
infants. 
Critique of 100ms as the upper acceptable limit for gas analyser 
rise time 
Professor Gustafsson proposed 100ms as the upper acceptable limit for gas analysers 
used to perform multiple breath washout of inert gas(Beydon et al. 2007). This figure 
is a statement in the online supplement of an influential standards guideline of the 
American Journal of Respiratory and Critical Care Medicine. This paper concerned 
MBW in infants and young children, but is the only recommendation for MBW so 
far. No reference is given to support this statement. 
An important paper by Brunner et al will be discussed in the following 
paragraphs(Brunner and Westenskow 1988). This article sought to establish the 
accuracy of both end-tidal gas concentration and integrated gas volume at different 
rise times. Far from recommending 100ms as the upper limit, this paper found that 
any device with a rise time of greater than 20ms would not be able to accurately 
estimate expired gas volume after a step change in concentration. As expired 
concentrations are not step change, reaching the maximum over around 70ms (see 
below), there are actually no data with which to recommend an upper rise time limit. 
A major aim of Innocor modification is to demonstrate accuracy at different signal 
rise times so as to refute this arbitrary upper rise time limit. 
Influence of signal rise time on gas analyser accuracy 
Understanding Innocor simply as a flow meter with a gas analyser, rather than a 
complex cardiac output device, simplifies the problem of how to overcome the slow 
rise time and error in gas signal. For MBW, the flow meter must accurately measure 
flow within the range expected in infants. This flow signal is integrated with the SF6 
concentration to calculate expired SF6 volume. Flow accuracy can be tested during 
calibration and is standardised by using appropriate equipment. Pneumotach 
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standards are readily available in published ATS/ERS guidelines(Frey et al. 2000a) 
to aid flow measurement accuracy. As a result, the gas analyser can be considered 
separately, according to first principles. This is explained in the following 
paragraphs. 
Slow signal rise time 
Gas signal rise time is influenced by factors that disrupt the gas front. At the extreme, 
a step change in gas concentration should change from 0% to 100% instantly but 
anything that causes mixing or turbulence spreads the gas concentration so the 
measured signal appears to rise more slowly. Figure 56 below illustrates how a 
sudden change in gas concentration delivered to a sampling gas analyser may be 















Slow rise time is contributed to by turbulence within tubing and connections. The 
likelihood of turbulence within a tube can be calculated using Reynolds number as 
reviewed by Rott(Rott 1990). The Reynolds number is a ratio of inertial to viscous 
forces in dynamic fluids (including air). This is limited to flow within a uniform 
tube. It is clear that any sudden widening or narrowing will cause turbulence and 
spreading of the gas front. Using a convenient online calculator 
(www.pipeflowcalculations.com/airflow/index/htm), the nafion itself has a low 
Figure 56- illustration of how a sudden change in gas concentration is measured as a 
slower rise in measured signal due to sample tubing 
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Reynolds number, with the conclusion that if turbulence within connections can be 
minimised, any spreading of gas due to turbulence can be minimal. 
Turbulence is not the only factor affecting spreading or mixing of gas during 
analysis. Any analysis step, such as the chamber where the gas concentration is 
measured, may also alter the true gas concentration during a rise or fall in 
signal(Tang et al. 2005). All sampling analysers have a degree of mixing due to such 
factors. The mass spectrometer device, for example, has narrow, high pressure low-
flow tubing, meaning that turbulence is very low. All the signal rise time (40-60ms) 
is thought to be due to the sample analysis rather than spreading within the 
tubing(Davies and Denison 1979). 
With the aim of reducing signal rise time, the relative contribution of turbulence 
within sample tubing and other causes of gas mixing was investigated in Innocor. 
Gas flow system and tubing connections in Innocor 
Innocor is constructed to measure gas concentrations during exercise and re-





















Figure 57 – Sequence of sampling within Innocor device. Gas is drawn in via the nafion tube to the 
Oxygraph O2 analyser, then to the photoacoustic analyser, PGA (SF6 and CO2). The pressure is generated 
by a pump, with an attenuator to prevent vibrations disrupting the gas signal. 
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As the Innocor method of analysis (photo-acoustic response) cannot be changed, the 
mechanical limitations in Innocor that may contribute to slow signal rise are: 
 
 Innocor samples a relatively large volume of gas from the breath stream 
(2ml/second ) and therefore has a higher sample flow rate. High sample flow 
increases the risk of turbulence and spreading of gas in non-linear tubing. 
 The nafion tubing has a number of connections including a dust filter. These 
may introduce turbulence and spreading of the gas front. 
 Innocor was designed to measure O2 concentration simultaneously with other 
gases, therefore the analyser places this separate O2 analyser before the 
photoacoustic device in series (Figure 57). The gas front therefore undergoes 
spreading before reaching the PGA.  
 Spread of gas as it passes through the PGA  sensor chamber.  
 
Washout modelling and quantification of gas analyser error 
All gas analysers have limitations. Publications quantifying the effect of these 
limitations on MBW tests are not currently available. While the priority is to validate 
the Innocor device, the following experiments are important for all breath-by-breath 
gas analysers. 
To begin to quantify the effect analyser limitations have on accuracy of multiple 
breath washout tests in paediatric subjects, a basic model was developed. This 
consisted of a mathematical curve generator to reflect expected curves from devices 
with different rise times and to quantify how these contribute to measurement error.  
Accurate gas concentration measurement is dependent on respiratory rate and breath 
volume. If the respiratory rate is high, the expiration time will be short. If the rise 
time of the equipment is slow, the concentration may not reach its peak before the 
concentration falls again at the new breath. At a respiratory rate of 60, the expiration 
time is approximately 0.3ms. The rise time therefore needs to be able to reach a 
plateau within this time(Sasse 1985). 
Furthermore, if the breath volume is low, the error in expired gas volume may be 
large. Figure 58 illustrates the effect of slow rise time when a step change in gas 
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concentration is delivered. The expected signal is shown, but if there is a slow rise in 
concentration as shown by the sigmoid curve, the estimated expired volume (area 
under curve) may be lower than reality (blue area). The difference in volume 
between measured and expected is the area under the curve shown in pink. The 
proportion of this pink area to the total measured volume increases with faster 
respiratory rates (shorter expiratory time). Therefore, error in expired gas volume due 



















The difference between measured and expected volume can be quantified by %error: 





For each breath and for FRC calculation, 5% error is considered the limit of 
acceptability (measured vs. expected breath volume or FRC volume)(Brunner and 
Westenskow 1988).  
Figure 58 - illustration of how delayed rise time contributes to error in area under curve 
calculations during washout testing. 
% error =  
208 
The effect of rise time on expired volume can be modelled in a number of ways. 
Brunner et al generated step changes in gas concentration, simulating the most 
extreme concentration change possible(Brunner and Westenskow 1988). While in-
vivo washout tests do not generate such extreme concentration changes, it was felt 
that any device that is accurate with a step change in concentration will also be 
accurate after more gradual changes. A number of different CO2 gas analysers were 
compared and only those with a very short rise time (40ms) were capable of 
measuring expired gas volumes to within 5% of expected volume.  
Mathematical lung model 
As tidal breath tests differ greatly from step-change tests, a more appropriate model 
was designed to assess the Innocor concentration signal. During human washouts, 
gas concentrations do not change in a step-wise manner. Spreading of the gas front 
during expiration causes the slow phase II rise in concentration. Even during 
inspiration, residual gas in the pneumotach mixes with inspired air, leading to a 
sloping fall in concentration. It is difficult to separate fall due to delayed response 
and real slope in concentration on side-stream analysers, therefore a sample curve 
was simulated. Mathematical concentration curves were also generated representing 
varying equipment rise times. The accuracy of this curve compared to the real 
concentration change was the outcome measure. 
 
True concentration change 
As a representation of a “real” washout curve, the response time from a sample infant 
washout signal was taken from a mainstream device with negligible rise time (molar 
mass signal, Ecomedics). The response of this equipment is approximately 3ms. The 
signal rise and fall were measured and used as the true change expected in this age 
group.  
 
The sample infant washout data below shows typical washout curve (Figure 59). The 
signal rise time is negligible (<5ms) and therefore represents the true rise and fall in 
gas concentration during a washout. The graph shows that the steepest part of curve 
is falling concentration (no gradation due to airway anatomy). Normally this would 
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be quantified as 90-10% fall time. Here, response is measured as 90-30% fall due to 
gas concentration not falling to 10% in the molar mass concentration signal. 
According to Brunner et al(Brunner and Westenskow 1988) this is equivalent to a 


















Expired breath simulation 
Mathematical sigmoid (Gompertz) curves, generated using Maple mathematical 
software (Maplesoft, Waterloo, Canada), were assembled by Dr Treven Wall, 
Department of Mathematics, Edinburgh University. Figure 60 shows hypothetical 
curves from a sequence of simulated devices with varying response times (units of 
volume over time, units.t
-1
). The area under each curve is equivalent to the estimated 





90-30% fall in 
concentration 
Figure 59 – Sample of infant breath (rise in concentration during expiration, with 
sudden fall during inspiration). Measurement of gas signal fall time in device with 

















It was assumed that if the machine rise time is faster than the true gas concentration 
rise there will be zero error as the rise in signal is a true reflection of the gas 
concentration rise. Device rise times slower than the true subject concentration rise 
will introduce error in gas volume calculations. This assumption is valid only if rise 
time is purely due to the analyser, rather than spreading of the sample up the sample 
line (in which case the rise time would add to the true rise in signal). The 
modifications made to the hardware described seek to minimise spreading of the gas 
front and therefore rise time can be thought of as originating only from analysis and 
electrical delay within the analyser. This represents a simplification of a complex 
picture. 
 
Error is quantified using the mathematical model and the real-life curve seen above. 
By calculating the area under the expected and measured curves, the % error can be 
calculated. The fall time in the real life patient above was 70ms (fall and rise in 
concentration taken to be equivalent). Therefore, any equipment rise time longer than 
70ms will introduce error in volume calculation. Error is also dependent on breath 
duration. An expiratory time of 600ms was chosen, representing 60% of a 60/min 
Rise time = 160ms 












Figure 60 - simulated sigmoid concentration curves. Each curve represents a signal 
rise at a different device rise time. Concentration is in relative units, with area under 
the curve to calculate expired volume. 
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cycle (normal I:E ratio is 1:2, however 600ms simplifies calculation). This is the 
maximal expected rate in young infants, as respiratory rate is highly variable in this 
age group. At 60 bpm, a device with an equipment rise time of 70ms or faster will 
have zero error in calculating the volume of gas of each breath in this simulation. 
Table 23 summarises the expected error in gas quantity estimation with increasing 
equipment rise time. A device with an 80ms rise/fall time would have a ~1.5% error, 
and a 100ms rise time will introduce a ~3.1% error. It can be seen that even small 
increases in equipment rise time result in large volume estimation errors. 
Furthermore, shortened expiratory time (increased rate) also contributes to increased 
error. This illustrates error in the measurement of a single expired breath, not error in 
FRC calculation, which is dependent on additive error over a number of breaths and 
is subject to other influences and assumptions (chapter 2). 
Table 23 – Estimated error from different rise times and respiratory rates, compared against a 
true concentration change from an infant washout breath, corresponding to a response time of 
70ms. 
 
From this modelling experiment it appears the Innocor with the standard rise time of 
160ms demonstrates unacceptable error when measuring simulated infant washouts. 
Current standards recommend a maximum rise time of 100ms(Beydon et al. 2007). 
Even at this speed, there would appear to be large errors in gas quantity estimated at 
faster respiratory rates. 
In light of these data, it was clear that prior to any comparison between Innocor and 
mass spectrometer improvements would have to be made to the Innocor gas analyser. 
To be within recommended limits the analyser speed should be less than 100ms, but 
the greater the reduction in rise time, the greater the accuracy of gas estimation. 
 
Equipment rise time (ms) 40 60 80 100 120 160 
Resp rate (min
-1
) Error in gas quantity estimation (%) 
60 0 0 1.54 3.07 7.49 13.49 
70 0 0 1.78 5.34 8.90 16.02 
80 0 0 2.07 6.21 10.35 18.62 
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Hardware modifications 
Two factors contribute to gas signal rise time: 
1. Spreading of the gas front in the sample tubing and analyser due to turbulent 
flow.  
2. Delay due to internal electrical and analysis steps. 
 
The method of analysis cannot be changed so the focus was in minimising spreading 
of the gas front by altering the following issues: 
1. The sequence of analysers places the oxygen module before the SF6 module, 
contributing to spreading of gas. Once the oxygen module is removed, the 
rise time should improve. 
2. The nafion tubing that samples gas has a number of connections that may 
introduce turbulence. If practical, improvements to these connections should 
improve rise time. 
 
As previously explained, the Innocor is manufactured with specific analysis steps to 
measure cardiac output during exercise testing. MBW testing requires optimisation 
of gas concentration, specifically SF6, rather than other gases – O2, CO2 or N2O. The 
two gas analysers are assembled in series, with the oxygraph analyser first to receive 
the gas sample. Therefore the gas front is disrupted by passing through the oxygraph 
before reaching the SF6 analyser.  
Delay in signal rise is also influenced by type of analysis, which cannot be altered. 
The 10-90% rise time according to Innovision is documented as <200ms. The most 
simple and feasible option to improve this was to bypass the oxygraph analyser step, 
so that gas was sampled straight into the PGA. This was proposed to Innovision and 






 To measure the improvement in 10-90% rise time by bypassing the oxygen 
analyser and improving sample tubing connections.  
 To achieve a target rise time of 100ms, according to published 
guidelines(Beydon et al. 2007). 
 To assess the relative contribution of gas spreading and analyser delay to the 
total rise time. 
Methods 
Rise time measurement 
SF6 rise time was assessed using a modified technique published by Brunner et 
al(Brunner and Westenskow 1988). This involves creating a step change in gas 
concentration using a specially prepared syringe. 
The syringe is illustrated below (Figure 61). The volume behind the plunger is filled 
with 0.2% SF6. The plunger is pushed quickly past the side port, where the sample 
capillary is sited right at the entrance to the syringe. There is constant gas sampling 
and once the plunger has passed, 0.2% SF6 is sampled immediately. This technique is 
simple and easily reproducible. Other methods, for example, have use automated 
devices that suddenly insert a sample capillary into a stream of flowing gas(Bates et 
al. 1983). This technique has the advantage of multiple repeats but is more 










Figure 61 - Illustration of rise time syringe. A volume syringe with 2 ports is filled behind the plunger with SF6. As 
the plunger  passes over the sample port, there is a sudden rise in gas concentration (step change). 
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The resulting gas concentration signal can be exported from Innocor and displayed as 
individual signal values with time. If a graph is drawn of concentration vs. time, the 
rise can be seen. Subtracting time taken to get from 10-90% of the final 
concentration is the rise time. 
 
Hardware modification 
After consultation with Innovision and the company-produced Innocor Service 
Manual(Innovision 2007-01) the oxygraph analyser was bypassed by diverting the 
tubing which feeds from the nafion straight to the PGA. No input is provided to the 
Oxygraph. A full description is given in a hardware alteration manual (Appendix 3). 
 
Nafion Alterations 
The standard nafion length is ~180cm. This is the standard length but is not essential 
for optimal gas sampling. Reductions in length are therefore feasible. Leuer-lock 
connections are fixed as standard onto the tubing to allow simple connection of 
components. The standard nafion has a filter placed in-line, just before gas enters the 
Innocor, to prevent dust particles damaging the gas analysers. The sample capillary, 
inserted into the side of the pneumotach port, is fashioned from a shortened i.v. line 
needle (16g). The hub of this needle, relatively large in comparison to the nafion 
diameter, may contribute to turbulence of flowing gas.  
It was hypothesised that the connections and the length of the nafion may affect the 
rise time by allowing turbulence and spreading of the gas sample front. Shortened 
nafion tubing was used with the nafion inserted inside the filter and sample needle 
hub by rubber bungs seemed to avoid changes in diameter likely to encourage 
turbulent flow. The sample capillary was also altered to make the needle extend 
inside the nafion, thereby encouraging a streamlines flow of gas whenever possible. 
The dust filter remains as this cannot be removed to protect the analysers.  
Turbulence is reduced by siting the nafion as close to the filter mesh as possible. 





















Sequence of testing 
The rise time was measured before and after oxygraph bypass. All other parameters 
(e.g. nafion tubing) were initially unaltered. Following this, further experiments were 
performed using the oxygraph bypassed Innocor with different lengths of nafion and 
improved connections to ensure there was minimal risk of turbulence due to wide 
bore connectors or port fittings. 
Results 
Pre-modification rise time was measured 16 times, with an average value recorded. 
Post-modification, rise time measurements were repeated approximately 10 times 
following each modification. Values are recorded to the nearest 10ms as the gas 





Figure 62 - nafion tubing modifications. Made to improve gas flow and minimise turbulence 
The nafion must have the plastic protective mesh stripped from both ends. 
Rubber bung is a short length of rubber tubing, just big enough to fit the stripped nafion. 
The bung is pushed into the capillary hub or filter with minimal space left for turbulence of sampled gas. 
The bung can be held in place with putty or similar to ensure a good seal. 
A sample capillary can be made from a white intravenous cannula needle cut to size. 
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 Number of 
repeats 
Mean 10-90% 
rise time (ms) 
SD Range (ms) 
1.Pre-modification     
Standard Innocor setup 16 168.75 7.19 160-180 
2. Post-modification     
Oxygraph bypass 10 139.00 5.68 130-140 
+ shortened internal tubing 10 133 4.83 130-140 
3. Nafion Shortening (oxygraph 
bypassed) 
    
Standard nafion length (176cm) 8 122.5 4.63 120-130 
90cm 9 108.89 3.33 100-110 
60cm 12 120.83 2.89 120-130 
30cm 12 97.50 4.52 90-100 
Table 24 - sequence of testing following sequential Innocor modifications. Values shown are the 
mean of all repeats, standard deviation and range. Less than 10 repeats were completed in some 
cases. However this does not represent discarded data. 
 
Bypassing the Oxygraph alone improved the rise time by 17.6%. Improvements of 
42% in total were seen when other improvements were added. These modifications 
do not seem to have caused any increased variability of rise time. 
Once these improvements were made, it is now assumed that all the remaining rise 
time comes from the analysis step, rather than spreading within the tubing as 
connections have been optimised. It was shown by Davies et al that sample tubing 
per se does not contribute to slow signal rise(Davies and Denison 1979), therefore 
only the filter can be contributing to slow rise time within the tubing. 
Experimentally, removing the filter (not possible for washouts) caused a 16% 
reduction in rise time, indicating that >80% of the best practical rise time originates 
only from the analysis step.  
Conclusions 
The total increase in signal rise time achieved with these modifications was 
approximately 42%. 
It is clear from these experiments that large improvements to signal rise time are 
possible with fairly moderate adjustments to the Innocor hardware. The biggest 
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change to the equipment was bypassing of the Oxygraph analyser. The largest 
changes in rise time, however, came from improvements to nafion tubing and 
connections. This demonstrates that, while the extra analysis step causes slowing in 
rise time, presumably due to gas front spreading, poor connections and long sample 
lines in themselves also contribute significantly to the rise time. 
It is not clear which components contribute to the final 97.5ms response time. With 
close, tight tubing connections and a low pressure sample flow it is unlikely there is 
much spreading of the gas front. The gas analysis within the PGA may contribute 
additional spreading, but also electrical and mechanical delays add to the signal rise 
time. It is likely that this setup is the fastest response time possible. Innovision have 
conducted experiments with higher sample flow rates. This does improve rise time 
but has disadvantages during MBW testing in infants due to high lost gas volume. 
The concept of lost gas is discussed later. 
As recommendations state that the minimum signal rise time should be <100ms, it is 
encouraging to achieve this improvement in the Innocor. I have stated my opinion 
about this figure, but to allow further validation to progress, achieving a rise time of 
less than 100ms is advantageous. It is important to note that the published 
recommendations are not based on in-vivo experiments in MBW washouts, and it has 
still to be shown exactly how slow signal response affects gas concentration 
measurement accuracy in an in-vivo setting.  
Consequences of Innocor improvements 
These improvements to analyser rise time introduce new complications to the 
equipment: 
 Signal alignment for MBW analysis. 
To align flow and concentration signals during analysis, an internal Innocor 
calibration programme is used. This programme relies on simultaneous oxygen 
analysis. Therefore if the oxygraph analyser is bypassed to improve signal rise time, 





 Equilibration of humidity in shortened nafion tubing. 
Nafion tubing is specifically designed to avoid adjustment for humidity differences 
between exhaled and ambient inspired air. A reduction in nafion length may affect its 
ability to equilibrate humidity. 
 
 Sample flow rate remaining high in relation to infant breath volumes. 
Increasing sample flow rate improves signal rise time. A reduction in sample flow 
rate is preferable to avoid affecting infant washout calculations. To maintain the fast 
analyser speed, the sample flow rate could be compensated for in washout analysis. 
 
Experiments assessing the above problems are described below. I performed these 
prior to measuring the effect of Innocor improvements on MBW measurements, and 
whether in-vivo comparisons of Innocor versus a mass spectrometer are justified. 
 
Signal alignment for MBW analysis 
This section deals with signal alignment, i.e. how the raw flow and gas concentration 
signals are analysed. Both are recorded as separate signals and any delay in one or 
the other means that, at the time of analysis, they will be misaligned. 
In Innocor there is a delay in gas signal measurement due to time taken for gas to 
reach the analyser and to be analysed. This causes a misalignment of flow and gas 
concentration. If left unaltered there is an error in gas concentration measurement 
which is proportional to the degree of misalignment. Time constants within the 
respiratory system affect the waveform of gas concentration produced during breath 
by breath assessments. In systems with shorter time-constants, a greater proportion of 
the tidal volume is expired early in the breath. The effect of misalignment of gas and 
flow signals is therefore more profound in respiratory systems with shorter time-
constants (less compliant lungs). This source of error has potentially greater effects 
in younger patients and those with respiratory disease(Tang et al. 2005).  
Correction of flow and concentration misalignment is most often achieved by 
applying a constant time-shift to one of the signals. Calculating this correction is 
more difficult. 
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As there are phases to each expiratory breath, gas concentration does not rise 
instantly as each breath begins. Therefore, the flow gas delay cannot be measured on 
a breath by breath basis. Also, flow gas delay varies depending on gas composition 
and temperature, so ambient changes may affect the value(Brunner et al. 1985, 
Eberhard et al. 1999). Flow gas delay in Innocor is determined as part of device 
calibration on a daily basis using a standardised manoeuvre.  
 
Standard Innocor manoeuvre 
According to the published standard operating procedure (Appendix 1), Innocor 
calculates flow-gas delay in a way similar to that described by Brunner et al(Brunner 
and Westenskow 1988). After a step change, measured concentration rises in a 
sigmoid fashion after the analyser delay. The 50% rise in concentration is considered 
the mid-point of the gas front. The time taken from the change in flow, minus the 
dead space portion between air and sample capillary to the 50 % rise in gas signal, is 
the flow gas delay. The 50% rise is calculated using the equal area technique, where 
the areas under the curve before and after are equal. This is shown in the shaded area 
in Figure 63. Delay time is shown under the time axis. The reference to “Rise Time 








Figure 63 - calculating the time delay (flow gas delay) between a change in flow (solid line) and 
the 50% rise in gas signal (shaded area). Taken from Brunner et al(Brunner and Westenskow 
1988). 
 
To achieve a sudden change in flow coinciding with change in concentration, a 
standard manoeuvre is incorporated into the Innocor software. This involves aligning 
a sudden fall in CO2 and change in flow at the time of a sharp intake of breath. The 
operator breathes out slowly to achieve a CO2 plateau, then sharply breathes in. 10 
repeats are performed to obtain an average. Clearing of the equipment dead space is 
taken into account in the calculation(Innovision 2005-05). 
The assumptions with this method are: 
 CO2 and SF6 responses are equivalent. 
 Fall and rise times are equivalent. 
 Delay is not dependent on flow.  
 
For the purposes of MBW in adults and older children, small errors in flow gas delay 
do not contribute to large errors in FRC or end-tidal gas concentration. However, as 
infants and young children have shorter respiratory system time constants, a larger 
proportion of the breath is expired early in the expiratory phase. Therefore there is 
less confidence with this protocol in younger patients. Also, a large flow is generated 
when an operator performs this manoeuvre; much larger than is seen in infant tidal 
breathing. This may not affect the accuracy of the signal alignment but it is difficult 
to test. It is intuitive for routine calibration to mimic the flow change seen in the 
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patient to be tested. Bypassing the oxygraph module during rise time shortening 
alterations renders the Innocor unable to measure flow gas delay by the standard 
manoeuvre. This is a “fault” with the software but cannot be resolved. Furthermore 
this manoeuvre may not be suitable for infant calibration. Alternative methods for 
deriving flow gas delay must therefore be sought. 
 
Alternative methods for deriving flow gas delay  
Generating a sudden change in gas concentration by opening an electronically 
controlled valve very close to a gas sample capillary reveals the time taken for the 
gas signal to rise. This method is adopted by Per Gustafsson in the mass spectrometer 
MBW setup. This is possible because the gas signal is inputted to a laptop controlling 
the electronic valve. Therefore the signal rise can be timed. As the Innocor is not able 
to output a real-time signal, the timed valve approach cannot be used. 
Equilibration of humidity in shortened nafion tubing 
The standard Innocor setup uses a 180cm length of nafion with leuer-lock 
attachments to connect to the sample capillary and Innocor inlet. Contrary to a 
published study measuring mass spectrometer rise time with varying lengths of 
tubing(Lerou et al. 1990), shortening the nafion length appeared to improve rise time. 
The obvious concern is that the shortened nafion is unable to equilibrate humidified 
exhaled gas in the time it takes to pass through the tube. Advice from Innovision was 
that 180cm is a convenient length, rather than being the minimum requirement.  
Humidity and gas volume 
Gas volume and pressure are related according to Boyles Law. Pressure and volume 
are also influenced by temperature, density and gas composition. Water vapour 
(humidity) decreases density and therefore volume increases at a constant pressure 
and temperature. This is important during gas sampling as temperature and humidity 
fluctuate as sampled gas changes from relatively dry and cool room air to relatively 
humid and warm expired air.  
Without adjusting for these variables, gas concentrations would be incorrectly 
estimated. Innocor adjusts for temperature fluctuations by heating the internal gas 
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analyser and sampled gas. Humidity is eliminated by the use of a Nafion sampling 
line.  
Nafion  
Information taken from Permapure website(Permapure 2009). 
Nafion is a complex co-polymer, developed by the Du-pont company in the 1960’s. 
It is modified from Teflon, and therefore has very high tolerance to heat. It was the 
first synthetic polymer with ionic properties. As such, it is able to act as an ion and 
proton exchange membrane. It is also widely used as a drying membrane due to 
selective and high permeability to water vapour in humidified gases. These unusual 
properties make it ideal for equilibration of humidified sampled gas. Nafion does not 
degrade over time and, while the surface may become coated with organic residues, 
the selective permeability to water is largely unaffected. 
 
In theory, a Nafion membrane is able to completely dry a gas to less than 1% relative 
humidity. This is only possible with a dry gas passing over the outside of the tubing, 
which is not practical or necessary for Innocor gas sampling. For MBW testing, 
sampled gas needs to equilibrate with the air (approx. 30-40% relative humidity) in 
the time it is within the tubing, prior to entering the analyser. 
 
Publications investigating nafion gas drying properties 
Few studies have investigated the efficiency of nafion tubing in drying humidified 
gas. Leckrone et al measured the ability of nafion tubing with varying diameters and 
lengths to completely dry humidified helium of different temperatures(Leckrone and 
Hayes 1997). This was to determine the factors that most influence the efficiency of 
nafion gas drying. Importantly humidified gas was passed through the tube, with dry 
gas passed round the outside, creating a large humidity gradient. 
 
The findings of this study were that nafion is able to completely dry (to <1% RH) 
saturated humidified gas efficiently. Efficiency is determined by temperature, 
diffusion coefficient of water vapour (cm
2
/s, TD) and the time gas is in the tubing 
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(length and flow rate, TR). The length of nafion required to dry humidified gas is 
determined by the following equation. 




L = length of tubing 
Fc = flow of gas within nafion (120ml/min) 




Therefore, according to this paper, the length of nafion required to completely dry 






/98.018) = 7724mm i.e. 7.7metres. 
 
This experiment has limited application as it was designed to make the gas sample 
completely dry (dew point <-40, RH<1%). This is not necessary for MBW gas 
samples as the nafion is only be expected to equilibrate with air (RH 20-40%) in a 
reasonable length of tubing without dry gas carrier passing over the outside. Graphs 
from this study indicate that 70% removal of water (approximate equilibration) is 
achieved in nafion lengths as low as 22cm, with flow rates of 95 ml/min (Innocor 
120ml/min). With a length of nafion 40cm, the residence time of gas within the 
tubing, at a flow rate of 120ml/min is approximately 4 seconds. Taking into account 
diffusion coefficient of water (Td) in air at 1 atmosphere pressure, the TR /TD is 1.44. 
70% removal of water is theoretically possible at this length, according to this paper. 
Using a 30cm length of nafion results in a Tr/Td of 1.3, which visually from the 
graph indicates only 65-70% removal of water. 
 
Experimental data 
Previous work in this department has demonstrated the stability of the SF6 signal 
with different humidity levels(A. R. Horsley et al. 2008). This was done using 
heated, humidified gas and full length nafion tubing (180cm). Shorter lengths of 
nafion appear to be advantageous in terms of signal rise time. Therefore, to 
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determine whether shorter nafion lengths are able to equilibrate humidity to room 
levels, as required in MBW testing the following assumptions were made: 
 
1. Humidity causes a decrease in density of gas and increase in volume. 
Therefore SF6 concentration will decrease if humidity is not equilibrated. 
2. Equilibration happens in both directions. Humid expired gas loses water to 
room air and dry inspired gas (from tank) takes water from room air. 
Aims 
1. Assess change in measured gas concentration between dry and humidified 
gas using different nafion lengths. 




 Innocor gas analyser. 
 SF6 supply – 0.2% (+/-5%). 
 DeVillbis nebuliser – cold humidification. 
 Fischer and Paykel Healthcare MR750 humidifier – warm humidification. 
 Elephant tubing to conduct gas. 
 Nafion tubing of various lengths. Fitted with leuer lock ends and metal or 
plastic sampling capillary. Dust filter in place proximal to Innocor inlet as 
standard (Figure 64). 
Sequence 
Gas concentration is measured with each length of nafion in turn from longest to 
shortest length. A stable concentration of dry gas was established first, which was 
then humidified.  
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Figure 64 - Nafion tubing with sample capillary and filter in-situ 
 
Analysis 
Gas signal data were transferred from the Innocor to lab computer. An excel 
spreadsheet displayed the signal as an x-y plot with time. A stable concentration 
period was identified and mean, SD, Signal/noise ratio, min and max for that period 
were calculated. 
 
Given that the standard deviation of the signal is very low, a t-test between dry and 
humid is not appropriate. Cohen’s d was chosen to represent the effect size of the 
difference between dry and humid gas concentration. Cohen’s d is defined as the 
difference between the means divided by a pooled standard deviation(Cohen 1992).  
 
          
                                                   
                         
 
 
If the d value increases, this indicates that the overlap of values in the two groups 
(humid vs. dry) is less. Therefore, a d of 0.0 indicates complete overlap, while a d of 
2 corresponds to less than 20% overlap of values around the mean. Increased 
Cohen’s number indicates difference in concentration between dry and humidified. 








3 experiments were conducted, 2 with a humidity and temperature probe to confirm 
100% relative humidity (RH) in the gas sample. Nafion lengths quoted include 
sample capillary and filter. 
Table 25 - Nafion experiment design 
 
A steady state of gas concentration was achieved with all lengths of nafion. Signal to 
noise ratio (standard deviation divided by mean) was maintained with all lengths and 
did not change with humidity. 
  
Experiment description Nafion Lengths (cm) 
Experiment 1 – 3 lengths of nafion 
Devillbis nebuliser, room temperature 
Dry gas RH <2% 





Experiment 2 – 5 lengths of nafion 
Devillbis nebuliser, room temperature 
Dry gas RH <2% 






31.5 (different piece of tubing) 
Experiment 3 – 4 lengths of nafion 








31.5 (different piece of tubing) 
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Cohen’s d, effect size measure, was small throughout, barely rising above 0.2 (Table 
26). However, d appeared to increase exponentially at smaller lengths of nafion 
(<40cm) in multiple experiments using more than one piece of nafion (Figure 65). 
Log transformation of length vs. d plot (Figure 66) shows a significant negative 
correlation between nafion length and Cohen’s d (r
2
 = 0.74, p=0.0003).  
 
Table 26 - Cohen's d values at different nafion lengths. Cohen's d represents the degree of 
overlap of values, with lower values indicating increased degree of overlap. 
 













(humid vs. dry 
concentrations) 
183.00 30.01 0.210 0.00038 30.01 0.210 0.00025 0.004 
182.00 20.01 0.203 0.00017 20.01 0.203 0.00016 0.006 
92.00 20.01 0.204 0.00016 20.01 0.203 0.00031 0.040 
91.40 28.01 0.210 0.00026 27.01 0.210 0.00021 0.032 
65.40 11.20 0.208 0.00028 6.01 0.208 0.00025 0.030 
52.50 20.39 0.209 0.00027 20.45 0.208 0.00025 0.048 
42.50 15.71 0.209 0.00019 15.01 0.208 0.00019 0.048 
34.00 9.21 0.208 0.00024 10.01 0.207 0.00024 0.020 
34.00 20.01 0.204 0.00028 20.01 0.204 0.00039 0.108 
32.00 22.55 0.226 0.00025 23.67 0.224 0.00025 0.183 
31.50 20.01 0.204 0.00020 20.01 0.203 0.00028 0.138 
31.50 8.95 0.208 0.00022 11.01 0.207 0.00023 0.204 
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Figure 65 - length of nafion vs. Cohen's d value. At lower lengths of nafion, an exponential rise 
(less overlap) was seen. 
Effect size measurements comparing humid vs. dry steady state sf6 at
decreasing nafion lengths






































Figure 66 - log transformed nafion length vs. Cohen's d indicates relationship between length 
and degree of overlap of dry vs. humidified values. 
Conclusions 
According to previous publications, the likely shortest length of nafion able to 
equilibrate expired gas humidity to room conditions is 40cm. This has been 
confirmed in these experiments, where there is a significant correlation between 
nafion length and Cohen’s d. Using lengths of nafion shorter than 40cm largely 
resulted in higher d values. 
Shortening the nafion length is important in improving the performance of the 
Innocor gas analyser for infant washout studies. There is a practical minimal length 
beyond which the nafion would not connect the pneumotach with the Innocor. I have 
shown that, in a comparable environment to MBW measurements, nafion lengths 
greater than 40cm perform well in equilibrating humid gas and ensuring a stable gas 
concentration throughout. It is therefore appropriate to limit the nafion length to no 
less than 40cm for the infant Innocor setup. 
Log-transformed regression


























 = 0.74 
p = 0.0003 
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Gas sample flow rate  
The Innocor sample flow rate was measured to determine the amount of lost gas 
during MBW testing. During normal testing gas is sampled from the pneumotach 
during MBW testing and is not included in expired or reinspired volumes (i.e. lost). 
This is more important for washouts in young children and infants compared with 
older children and adults, as the gas sampling rate is large relative to the tidal 
volume. Each Innocor machine differs slightly and the documented gas sample flow 
rate according to the user manual is 120-130ml/min. Innovision have stated that this 
can be increased to improve signal response time but this may affect the stability of 
the gas signal and will also increase lost gas. Also, this needs to be done by 
Innovision technicians. 
Aim  
The documented sample flow rate from the official Innocor documentation is 
120ml/min. To determine the actual sample flow rate in the RHSC Innocor to allow 
calculation of lost gas during washouts, the following experiment was conducted. 
Method  
Flow was measured through the pneumotach with one end blocked. The flow 

































All flow pressure transducers have a baseline drift. This is due to slight inaccuracies 
in calibration and electrical signal drift over time. This baseline slope of the flow 
signal was accounted for by determining the intercept of a linear regression line 
through all the values. The slope of the regression fit is the flow drift of the pressure 
transducer. The negative offset is the constant sample flow rate 
Results  





















Figure 68). Mean(SD) flow in one experiment was -2.90 (0.65)ml/sec, coefficient of 
variation (%) was 22.5%.  
A sample graph is shown here with flow measured over time just after a flow meter 





















Figure 68 - Raw flow reading during gas sampling. Variability of real time measurements 
shown, with drift in flow shown by the black regression line. Intersection of the regression is the 
underlying sample flow rate. 
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The mean sample flow rate, measured over 3 experiments, is shown in Table 27 
 
Experiment no. Measurement time 
(seconds) 
Sample Flow Rate 
(ml/min) 
1 344 125.45 
2 362 138.78 
3 240 151.20 
Mean  138.48 
           Table 27 - three sample flow rate experiments. Sample flow rate and mean value shown. 
  Conclusions  
This basic experiment indicates the sample flow rate is highly variable and on 
average slightly higher than documented in the official Innovision documentation. It 
is expected this could have resulted in a faster response time, but this was not seen in 
practice. Other factors may of course contribute to this. 
When considering infant washouts, approximately 2.3ml is lost from the system 
every second. As this is a large volume in proportion to tidal volumes seen in infants, 
this is a factor that will contribute to MBW expired and inspired gas volume 
inaccuracies. 
Chapter summary and conclusions 
Innocor has already been adapted for adults and older children with some technical 
adjustments. In previous experiments, conducted by Alex Horsley, the Innocor was 
altered by replacing the large dead space Pneumotach and gas switching system for a 
standard low dead space pneumotach and side-stream sample capillary needle. This 
setup was based on similar mass spectrometer equipment designed by Per 
Gustafsson. A comparison with the mass spectrometer system showed that with 
simple SF6 signal speeding, acceptable results were achieved, relevant to washouts 
conducted in children as young as 5 years old. 
To summarise the issues discussed in this chapter: 
 Standard speed of Innocor gas sample analysis is too slow for infant washouts 
based on mathematical modelling of gas concentration curves. 
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 A rise time of less than 100ms, as recommended in current literature, may 
still result in large errors in gas volume estimation at higher respiratory rates. 
 The Innocor has extra internal steps, not needed for MBW, which can be 
bypassed. 
 Simple hardware modifications can speed step concentration rise time to less 
than 100ms. 
 The nafion tubing can be shortened without affecting its drying properties. 
 The sample flow rate in Innocor is 138ml/min, which may lead to large errors 
if not compensated for. 
 Current methods for measuring gas sample delay may not be adequate for 
infant equipment. 
MBW in young children and infants requires detailed adherence to published 
guidelines. Attention must be paid to equipment dead space, re-inspired gas volume, 
gas analyser speed and acceptability of the test to the age group in question. 
Specifications for all of these are well documented, but it may be that some are not 
based on published experimental evidence, as studies in this field are few. 
It is unlikely that the standard Innocor setup, even with a reduced equipment dead 
space, will be able to accurately estimate expired gas volume in subjects with higher 
respiratory rates and low tidal volume, due to slow signal rise time. This is indicated 
from mathematical gas concentration curves.  Simple, in-house technical 
modifications have improved the signal rise time to a value that is acceptable to the 
most recent infant lung function guidelines. As a result of these modifications, the 
standard daily signal alignment calibration process needs to be revised.  
These experiments were necessary to investigate the feasibility of further in-vitro and 
in-vivo experiments, performing washouts in subjects with small tidal volumes and 
fast respiratory rates. The Innocor has a number of advantages over other MBW 
devices and these modifications may mean it is of interest to other research groups 
interested in performing MBW in larger populations. While it appears from 
mathematical modelling that there may be 3-4% error in infant washouts, even with 
the modifications made, this may be acceptable given the variability of the MBW test 
in human subjects. The only way to assess the accuracy of the modified Innocor 
device is to perform a clinical comparison with a known lung volume or against the 
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accepted gold standard MBW device. A known volume can only be measured with a 
mechanical lung model and the next chapter presents this model study and describes 
a clinical comparison across the age range with an MBW mass spectrometer. 
Learning points and contribution to thesis 
This is the first time that the Innocor has been subjected to rigorous investigation in 
preparation for infant MBW. Since no published guidelines exist for such equipment, 
all aspects have been addressed from first principles. This does not answer whether 
Innocor is able to accurately measure breath-by-breath gas concentration in infant 
washouts. Only a clinical study will demonstrate this. This chapter serves to provide 







Chapter 9 - Validation of modified Innocor using 
mechanical lung model and comparison with mass 
spectrometer 
Introduction 
As stated previously, Innocor has a number of advantages in terms of size, ease of 
operation, cost and portability compared with other available MBW devices. In 
addition, because it uses 40 times less gas, Innocor has an environmental advantage 
for larger, multi-centre studies. As MBW has gained prominence as a suitable infant 
lung function measurement, these factors have been examined in more detail. To 
make the transition from experimental research measurement to widely conducted 
research and clinical test, LCI (as well as other MBW indices) must be able to be 
conducted in clinical situations, and the devices be validated for use in the subjects in 
question. There are a number of published standards for infant lung function, 
covering a number of different techniques, such as MBW, forced oscillation 
manoeuvres, plethysmography and airway resistance(Bates et al. 2000, 'ATS/ERS 
Statement: Raised Volume Forced Expirations in Infants: Guidelines for Current 
Practice'  2005, Beardsmore et al. 2007, Beydon et al. 2007, Frey et al. 2000b, Frey 
et al. 2000a, Frey et al. 2001, Frey 2005, Gaultier et al. 1995, Sly et al. 2000, Stocks 
et al. 1989, Stocks and Quanjer 1995, Stocks et al. 2001). Many groups who conduct 
MBW in research situations contributed to these standards, increasing confidence 
that equipment used is suitable. Validation of new equipment and techniques should 
thus stem from evidence based standards. A criticism of published standards is that 
in order to validate equipment developed prior to publication of standards, statements 
made in these standards publications may simply justify current practice, rather than 
reflect evidence. A good example of this, discussed earlier in this thesis, is the 
statement made about the upper acceptable limit for signal rise time during breath by 
breath gas washout measurement. While 100ms is a reasonable number, there is little 
evidence to support this. 
Technical specifications, specifically related to the analyser, limit use of Innocor to 
older children and adults. These limitations stem from published standards, rather 
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than clear evidence of inaccuracies from experimental data. This chapter describes 
the first known experiments to validate Innocor for use in younger age groups. This 
is therefore key to the overall message of the thesis, and is of interest to researchers 
in other fields, looking to perform physiological measurements in young children, 
with equipment that may or may not have been validated appropriately. The 
importance of not taking reported technical limitations for granted, and rigorously 
testing equipment against an appropriate standard, will become clear as the chapter 
progresses. 
The mass spectrometer system, using the AMIS2000 quadrapole mass spectrometer 
(Innovision, Denmark) was initially designed in Professor Per Gustafsson’s 
department, Goteborg, Sweden. A number of published studies have explored the use 
of this mass spectrometer equipment in children with lung disease. Many have been 
mentioned throughout this thesis. Over the past 10 years he has set up similar 
systems in other centres, most notably the Institute of Child Health, Great Ormond 
Street Children’s Hospital, London. As a result of these collaborations, the mass 
spectrometer system is considered the Gold Standard device for MBW in all age 
groups.  
Despite performing well in experimental and clinical studies in older children and 
adults, there are specific limitations to Innocor which are considered to invalidate its 
use in younger children (< 5yrs). This chapter describes a lung model experiment and 
a clinical study undertaken to answer whether modified Innocor, as described in 
chapter 8, performs as well as the currently accepted gold standard mass 
spectrometer device. 
Importance of rigorous validation 
The previous methods description (Chapter 8) has shown how technical gas analysis 
limitations contribute to error in calculated gas concentration and volume. The 
following factors were both important and modifiable, disrupting the sampled gas 
front, thereby increasing the signal rise time: 
 Nafion tubing and connections  




In addition, technical methodological issues became apparent during initial 
experiments which were addressed to improve washout accuracy: 
 Signal alignment and measurement of flow gas delay 
 Sample flow rate measurement 
 Compensation for sampled gas lost from volume calculations 
 
I have proposed solutions to these errors with hardware and mathematical 
compensation. The results of these experiments indicate Innocor may still lead to 
unacceptable error in volume calculation in younger age groups. Rigorous testing, 
involving human subjects, appeared the only way to properly address this question. 
Previous comparisons with a mass spectrometer 
Two previous studies (discussed in detail later in this chapter) have tested alternative 
MBW systems in-vivo, performing direct comparisons between mass spectrometry 
(MS) and the novel device in adults and infants(Fuchs et al. 2006, Pillow et al. 2004). 
Overall, these studies show that different devices can give very similar results when 
measuring FRC. However, it is clear that there are technical differences between the 
devices. While the mass spectrometer is considered the gold standard against which 
other devices should be compared, it must be borne in mind that this reference device 
may have an unrecognised technical or methodological error. 
Need for comparison in health and disease 
An important factor in equipment validation is the importance of testing equipment 
on those on whom future studies will be conducted. This has not been done before in 
MBW device comparisons. After investigating and adapting Innocor using 
mathematical modelling, it was shown that error in estimated expired volume is 
dependent on length of breath and tidal volume (Chapter 8). Because washouts are 
prolonged in disease, particularly cystic fibrosis, washout error may be dependent on 
presence or absence of disease. Any comparison for validation should include those 
with respiratory disease, as well as a healthy group. 
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Lung model washout method 
Planning Innocor validation 
Experienced research groups 
Innocor had been adapted in the early stages by my colleague Dr Alex Horsley, 
clinical research fellow in Edinburgh, with considerable input from Professor Per 
Gustafsson. Two visits were made by Dr Horsley to Professor Gustafsson’s 
department in Goteborg, Sweden. Simple experiments were conducted using volume 
syringes as a basic lung model and with a human subject breathing at different rates. 
Some of these data are published in this important Thorax journal publication(A. R. 
Horsley et al. 2008). 
Initial planning for a clinical validation of Innocor involved obtaining a mass 
spectrometer for use in Edinburgh. As the simple gas signal was all that was needed, 
with flow data collected by Innocor, a full MBW setup was not required. 
The cost of a new respiratory mass spectrometer was prohibitive, but after 
researching local institutions, a device was found in Glasgow University department 
of physiology. This was a quadropole mass spectrometer, with similar specifications 
to the AMIS2000. It was in the department for exercise testing of humans and 
seemed a suitable device for comparison of gas concentration data with Innocor. We 
proposed to this department a loan of the device, for a cost, as they were not using it 
at that time. 
An agreement in principle was made with the professor of that department. However, 
following an initial positive meeting, it came to light that the device required 
considerable servicing as it had been out of use for some time. Another group also 
planned to use it, meaning we would have to wait until they were finished. This was 
a frustrating disappointment as there were no other available devices in the local 
area. After a number of weeks of negotiation it became clear this project was not 
going to happen within a reasonable timescale. 
During this planning stage, further separate links were made between our department 
in Edinburgh and 2 other research institutes experienced in infant and paediatric lung 
function research. The following is a description of their input to the validation 
project: 
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 Department of Paediatric Respiratory Medicine, University Children’s 
Hospital of Bern, Switzerland 
This department was then led by Professor Urs Frey, who has since moved to 
another institute. Professor Frey was closely involved in publishing Infant 
Lung function ERS task force documents (Frey et al. 2001, Frey et al. 2000a, 
Frey et al. 2000b).  
Following a presentation made at the European Respiratory Society 
international conference in 2007, I was approached by Dr Phillip Latzin, a 
clinical researcher for Prof. Frey. He was interested in the work done using 
Innocor, and how it could be improved. An invitation was made for me to 
visit their department to compare Innocor with the ExhalyzerD device (Eco 
Medics, Switzerland), the device used for MBW in their department.  
In January 2008, I took the Innocor to Bern by train. Three days were spent 
assembling the equipment, looking at data analysis, and testing Innocor using 
an in-house mechanical lung model. 
While it proved more difficult than expected to get Innocor to work using an 
infant-sized pneumotach, much useful experience was gained from this visit. 
I was able to spend time discussing important issues with experts in signal 
processing and multiple breath washout. The greatest benefit of this visit was 
being introduced to a mechanical lung model. This simple device was 
invaluable to preliminary Innocor validation experiments. It will be described 
in detail later. The device was built by Reudi Isler, a support and research 
representative of Eco Medics. He was kind enough to lend me the lung model 
to take back to Edinburgh.  
Once in Edinburgh, I was able to redesign a similar version to keep and use 
for further lung model washouts. This redesigned version was built by Mr 






 The Department of Paediatric Respiratory Medicine, Royal Brompton 
Hospital, London 
Following a presentation of data from chapter 4, at the British Thoracic 
Society Winter Meeting, London, Professor Andy Bush proposed a clinical 
study comparing his newly purchased Innocor and mass spectrometer 
devices.  
Professor Bush is a world expert in paediatric respiratory medicine, with a 
highly respected research profile. The opportunity to work with him and his 
research fellow, Samantha Irving, was good for the thesis project as well for 
my personal research development. This was also a timely solution to the 
problem of difficult access to a respiratory mass spectrometer. The design of 
the clinical study that follows is discussed in detail in the following pages. 
Through previous contacts and interest from presentations made at research 
meetings, I was able to discuss work with international experts and refine the study 
that follows. This enhanced the thesis project, allowing basic validation work to 
become important to the wider research community, in the context of equipment 
validation for infant respiratory function measurements. 
Study 1 – In-vitro validation of Innocor using a mechanical 
lung model 
In February 2008, I visited the department of paediatric respiratory medicine in Bern 
Switzerland. In collaboration with the manufacturers of the ExhalyzerD MBW 
device (Eco Medics), a lung model was assembled to measure accuracy of Innocor 
measuring SF6 washout from a small volume compartment. The main aim of the 
lung model is to mimic small volumes seen in infants, but with controlled and 
variable specifications. Therefore, if the washout device in question can accurately 
measure known model volumes, it would be inferred that it could accurately measure 
infant volumes in-vivo. 
Description of Bern lung model 
The Bern lung model consists of a dual compartment Perspex box partially filled 
with water. The two compartments communicate below water line, meaning that as 
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one side is filled with air, the other side rises. The washout volume (equivalent to 
FRC) is varied by different volumes of water. The breaths are driven by a motorised 
syringe, therefore tidal volume is constant, with a variable breath rate depending on 
the speed of the motor. This setup is ideal for simple washout experiments, but does 
not have any of the complexity of the human respiratory tree, therefore ventilation 
heterogeneity is not measured. The compartment “FRC” is derived from the normal 
dilution equations described in chapter 2.  
This lung model allows validation of a washout device by mimicking the lung, in that 
gas is washed in and out of the compartment with tidal volume exchange. The 
volume in the model is known, either by volume displacement or by placing a scale 
on the box, and knowing the internal dimensions to calculate the volume. The 
volume of the connection hub and pneumotach must also be measured. High 
accuracy is required to quantify washout precision and error. A similar version of 
this lung model has very recently been used to validate a nitrogen MBW system, 
however a temperature control was added(Singer et al. 2012). 
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Below are pictures of the Bern lung model (Figure 69-71). 
 
Figure 69 - lung model with dual compartments communicating below the water line. Left 
compartment is the variable “lung” volume and pneumotach with gas sample line set up for 
MBW. The ruler scale is stuck to the box, with pre-measured volumes written on the paper. 
Right compartment with blue foam to dampen waves has elephant tubing connected to the 
motorised syringe to deliver tidal volumes. 
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Figure 70 - motorised syringe. This syringe is fixed to the platform. A motor underneath the 
platform turns an arm, which pushes and pulls the syringe plunger. The volume on this setup is 
fixed. Speed (breath rate) is varied by the power supply voltage. 
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Figure 71 - the full lung model setup shows how the components connect. Power is varied using 
a DC power supply. 
Description of Edinburgh lung model 
Based on the design of the Bern lung model, a copy was developed for use in 
Edinburgh. The following slides ( 
 








































Figure 72 - specifications for copy lung model, presented to the Western General Hospital 
medical technician. The only change to the Edinburgh version of the lung model was to 
introduce variable tidal volumes by being able to attach the plunger at variable positions up the 
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rotating arm. It was only desirable to have variable tidal volume, rather than to be able to 
specify tidal volumes based on the length of the arm and the calibre of the syringe. 
The resulting lung model is shown below. A higher torque is required to rotate the 
arm when the plunger is close to the axis, and the motor was of limited power. 
Because of this and the short length of the rotating arm, it was only possible to have 
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Lung model variables 
Washout volume (FRC) –  
 As previously described, the plastic box is partially filled with water, above 
the level of the divider. Thus, the washout volume can be varied. By knowing the 
internal diameters of the box, the volume in question can be measured. Alternatively, 
the volume was confirmed by filling the washout volume with water to the top. 
Tidal volume –  
 The syringe is made from a clear plastic tube with a custom-built plunger. It 
was constructed in a similar fashion to a calibrated volume syringe, but does not 
deliver a set volume. It is not important what the exact volume is, however this must 
be determined to ensure this is appropriate to that expected in an infant. The tidal 
volume is varied by adjusting axis on rotating motor arm. There are 2 tidal volume 
settings. 
Breath rate –  
Infants have a faster respiratory rate than older subjects. Short tidal volume has been 
associated with increasing error in end-tidal expired gas concentration (Brunner and 
Westenskow 1988). For a lung model to mimic infant parameters, it must have a 
breath rate of approximately 60/min. The breath rate of the lung model was varied by 
adjusting speed of motor. A simple linear variable power pack supplied voltage 
within the specifications of the motor. 
Using the Edinburgh lung model, the following experiments were performed 
1. Measurement of lung model volumes 
2. Pilot washouts to test adequacy of washout calculations at low lung volume, 
adjusting for BTPS, reinspired gas and lost sampled gas 
3. Comparison of washout results between unmodified and rise time improved 
Innocor. 
4. Effect of reducing lung model washout volume and tidal volume 
Measurement of lung model volumes 
It is important to determine the exact volume of the lung model components to 
compare washout results. This was done by filling the model with a volume of water, 
measured using scientific beakers and syringes. The volume of the lung model was 
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taken from the water surface at “expiration” (motorised syringe fully depressed) to 
the level of the sample capillary within the pneumotach. This was the washout 
volume or “FRC”.  An alternative approach to this is to measure the internal 
dimensions of the model and calculate the volume. While this seemed more 
mathematical and allowed a measuring tape to be fixed to the box to measure 
changes in volume, I was less certain about the accuracy of this as it assumed the 
tape was accurate and the box walls were absolutely perpendicular to each other. I 
opted to measure the volume directly.  
The tidal volume was measured by the difference in the washout volume between 
full expiration and full inspiration. There are 2 tidal volume options, as the rotating 
arm could only allow two settings.  
Pilot washouts to test adequacy of washout calculations at low 
lung volume, adjusting for BTPS, reinspired gas and lost sampled 
gas 
Initial washouts to test the system were instructive. While it is easy to get accurate 
results (estimated washout FRC vs. known model volume) at larger lung volumes, it 
became difficult to get accurate results as the estimated volume was consistently 
10% lower than the actual volume. The proposed reasons for this were: 
 There is higher humidity within the lung model compared with room air, 
therefore, gas volumes should be adjusted for this. 
 Re-inspired volume is over-estimated, resulting in a lower net expired 
volume for each breath, reducing the final FRC. 
 Error in end-tidal concentration measurement.  
 Sampled gas is lost from the system into PGA.  
  
In retrospect it is easy to see the relative contributions of these factors to washout 
inaccuracy. Working through the problem at the time was challenging. There is an 
inherent physiological variability in MBW lung volume and ventilation heterogeneity 
in humans, which is conventionally tolerated up to approximately 10%. There is no 
variability in the lung model; therefore all error should be accounted for.  Accuracy 
of the washout calculation is also only as accurate as the initial model lung washout 
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volume measurement. When the washout volume is as low as 100ml, a proportion of 
error can be attributed to this.  
All measured gas volumes must account for the differences in humidity and 
temperature within the lung compared with room air that change the volume of 
measured expired and inspired gas. To standardise lung function tests, volumes are 
corrected to BTPS. The humidity within the box is higher than room air, and there 
should be an acknowledgement of this in the calculations.  
Further analysis of this showed that humidity was higher in the box than air, only the 
reinspired gas portion is of importance to the calculations. This reinspired portion, 
residing within the pneumotach, is of the same humidity as within the box. It is not 
necessary to adjust for the humidity of the rest of inspiration, as the gas concentration 
of this part is zero, and doesn’t contribute to the FRC calculations. BTPS was 
therefore not included in the final calculation. 
The initial inaccuracy in Innocor measurements at low lung volumes are thought to 
occur from inaccurate estimation of changes in gas concentration due to slow signal 
rise and fall time. The adjustments made in chapter 8 aimed to resolve this 
inaccuracy but the analyser response time is still slower than the mass spectrometer 
(100ms vs. 40-60ms). It is feasible that even following the improvements, there may 
be under-estimation of expired gas concentration, or overestimation of re-inspired 
gas, resulting in low FRC. This is one possible explanation for the under-estimation 
of FRC in the initial experiments. 
Another concern about slow rise time gas analysers is that with short expiratory 
times, seen in infants, there may be insufficient time for the gas concentration to 
plateau before the subject has started inspiring again(Brunner and Westenskow 
1988). Therefore the end-tidal concentration – important for FRC and LCI 
calculations – will be under-estimated, artificially lowering the LCI, but in theory 
should not result in much difference in FRC, assuming the error at the beginning of 
the washout, is the same as at the end. Also, a lack of alveolar plateau can be 
observed during analysis. The lung model does not have the same breath 
concentration phases and reaches the maximum tidal concentration quicker than in a 
human breath. No premature falls in concentration were seen, as the breath time was 
always much longer than the rise time of the analyser (100ms). 
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Finally, a major concern about Innocor, raised during discussions with other 
researchers using alternative devices, was how much gas sample rate contributes to 
washout error. As discussed previously, Innocor samples gas at 2ml/second. This gas 
is lost from the equation as it is lost from both expiration and re-inspired portions. 
This is different from the bias applied to flow meter, which is compensated for 
during calibration. There is gas which is measured, on inspiration, which does not 
enter the lung, and gas which is measured on expiration, which does not exit the 
pneumotach. The proportion of this to the overall gas volume is small in larger 
subjects but is a large proportion of younger subjects’ breath volumes. 
Lost sample gas leads to under-estimation of FRC because re-inspired gas is over-
estimated, as it is measured by the pneumotach and analyser, but doesn’t reach the 
lung. The net expired SF6 (expired – inspired) is therefore greatly underestimated in 
younger patients, where this bias is large compared to the expired volume.  
The solution to this problem had to be considered carefully. During flowmeter 
calibration, the calibration syringe is attached with the sample flow turned on. 
Therefore, the flowmeter is calibrated so that the bias created by the sample capillary 
is compensated for. For example, if 1 litre is pushed through the pneumotach with 
the sample capillary proximal to the screen mesh, slightly less than 1 litre will be 
measured. The calibration adjusts this up to 1litre. Similarly, if 1 litre is sucked back 
through, slightly more than 1 litre will be pulled as there is additional suction from 
the sample capillary.  Again, the calibration adjusts for this. This calibration process 
means that even though there is a bias, the breath volume measured is the same as 
has come out or has been breathed by to the subject.  
Unfortunately, this does not hold true for gas concentration. Calibration means 
underestimation of gas as it doesn’t account for that which was removed from the 
equation. During re-inspiration, the flowmeter measures a volume of gas, integrated 
with concentration to calculate gas volume inspired. The flow meter is reading 1litre, 
when slightly less than that actually enters the subjects’ lungs (over estimation of re-
inspired gas). During expiration, the flowmeter reads 1 litre breathed out, but since 
this gas is removed from the equation anyway, it doesn’t matter than it is partially 
sampled by the analyser. 
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Therefore, expired gas is accurately measured, but re-inspired gas, is over-estimated. 
Re-inspired gas is more important to the equation as the washout progresses, because 
in small subjects the PNT volume can be up to 20% of the breath volume. Therefore, 
approximately 20% of gas is re-inspired. If this is overestimated due to slow fall in 
gas concentration due to the analyser and over-estimation due to flowmeter error is 
unadjusted, the net expired volume can actually be negative. 
After deliberation, I opted to reverse the bias generated during flow meter 
calculation. By adding the sample flow rate back to the pneumotach measurements, 
the true re-inspired gas concentration could be calculated.  An ideal solution would 
be to adjust the flow only for the inspired portion of the washout, but this is 
technically difficult with the software I was using. It was very simple to generate a 
bias to both expired and inspired flow prior to analysis, reversing the calibration bias, 
but providing an accurate measure of re-inspired gas. Expired gas will therefore be 
over-estimated, but re-inspired gas, crucial to accurate washout measurements will 
be accurately measured. The adjustment above proposed to make the re-inspired 
concentration accurate, and slightly over-estimate the expired concentration to 
compensate for the slow fall in the gas analyser still over-estimating expired gas 
concentration. 
This resolution is acceptable for FRC calculation, as absolute flow is not important. 
During LCI calculation, absolute flow is vital for measuring the cumulative expired 
volume during the washout. Therefore, the decision was made to analyse the FRC 
and CEV separately, before and after adjusting the flow readings, so that the most 
accurate measurements were made. This is relevant during the clinical comparison in 
human subjects. 
Therefore, the only major influence on accuracy of lung model washouts, was the 
sampled “lost” gas. The analyser speed (100ms) may still be contributing error, but 
the empirical over-adjustment of expired gas is likely to compensate for this. 
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Comparison of washout results between unmodified and rise time 
improved Innocor. 
The major alteration to Innocor was speeding the rise time from 160ms to 97ms. It 
was hoped that this improvement would be adequate to allow washouts to be 
performed in young children and infants. A comparison was made, before and after 
Innocor modification, quantifying to some extent the effect of speeding rise time on 
washout accuracy. 
Using the lung model, 3 washouts were performed on the factory standard Innocor 
with 2 washouts performed on the rise time speeded version. The same flowmeter 
was used for both sets of washouts, calibrated for low flow and small tidal volume. 
With the rise time speeded device, analysis was done on data adjusted for sample gas 
flow. The sample capillary was positioned proximal to the flowmeter mesh. The 
standard Innocor setup had no alterations made to the standard washout setup. 
Only a small number of washouts were recorded because of multiple adjustments to 
the analysis algorithm to accommodate the new setup. This was not to firmly 
quantify the relationship between analyser speed and washout accuracy at low 
volumes, because there are multiple factors involved, apart from analyser speed.  
Effect of reducing lung model washout volume and tidal volume 
Final experiments were performed using only the rise time modified Innocor. The 
setup is as described in chapter 8. 
The aim of these experiments was to perform multiple runs of washouts using the 
lung model, varying washout volume and tidal volume to look at Innocor accuracy at 
these volumes. Values were chosen to mimic an infant, although the limits of the 
model were reached with a respiratory rate of 50, as the motor would not drive the 
arm any quicker. All washouts were therefore performed at a rate of 40 -50/min. 
While it is recognised infants often demonstrate periodic breathing, with periods 
quicker than 60/min, it was not possible to mimic this with the equipment I had.  
A series of washouts was then performed on separate days. Setup of the lung model 
involved filling the plastic tank with water to a marked point, with the motorised 
syringe at full “expiration”. The model was then filled to the brim with a volume of 
water measured with scientific beakers and clinical standard syringes. The model 
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was emptied and refilled to the original fill mark. Thus the washout volume was 
determined. Different lung volumes were chosen to reflect those seen in infants and 
young children (Table 29). Some washouts were performed with different tidal 
volume, again to reflect breath volumes seen in infants. 
It was noticed that there was a drift in the water level after each washout. This was 
presumably due to slight leak in the system due to the motorised syringe. The seal 
was re-established and the washouts restarted. The level of the water on a taped ruler 
was noted so that the internal dimensions of the tank could be used to determine the 
change in washout volume after each run. 
The collected washout data were adjusted to correct for the lost sampled gas, then 
analysed using Professor Per Gustafsson’s software. At that time, the software 
version was not able to detect breaths with low flow, such as those generated by the 
lung model. Therefore, there was no way to automatically detect breaths, and the 
markers had to be moved manually for each breath. This was very time-consuming 
but allowed accurate analysis. Since then, a software upgrade has been written which 
allows variable breath detection thresholds. Now lung model and infant washouts can 
be analysed automatically. 
The mean FRC was determined for each set of washouts, and compared with the 
actual lung model volume. % error was calculated by comparing the difference 
between measured and actual volume, divided by actual lung model volume. Mean 
values for each set of washouts was plotted against average difference, and 95% 
limits of agreement calculated to show effect of lung volume on washout accuracy.  
Lung model washout results 
1. Compare original vs. modified 
Washout results were compared from the un-modified Innocor and the rise time 
modified version. Lung model parameters are shown (Table 28). The unmodified 
Innocor was setup with the PNT sample capillary positioned distal to the flow 
pressure lines, as per the standard MBW setup for older children and adults. This 
renders the post-capillary dead space less than 5ml, and re-inspired gas is 
unaccounted for. The modified Innocor setup positioned the PNT with the sample 
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capillary proximal to the flow pressure lines, which requires re-inspired gas to be 
taken into account (post-capillary dead space 8ml). 
Washout volume (FRC) results from each Innocor version were compared with the 
expected lung model volume (219ml). In both cases, a tidal volume of 50ml was 
used, with a breath rate of 40/minute. There was a mean over-estimation of 19% 
using the factory standard version. This over estimation was 1.2% when using the 
modified setup. Full results are shown in Table 28. This confirmed the basic 
hypothesis - that modifications improve washout volume estimation compared with 
the factory standard version with a longer rise time. 
 
 
 Factory standard Rise time modified 
Breath rate 40 40 
Lung model FRC (ml) 219  219  
Number of washouts performed 2 2 
 
  10 – 90% rise time (ms) 168 97 
Flow gas delay (ms) 1496 450 
Gas sample flow rate (ml/s) 2 2  
Mean(SD) measured FRC (ml) 260.7(3.27)  221.6(2.74)  
Mean(SD) error in FRC (%) 19.03 (1.49)  1.18 (2.25) 
Table 28 - comparison of unaltered factory standard Innocor vs. the rise time modified version. 
Mean (standard deviation) FRC values are shown. Rise time, flow gas delay and gas sample flow 










2. Compare series of washouts at different lung volumes and tidal volumes 
Following the basic comparison of modified vs. unmodified Innocor, a series of 
washouts were performed using only the modified version. Sequences of washouts 
were performed on 7 separate days at various lung model volumes and tidal volumes. 
At each time, multiple washouts were performed, the number shown in the results 
table (Table 29). The experiments have been ordered by lung model volume and 
breath (tidal) volume for simplicity. These are the final satisfactory washouts once 
technical issues regarding model leaks, signal alignment and lost gas compensation 
had been resolved. In all of these washouts, no modifications were made to the 
equipment or analysis method. All washouts and analysis were completed as per the 
























1 14 50 58 162.0 159.8 (2.6) -2.17 (2.2) -1.3 (1.6) 
2 6 50 58 139.5 138.3 (2.0) -0.01 (0.8) -0.0 (0.6) 
3 6 50 58 118.0 118.1 (0.9) 0.06 (0.9) 0.1 (0.7) 
4 6 50 58 101.0 100.9 (0.7) -0.09 (0.7) -0.1 (0.7) 
5 6 50 28 142.5 141.9 (1.9) -0.58 (1.9) -0.4 (1.4) 
6 6 50 28 114.0 113.1 (2.2) -0.89 (2.2) -0.8 (1.9) 
7 8 50 28 98.0 98.3  (3.5) 0.30 (3.6) 0.3 (3.6) 
Table 29 - Series of lung model washouts using variable tidal volume and FRC settings. Mean 
error is calculated from the difference in estimated minus known lung volume. 
 
Overall, there was no significant mean error when estimated FRC was compared 
against actual lung model volume (p=0.08). Table 29 demonstrates that mean error 
does not change at smaller model volumes. Plotting expected FRC against difference 
(Figure 74) shows that at a small volume of 98ml, approximately that of a newborn 
infant, there was a slight increase in variability (Coefficient of variation, CV 6%) 
compared with the other volumes (CV 1.4%). 95% limits of agreement based on a 
pooled standard deviation are shown (dotted lines). It is obvious that in the smallest 
volumes, variability was significantly higher. It is important to emphasise that this 
graph shows proportional differences. Mean(SD) absolute differences (ml) at the 
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smallest volumes were less than 0.5ml. There is also no evidence of bias at low lung 
volumes, as would be seen in the scenario of under or over estimation of expired gas 
due to limitations of the Innocor gas analyser. There is an appearance of a trend 
towards over-estimating of smaller lung volumes and under-estimating of larger lung 
volumes. While there is no statistical difference in error when comparing pairs of 
experiments in turn, experiment 1, with the largest lung volume comes close to a 
statistically significant difference in error when compared with some of the other 
experiment errors (p=0.06). This visual trend could be due to experimental error or 
drift in the lung model volume. Importantly, error in the gas signal would result in 
under-estimation of smaller lung volumes with lower tidal volumes. 
 
Figure 74 - Plot of expected FRC vs. % difference. Dotted lines indicate 95% limits of 
agreement(Bland and Altman 1986) 
 
Innocor / mass spectrometer comparison  
As a result of the above lung model work, a clinical comparison of Innocor against 
mass spectrometer was undertaken. Because of links with Professor Bush’s research 
department, access was available to both an Innocor and AMIS 2000 respiratory 
mass spectrometer.  

















































Initial protocol development had been started in Edinburgh prior to this link with 
Professor Bush. We had established the principles of device comparison. A literature 
search resulted in two relevant studies comparing multiple breath washout devices. 
Pillow et al conducted a comparison study of an early version of the Ecomedics 
ultrasonic molar mass technology flow meter vs. mass spectrometer(Pillow et al. 
2004). 23 healthy infants (mean gestation 39.7 weeks) performed multiple breath 
washout 2-3 times on each device in turn to obtain an average of technically 
acceptable washouts. While there was a strong correlation between FRC values 
measured on both devices, there was a mean(SD) under-estimation of FRC on the 
ultrasound device compared to the mass spectrometer of 5.7 (1.0)%. This was 
statistically significant, although the differences were small. There was a wide scatter 
of differences (95% CI 1.0 – 10.4%), explained by the inherent physiological, 
technical and methodological variability.  This study was concerned only with gas 




b) Bland-Altman plot of the % difference in FRC obtained using the mass spectrometer 
and ultrasonic flow meter plotted against the average FRC. Solid line indicates mean 
difference while the dashed line indicates 95% limits of agreement (mean difference 
1.96SD). The dotted line demarcates 20% of the mean difference between the two 
techniques.  FRCMS with Rendell-Baker 1 Mask and FRCUS with Laerdal 0/1 Mask;  
FRCMS with Rendell-Baker 2 Mask and FRCUS with Laerdal 0/1 Mask; FRCMS with 
Rendell-Baker 2 Mask and FRCUS with Rendell-Baker 2 Mask. 
 
Figure 75 - extract from Pillow et al 2004. 
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In another study, Fuchs et al aimed to compare a different ultrasound molar mass 
device (Spiroson, ndd medical technologies, Switzerland) with mass 
spectrometer(Fuchs et al. 2006). This prototype device was altered during the study 
so that molar mass gas concentration was taken from a side-stream sampled 
technique, rather than mainstream analysis (for technical reasons, as the beginning of 
the washout could not be determined from the mainstream signal). Another side-
stream sample tube was sited to directly measure CO2, as this needed to be 
subtracted from the molar mass signal. Finally, the mass spectrometer sample 
capillary was positioned in the same flow meter as the molar mass, so that 
simultaneous gas concentration measurements could be made during the same 
washout. This has the advantage of eliminating inter-test variability. This study was 
conducted in 14 healthy adults, with 5 subjects’ results subsequently discarded 
because of technical issues. Intra-subject variability was low (<5%). There was a 
mean (95%CI) difference (mass spectrometer – ultrasound flow meter) of 0.124L 
(0.08 to 1.7), which amounts to a small but statistically significant mean difference 
of 2.8%.  
These studies indicate important principles for any comparison of devices for 
validation. Firstly, there are complexities in such studies. The implication of the text 
is that Fuchs et al had to substantially change the ultrasound equipment to get 
comparable results with the mass spectrometer. Such changes to hardware and 
analysis may make equipment complex and prone to further unknown errors. The 
population was limited to healthy adults, therefore it is difficult to draw conclusions 
on how useful this equipment is in younger children or infants. The multiple side 
stream sampling may generate a large flow bias, requiring careful compensation. In 
addition, Pillow et al studied a well-controlled population of sleeping infants. Even 
in this situation, there is still a wide inter-device variability up to +/-20%, indicating 
physiological variability is high. In comparison, the Fuchs study eliminates 
physiological variability between devices with simultaneous gas sampling from a 
single flow meter, resulting in differences of up to 300ml (10%) between devices 
(numbers approximate as not explicitly stated in text). The graph of FRC difference 









Originally, the Innocor – mass spectrometer comparison, comprised of simultaneous 
sampling of gas to both devices from the same pneumotach. This was decided when 
planning to use the quadropole mass spectrometer from Glasgow University. When 
changing to using the London equipment, a discussion was initiated with Professor 
Gustafsson, whose mass spectrometer setup was to be used. An important difference 
between the devices is the concentration of SF6 used (4% for mass spectrometer, 
compared with 0.2% for Innocor). One solution was to compromise the Innocor by 
measuring 1% (within its calibrated range) and tolerating the increased MS noise. 
This is unsatisfactory, as changing both sets of equipment reduces the clinical 
applicability of the study in the future. Innocor cannot be calibrated easily to measure 
4% SF6 without extensive expert input thereby raising the question of whether 
conclusions from that protocol could be applied to the Innocor when measuring 
0.2%. A decision was therefore taken to perform sequential randomised 
measurements, with order determined by random number. Healthy volunteers and 
children with cystic fibrosis were selected to perform up to 3 washouts on each 
device. The intention was to have subjects over a wide age-range, including young 
children. This was the first time subjects had been tested using the modified Innocor. 
Whilst the pneumotach was of standard construction, there was a degree of caution 
amongst the research group about such a comparison without knowing whether the 
device was accurate in older children and adults. Therefore, adults were recruited 
first, and then children of descending age. Children with cystic fibrosis were 
recruited, as device errors may be more apparent with prolonged washouts. Adults 
and older children with CF were not recruited as many were at that time involved in 





Healthy volunteer patients 
(a) 4 age groups 
 adult - >16yrs 
child – 5-16 years 
 young child – 2-5 years 
 infant – 1-24 months 
(b) No history of respiratory disease 
(c) No significant medical history 
(d) Non-smoker 
 
Cystic Fibrosis patients 
(a) 3 age groups 
child – 5-9 years 
young child – 2-5 years 
infant – 1-24 months 
(b) Confirmed diagnosis of cystic fibrosis (positive sweat test or genetic 
testing) 
(c) Clinically stable – no recent exacerbations (requiring antibiotics) in past 
4 weeks. 
(d) FEV1 ≥ 40% predicted 
(e)  
Subject Exclusion Criteria  
For Child volunteers 
(a) Any past history of: recurrent wheezing episodes, pneumonia, cystic 
fibrosis pertussis or tuberculosis. 
(b) Previous diagnosis of asthma or taking anti-asthma medication. 
(c) Previous hospitalisation for respiratory infection. 
(d) Born before 34 weeks gestation. 
(e) Neuromuscular weakness or bone disease likely to affect respiration. 
(f) Congenital cardiac defects requiring treatment. 
(g) Previous adverse reaction to sedating agent used during testing 
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For adult volunteers 
 -As above for children, plus: 
(h) Any ongoing or recurrent respiratory symptoms, such as cough, wheeze, 
breathlessness or nocturnal waking. 
(i) Current smoker (within last 6months). 
(j) Ex-smoker with >10pack yrs smoking history. 
(k) Any other co-morbidity requiring ongoing treatment or medical review. 
 
For CF paediatric patients 
(a) FEV1 < 40% 
(b) Recent chest exacerbation (in past 4 weeks) 
(c) Born before 34 weeks gestation. 
(d) Neuromuscular weakness or bone disease likely to affect respiration. 
(e) Congenital cardiac defects requiring treatment. 
(f) Previous adverse reaction to sedating agent (if required for testing).  
 
Subject Withdrawal Criteria 
(a) Respiratory symptoms 7 days prior to attending (healthy volunteers) 
(b) Patients/parents will be able to withdraw at any point during the testing if 
they wish. 
Ethical approval 
Prior to being unable to get access to a mass spectrometer, we planned to conduct 
this study in Edinburgh. At that time the expectation was that the youngest patients 
would require sedation. Following guidance from others performing infant lung 
function studies (Institute of Child Health, University College, London), a sedation 
protocol was drawn up. This would have been possible in Edinburgh, as there is a 
fully staffed clinical research facility. This was not available in the Royal Brompton 
at that time, so for ethical reasons the decision was made not to sedate. We were then 
only able to select those children who would be likely to sit still, or sleep naturally 
during the test. The most difficult group is from 6 months to 2 years. This still 
allowed recruitment of the youngest infants, those most of interest to this study. 
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Ethical approval was initially sought from the Lothian Research Ethics Committee 
for a study based in Edinburgh. Once the study was moved to London, a transfer and 
approval was received from the Royal Brompton and Harefield Research Ethics 
Committee (REC 07/S1102/40). A learning point for this thesis as a whole is that 
research ethics committee processes are complex, and require good communication. 
A decision from one committee does not mean approval from another. The forms are 
often not easily transferred from one centre to another as it is not a truly online 
system. It took a number of months before ethical approval was received in London. 
It would have been simpler to re-apply with a new application, rather than transfer. 
Paediatric clinical research in the Royal Brompton Hospital, 
London 
It was a great advantage to this project to have access to both a respiratory mass 
spectrometer, set up by Professor Gustafsson, and Innocor in the same department. 
Mrs Sam Irving was employed to conduct such studies in London by Professor Bush. 
Sam has a background in engineering, making her ideal for operating the mass 
spectrometer. In addition, she attended a mass spectrometer training course at 
Innovision’s headquarters in Denmark. At the time of the study Sam had experience 
of conducting MBW in teenagers and older children. She had received training in 
using the Innocor from me and Clare Saunders, a clinical physiologist conducting 
MBW for the CF Gene Therapy Consortium in London. The AMIS 2000 was 
installed and set up by Prof Gustafsson in April 2008. At that time a period of 
training was started to prepare for the comparison study. I produced 3 documents, 
with the help of Sam Irving and Prof Gustafsson. One gives details on conducting 
MBW using the mass spectrometer equipment. The others describe the hardware 
modifications for Innocor, and important techniques for determining the flow gas 
delay. These are included in the thesis as appendices. 
There were drawbacks to performing the study in London. The lack of a proper 
research facility meant families had to attend a smaller room which was not 
exclusively set aside for clinical work. Also, recruitment of younger patients proved 
very difficult. Despite the large population, access to the Royal Brompton Hospital 
from outwith central London is very time-consuming. Asking families to come for 
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this validation study required persuasion, and was usually those with a staff 
connection to the department or attending with a sibling for another reason. 
Statistical analysis 
Mean results from the individual washouts were obtained, and compared between 
devices.  
Clinical results from the Innocor device in each subject were compared with mass 
spectrometer using Students paired t-test of average FRC and LCI measurements. 
Variability of between-device results were compared with intra-test coefficient of 
variation (CV%) on each device. Modified Bland-Altman plots (mean of device 
results vs. % difference) were used to show evidence of Innocor bias. Prism 
(Graphpad software, USA) was used for statistical analysis. 
Raw data from mass spectrometer and Innocor were analysed by independent 
researchers. Sam Irving analysed data from the mass spectrometer blinded to the 
Innocor results, analysed by me. When finalised, the results from the two devices 
were compared. 
Innocor / mass spectrometer comparison results  
16 Healthy volunteers (median [range] age 11 [3-49] years) and 9 children with 
cystic fibrosis (median [range] age 7.4 [0.4-11] years) were recruited. Unfortunately, 
in 3 young children, only one washout was possible on each device due to poor 
subject tolerance; these have all been included in the analysis. 12 individual 
washouts (10%) were removed due to poor test quality (Evidence of leak or erratic 
breathing pattern, resulting in FRC >10% higher or lower than the other washouts). 
Mean FRC and LCI were measured using the modified Innocor in healthy and CF 









 Health Volunteer Cystic Fibrosis 
N 16 9 
Median Age (yrs) 11.7 7.4 
[Range] [3 – 49] [0.4 – 11] 
 
Mass Spec Innocor 
Mean [95% CI] 
difference Mass Spec Innocor 
Mean [95% CI] 
difference 
Mean (SD) FRC (L) 1.56 (0.9) 1.46 (0.9) -0.10 0.86 (0.6) 0.87 (0.6) 0.01 
[Range] [0.48 – 3.40] [0.54 – 3.40] [-0.22 to 0.02] [0.11 – 1.75] [0.15 – 1.72] [-0.05 to 0.07] 
Mean (SD) CEV (L) 11.10 (5.8) 9.90 (5.6) -1.21* 8.62 (6.0) 9.23 (6.1) 0.61 
[Range] [3.61 – 22.07] [3.69 – 21.91] [-2.16 to -0.26] [1.03 – 21.24] [1.68 – 19.88] [-0.78 to 2.00] 
Mean (SD) LCI  7.46 (0.8) 6.85 (0.6) -0.61† 10.4 (1.5) 10.66 (2.2) 0.26 
[Range] [6.50 – 9.33] [6.21 – 8.64] [-1.03 to -0.19] [7.96 – 12.30] [7.03 – 14.25] [-0.73 to 1.26] 
Mean (SD) Vt (L) 0.57 (0.2) 0.46 (0.2) -0.11† 0.31 (0.1) 0.29 (0.1) -0.02 
[Range] [0.23 – 0.96] [0.17 – 0.86] [-0.18 to -0.04] [0.10 – 0.51] [0.10 – 0.48] [-0.06 to 0.02] 
Table 30 - Comparison of results between devices in 2 clinical groups. Mean difference between 
devices indicating significant differences. Mean differences non-significant (p>0.05), except * 
p<0.05, † p<0.01. FRC, functional residual capacity, CEV, Cumulative Expired Volume during 
washout, LCI, Lung Clearance Index, Vt, average washout tidal volume. 
 
There was no mean difference in FRC in healthy controls. The modified Innocor 
gave a slightly lower LCI than mass spectrometer (mean [95%CI] difference -0.6, [-
1.0 to -0.2], p=0.007), and a lower CEV (mean [95% CI] difference -1.2L [-2.2 to -
0.3], p=0.02) and Vt (mean [95% CI] difference -0.1L [-0.2 to -0.04], p=0.005). No 
significant mean differences were seen between devices in children with CF (table 
2). All subjects with CF had a raised LCI, defined by previous published ranges as 
>7.5 (A. R. Horsley et al. 2008, Gustafsson et al. 2003a), detected by the mass 
spectrometer washouts. To investigate the above differences in healthy controls, the 
within-device coefficient of variation (CV%) of the 2 or 3 washouts on each device 
was compared with the between-device CV% and found to be comparable (table 3). 
In addition, between device differences in LCI were associated with differences in 
CEV (p=0.005), suggesting that observed differences between devices are likely to 
be due to physiological variability rather than Innocor inaccuracies. There was no 
correlation between differences in LCI and differences in Vt between devices 






Innocor  Between-device 





Mean (SD) CV% in FRC 9.36 (6.82) 5.92 (3.71)  8.36 (6.97) 
Mean (SD) CV% in LCI 8.12 (6.74) 5.08 (2.78)  6.80 (6.38) 
Cystic Fibrosis  
(n=9)   
 
 
Mean (SD) CV% in FRC 6.06 (8.68) 6.63 (5.29)  9.15 (9.45) 
Mean (SD) CV% in LCI 8.95 (6.83) 5.19 (5.02)  6.08 (5.66) 
Table 31 - comparison of within- and between- device coefficient of variation (CV%) in health 
volunteers and children with CF 
Effect of age on washout results 
It was expected that in the youngest subjects (<5yrs), the modified Innocor might 
under-estimate expired gas volume, due to slow rise time effects. There is no 
evidence, using the modified Innocor, of overall FRC or LCI bias in younger 
patients, and FRC is not under-estimated (Figure 77 and 78). The youngest child (4.8 
months), demonstrated a high CV between devices (24.2%), but also had a high 
CV% within each set of washouts (mass spectrometer 16.6, Innocor 17.6). 
Figure 79 and 80 illustrate the effect of magnitude of FRC and LCI on difference 
between devices. In those with a higher LCI, there is some evidence of over-
estimation of LCI measured with Innocor. This may suggest that the devices cannot 




Figure 77 and 78 - between device differences in FRC and LCI by age (healthy volunteer – blue, 
children with CF – red). 








































































































Figure 79 - comparison of average FRC between devices vs. %difference. Dotted lines indicate 





Figure 80 - comparison of average LCI between devices vs. %difference. Dotted lines indicate 
95% limits of agreement (healthy volunteer – blue, children with CF – red). 
 






































































































Following hardware modifications, and testing using a lung model, this study aimed 
ultimately to compare Innocor against the current gold standard device in young 
children and infants. This is a culmination of 2 years of preparation, and is important 
to the wider MBW research community as well as to this thesis. Innocor is a 
compact, portable device which, if accurate in younger children, may be very useful 
in multi-site research studies. These arguments have been well made previously. 
Modifications to improve gas signal rise time led to improvements in volume 
estimation using a basic lung model. When performing multiple washouts at low 
lung volumes there was no evidence of bias. Variability was higher, raising the 
question of how accurate signal alignment, breath detection, volume-concentration 
integration and lost gas compensation is. The volumes concerned, however, are very 
small (less than 6ml) and could be considered to be insignificant, within the normal 
within-test variability of the measurement (normally around 5%). 
The new Innocor rise time is just under 100ms. Available recommendations state that 
the optimal rise time should not exceed 100ms and, despite this not being firmly 
based on evidence, it is reasonable to be able to adhere to this standard(Beydon et al. 
2007). It was convenient that modifications improved the rise time to just lower than 
the recommended value, and results show that with this rise time, Innocor accurately 
estimates small washout volumes at faster respiratory rates. 
To reach the stage where a lung model could be used to assess Innocor, careful 
consideration was applied to technical issues, including signal alignment, breath 
detection and lost gas compensation. Adjusting results for BTPS, flow bias and 
signal alignment can alter results greatly. Care must be taken to justify each 
adjustment, as additive errors may make results look more accurate than they 
actually are. 
There are great advantages in using a device which measures raw signal rather than 
deriving gas concentration from more complex calculations. Ultrasound 
measurement of gas concentration (molar mass) is a complex technique, as 
fluctuations in oxygen, CO2, humidity and temperature alter the molar mass signal. 
The visit to the Bern group showed that slight adjustments to BTPS especially, has 
large effects on the washout pattern. The algorithm used is based on making the 
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washout trace look like a standard washout trace. No adjustments are made to the 
Innocor gas concentration signal, and all other adjustments to flow and integrated 
volume are derived from first principles. 
Drawbacks to this study are that only 2 washouts were performed when comparing 
the factory standard to the modified Innocor. More washouts could have been 
performed, but time limitations (setting up lung model and equipment), combined 
with convincing initial results, led to moving to performing series of washouts only 
using the modified Innocor.  
A further limitation to this study is the basic lung model used. While this design was 
obtained from experienced colleagues, it is clear that this model only mimics a lung 
in terms of volume, and not in terms of temperature, humidity or gas mixing. Only 
limited conclusions can be made from such a lung model, and a clinical comparison 
was planned as a result of these limitations. 
Finally, this study contains a number of novel calculations.  There is no published 
evidence of compensating for lost gas in multiple breath washout. The calculations 
have not been verified, and results obtained could be accurate numerically, but 
obtained from conflicting additive errors. Results may not be so accurate in different 
age groups or in the presence of disease, where washout duration is longer. Care has 
been taken to justify each calculation, but a lung model study where LCI can 
artificially be prolonged would be ideal. This thesis has not addressed whether a lung 
model can be created with in-homogenous gas mixing. Most importantly, this study 
provides a hypothesis for a clinical study of Innocor use in young children.  
The clinical comparison is the first to compare Innocor and mass spectrometer MBW 
devices in humans. Despite a slower 10-90% rise time in the Innocor, there is no 
evidence of bias in FRC measurements. Variability between devices is comparable to 
the within-device variability on each device. Innocor, in fact demonstrates less 
variability than mass spectrometer. There is a suggestion of a trend towards a greater 
difference in LCI measurements as LCI increases (Figure 80). This may suggest that 
results measured on different devices are not interchangeable in children with 
disease. 
Even in the youngest subjects (down to 4 months of age) there is no evidence of 
underestimation of FRC, which would be expected if the gas signal was the source of 
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the error. Also, in children with CF, where washouts are prolonged due to lung 
disease, there is no increase in variability and no evidence of bias. This indicates that 
the modified Innocor, with a rise time of <100ms and infant appropriate PNT and 
patient interface, is suitable for washouts in younger ages. 
Study limitations 
While the aim of the study was to recruit children in descending ages, including 
young infants, this has not fully been achieved. It is disappointing not to report larger 
numbers of infants, as they are relatively simple to test, and represent that most 
extreme group in terms of volume (except preterm infants). The factors that 
confounded this aim were the location of the study, at a central London location with 
difficult access. Families of young children attending for other reasons did not have 
time to stay for another lung function study. Sam Irving found it extremely difficult 
to identify and recruit significant numbers. Technical complications from Innocor 
and mass spectrometer increased these difficulties, resulting in some results being 
discarded, or visits cancelled. 
While Sam Irving was competent to conduct studies, dealing with young children 
was a relatively new experience for her. To conduct the study in Edinburgh, with a 
paediatric nurse present would have been ideal, but not possible as I have already 
explained. 
The limitations to the study stem from this. Only five children under 5 years 
completed the study. Only one infant was recruited. Of these younger children, only 
one washout was possible in 2 subjects. This greatly limits the conclusions of the 
study, even though the lung model study reinforces the conclusion that volume 
estimation is accurate at low lung volumes.  
Time did not allow a similar lung model study using the mass spectrometer. There 
were a number of demands on the testing room in London, and my visits were 
occupied with resolving technical difficulties and testing patients. This lung model 
study may have been instructive but is contrary to the hypothesis that mass 
spectrometer is the gold standard device.  
FRC measurement appears highly accurate, with no significant difference between 
devices. There are differences in LCI, CEV and Vt, however, which require 
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discussion. To assess why these measurements are different between devices, while 
FRC appears accurate, Table 32, below, indicates the effects of various errors on 
FRC and LCI. If FRC is unaffected, it is the cumulative expired volume that is 
primarily different. If FRC is affected, LCI is dependent on this and will also be 
different. The theoretical basis for these descriptions is in previous chapters. 
 
  Primary effects 
Gas analyser error Underestimation of expired 
volume due to slow 10-90% 
rise time 
FRC, LCI 
Flow meter error Incorrect linearisation or 
calibration leading to volume 
inaccuracy  
FRC, LCI 
Physiological variability “natural” changes in lung 
volume over time due to 
changes in central breathing 
control. Affected by changes in 
flow meter resistance and 
equipment dead space. 
LCI (FRC to some 
extent) 
Poor subject compliance Irregular breathing pattern, 
sighing, laughing etc. causing 
leaks or washout rate changes 
LCI (FRC to some 
extent) 
Operator error Incomplete washin of SF6, 
incorrect washout detachment 
timing and premature washout 
termination  
FRC, LCI 
Analysis differences Differences in processing of 
data such as breath detection 
thresholds and subtraction of 
dead space. 
FRC, LCI 




These data indicate that for LCI to be affected, independent of FRC, it is mainly 
physiological variability and poor subject compliance that are implicated, as any 
hardware error is likely to affect FRC. It is clearly not the case that physiological 
variability and subject compliance do not affect FRC measurements. There is a 
higher within test variability than is demonstrated in other studies in this thesis. 
 
FRC is influenced by tidal volume, in that a subject can breathe more or less deeply. 
Depth of breathing is regulated by central chemoreceptors and depends on blood O2 
and CO2 levels(West 2005). The level of distraction can also influence this, in that a 
well-distracted subject is likely to breath naturally, less aware of the apparatus and 
slightly increased work of breathing required to ventilate through the flow meter.  
An important difference in equipment in this study could have been overlooked. The 
flow meter used in Innocor for older children and adults was the Hans Rudolph 
(3500 or 3719). The mass spectrometer equipment used a size 00 or 01 Fleisch 
pneumotach. While the resistance of each is acceptable within the normal range of 
flow, the resistance is not necessarily the same. A small difference in resistance may 
have altered tidal volume and thereby influenced FRC or CEV. It is feasible that 
differences in resistance may have affected CEV disproportionately, resulting in the 
outcomes seen. In addition, poor washout quality in some instances is a factor.  
It is clear from this study, as well as other similar published work, that device 
comparison is a complicated validation step. There is tension between testing each 
device as it is normally used, and wanting to control for all of the many variables. 
This project seeks to balance these opposing forces, but is a victim to some extent of 
the two devices having significant differences which may have contributed to the 
physiological variability. Also, as the test is relatively long, subjects may have had 
some fatigue, or simply became bored. 
The most accurate way to compare devices is using a mechanical lung. Unlike the 
simple device used for this study, the same group that loaned me that version have 
now marketed a larger, more complex lung model for the purpose of device 
development. This should encourage manufacturers to build alternative devices with 
refined technology. This lung model is similar to the simple Perspex box, but is 
submerged in a water bath to control temperature. CO2 is added to the washout 
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volume, and breaths are driven by a volume regulated mechanical ventilator. This 
enhanced device is expensive, but variables can more accurately be controlled.  
Learning points and contribution to thesis 
This chapter is central to the theme of Innocor validation. Clinical studies conducted 
prior to hardware modifications were unable to answer the question of whether 
Innocor could be used in younger children and infants.  
To some extent the chapter is successful in confirming that Innocor, with specific 
modifications can measure gas concentration accurately even in young subjects. This 
project proved to be more difficult to conduct than expected. This was mainly 
because of having to move the study to London, with another person performing 
measurements.  
The results were difficult to interpret as physiological variability and washout quality 
may have prevented true differences between Innocor and Mass Spectrometer being 
elicited. The large scatter of differences about the mean are initially concerning, but 
with further analysis show that FRC is measured accurately, whereas other 
measurements are subject to bias and higher variability.  
The main aim of this thesis is to validate Innocor for use in children and infants by 
providing sources of error in measurements. The conclusion of this is that because of 
high inter-test variability a direct comparison such as was performed is not practical 
for device validation. Further use of a lung model would have provided better 
evidence of performance.  
With more time and better access to equipment, a full lung model series of 
experiments would have been the ideal study to perform. It was not clear at the start 
how difficult this would have been to perform. The delays due to obtaining 
equipment, getting ethical approval and difficulties in recruiting adequate numbers of 
children were the main barriers. A lung model, once set up, would be able to 
accurately compare washout results between Innocor and mass spectrometer with 
known and reproducible lung volumes. 
While a lung model study is ideal to compare the gas analyser and flow meter, this 
does not bring Innocor, and other washout devices for that matter, closer to the 
clinical domain. Only by recognising and quantifying sources of error in real patients 
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with lung disease as well as healthy controls, can the true utility of clinical washout 
devices be assessed. This study would suggest that washouts performed by a 
relatively inexperienced, although fully trained, operator vary considerably. This 
variability can be up to 40% in younger patients. This reduces the confidence of 





Chapter 10 Thesis summary and future directions 
The overall aims of this thesis were as follows: 
1. Show that MBW indices are a suitable selection for detecting and tracking 
lung disease in CF and other paediatric airway diseases. 
2. Describe the MBW technique and modified Innocor equipment in detail. 
3. Demonstrate through a series of clinical studies the use of Innocor in health 
and disease. 
4. Evaluate suitability of Innocor equipment in younger children (<5 years) and 
demonstrate validity. 
 
Upon commencing this thesis project in 2006, there was emerging experience of 
MBW in children, particularly from Professor Gustafsson’s group, and associated 
researchers in London. Professor Frey’s group in Switzerland have also achieved 
important milestones in the use of MBW indices in young children and infants. Now 
this thesis is complete, the field of paediatric MBW has not changed greatly. Many 
groups are still validating equipment and performing observations studies. Whilst it 
is very likely that data will be presented in the near future involving longitudinal 
observations in larger groups, there are only a very small number of therapeutic 
studies involving LCI as an outcome measure in children (Fuchs et al. 2010, Amin et 
al. 2010, Amin et al. 2011).  This lack of progress in expanding use of MBW in 
paediatric populations is indicative of the lack of spread of use outside the limited 
centres that have pioneered the technique. The state of the art document, currently in 
press, should provide greater standardisation of equipment and technique to allow 
other centres to use MBW in larger therapeutic studies. 
Since starting this thesis, there has been some progress by Innovision in the 
development of dedicated MBW equipment. Unfortunately this equipment did not 
use any of the validation experience from Edinburgh, and while it is marketed for 
children as young as 3 years, there are no validation data to support this. Ecomedics, 
manufacturers of the molar mass MBW device, are currently marketing a nitrogen 
washout system, in conjunction with Professor Gustafsson. While this may provide a 
much simpler solution to the complexities of SF6 washout, there is still concern 
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about the validity of nitrogen washout with 100% O2 in infants. A new sequence of 
validation studies will presumably emerge in the near future.  
The adaptation of Innocor began because of the need for a cheaper, portable 
alternative to mass spectrometry in UKCFGT consortium clinical studies. Further 
validation in younger age groups continued because of the appeal of Innocor as a 
commercially suitable device and interest shown at international meetings. The 
clinical studies presented in this thesis show that Innocor performs well compared 
with similar devices, and fulfils the aims of the thesis. 
The detailed description of methods and technical specifications are documented to 
demonstrate Innocor MBW technology is based on available evidence and peer 
reviewed recommendations. The modifications described in chapter 8 were done 
with careful consideration of the recommendations and appropriately improved the 
specifications without harming precision or accuracy. The setup described in chapter 
8 is feasible for larger research and clinical studies. Commercial development would 
address the need for manual alterations to the hardware and software limitations. The 
problems experienced in parts of North America in accessing large volumes of SF6 
are not addressed in this thesis but would currently limit use of the modified Innocor 
there.  
Data from healthy paediatric populations and those with CF and asthma show that 
Innocor produces similar results to other equipment. Innocor is able to distinguish 
disease from health, and detects subtle responses to acute changes such as 
bronchodilation and posture. Innocor LCI was measured over time in children with 
CF and may be more appropriate as a measure of disease progression than FEV1 
given its ease of use and measurement of a different aspect of airways disease. 
Innocor was used in multiple locations in the department in RHSC, Edinburgh. There 
were no analyser accuracy concerns in the areas where it was used. Software crashes 
happened occasionally, but were easily resolved (computer reboot). In comparison, 
the mass spectrometer is difficult to operate and does not tolerate being transported. 
In addition, a regular service is required to maintain the accuracy of the analyser, 
which incurs expense. Unexpected problems can result in the equipment being 
unavailable until expert unscheduled servicing takes place. This was not the case 
with Innocor. 
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All of the above findings show that Innocor is suitable for MBW in children, as was 
shown in adult studies published by Dr Alex Horsley in our department. The studies 
in this thesis go further to investigate Innocor MBW in children and cover important 
issues of test standardisation and effect of interventions (bronchodilation, 
physiotherapy and posture) on lung function in children with measureable lung 
disease. Innocor was previously untested in children and limitations to the original 
Innocor setup were addressed with novel adaptations. The resulting equipment was 
further validated for use in younger children. It is these novel adaptations and 
validation experiments that are most important to the thesis. The lung model 
experiments, in particular, demonstrate that the photoacoustic analyser is able to 
accurately estimate infant lung volumes at faster respiratory rates. The reduction in 
analyser rise time, along with improvements in gas sampling lines contributed most 
to the improvements in signal response. 
A further strength of this thesis is the adherence to published infant lung function 
standards. While many modifications were novel, use of published standards adds to 
the validity of the findings. It is convenient that such standards were being improved 
just prior to the thesis commencing, but this reflects the desire amongst the paediatric 
respiratory research community for progress in lung function use in the youngest 
patients. 
  
The weaknesses of this thesis are, firstly, that effects of interventions on lung 
function were not able to be linked with effects on different domains of disease 
(structure, inflammation, infection). It was not possible given limitations in funding, 
staffing and time to organise this type of study. In addition, limitations in numbers 
tested severely hampered the conclusions of the second section of the thesis (chapter 
9). On reflection, greater numbers of infant subjects would have been more 
conclusive but, given the variability of the test in unsedated infants, it may still have 
proved difficult to draw meaningful conclusions as to the accuracy of Innocor vs. 
mass spectrometer. The recent publication of the use of a more sophisticated lung 
model shows this type of MBW equipment validation may be superior to a clinical 
comparison in infants(Singer et al. 2012). 
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Another weakness is in sequencing of assays in the studies. Whilst all studies were 
conducted in a uniform way, performing spirometry prior to exhaled NO may have 
altered the usefulness of this assay. In addition, there were multiple assays performed 
as part of the CFGTC “run-in” study. While I reported only the lung function, airway 
clearance manoeuvres and sputum expectoration, as well as exhaled breath 
condensate measurement may have altered the LCI results. Taking these tests in 
isolation and comparing with other data may have reduced the validity of the results. 
A final weakness is to do with MBW protocol. MBW is a long test, and efforts to 
shorten it with fewer washouts would be welcome. A concern with performing 2 
washouts is that data quality may suffer. Throughout this thesis 3 washouts were 
performed unless the patient was unable (i.e. infants only). A proportion of washouts 
were discarded if the FRC or LCI values were too variable according to pre-defined 
parameters. In the run-in study, where 34 children performed measurements on 4 
separate occasions, 12% of washouts were discarded. This is less than the 30% of 
washouts discarded during the study in asthmatic children and healthy controls, 
possibly relating to the different age-group and the larger proportion of children 
naïve to lung function. Examining the change in values over the 3 washouts, there is 
no significant difference comparing LCI 1 with LCI 2 or 3 in the sequence at any one 
visit. There is no evidence of a trend in those with higher LCI values (more advanced 
lung disease), even though test variability is often higher (Figure 81). There is 
currently no evidence to reduce the number of washouts from 3 to 2, as this might 
result in more subjects being excluded from analysis, given that there was no 
evidence of washout 3 being more reliable than 2 or 1 for example. Given that 
relying on only 1 washout is unacceptable, 3 washouts serves as a reasonable 




Figure 81 - Bland Altman plot of average LCI from washout 1 and 3 vs difference in children 
with CF recruited for chapter 7. Shows uniform variability across disease severity. 
 
Future directions 
Innocor shows great promise throughout all age groups. It is frustrating for me not to 
be able to be more positive about its use in infants. Future studies, particularly lung 
model studies may provide the necessary validation data to begin Innocor use in 
younger children. With full validation Innocor may be more widely used. The 
UKCFGTC has adopted its use in currently ongoing gene therapy trials. This 
indicates the Innocor has a utility for such multi-centre studies. 
Wider use of Innocor requires commercial development. Innovision have made 
progress with commercialising Innocor for MBW. Unfortunately this version 
involves a re-breathing washin manoeuvre which, as a significant change to the test 
protocol, was not validated publicly. A recent paper suggests this method causes 
large changes in tidal volume from washin to washout, increasing test 
variability(Pittman et al. 2012). An alternative commercial setup could retain the 
open-circuit washin manoeuvre, with the speeded Innocor. This would obviously 
require the external gas supply, which is bulky. This would be an important future 
direction. 
Comparison of washout number

































Finally, Innocor allows larger clinical studies to be performed in multiple centres. 
With the advent of novel treatments for CF, Innocor may be able to access the 
necessary patient numbers for studies of class-specific agents such as VX-
770(Ramsey et al. 2011). These new agents suggest that CFTR function can be 
restored to levels that normalise sweat chloride and improve lung function (FEV1) 
and weight. For these to be used in infants, repeatable assays such as LCI may be key 
to demonstrating efficacy in this age group. The number of subjects is greatly 
limited; therefore a single centre trial may not be ideal. Evidence that lung function is 
abnormal at 3 months of age in screened infants(Hoo et al. 2012) should increase the 
interest in finding sensitive repeatable assays with which to test these novel therapies 
in young children to halt, or even reverse early lung damage.  
Final conclusion 
The central aim of this thesis was to investigate how appropriate Innocor is in larger 
research studies and clinical use. From a device capable of measuring LCI in adults, 
Innocor has been adapted, validated and used in 5 moderately sized paediatric studies 
with important outcomes relevant to the wider research community. Each study has 
contributed to the main thesis aims, but also generated important results which allow 
further research work to be continued in Edinburgh.  
On starting the thesis project there was no respiratory research lab in the RHSC, 
Edinburgh. Because of the CFGTC funding, and as a result of the studies in this 
thesis, there is now a programme of paediatric respiratory physiology research. 
While Innocor cannot yet be used as a clinical device, further research work is 
ongoing which may provide important new data on the natural history of lung 
diseases such as CF and asthma, the effect of interventions and disease severity on 
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